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ABSTRACT 
 
 
Heparin administration during extracorporeal procedures such as kidney dialysis and 
heart surgeries is a challenging problem, as under heparinisation leads to clotting and 
over heparinisation may cause excessive bleeding complications. Various reactor 
designs including the use of heparinase and poly-L-lysine.HBr hollow fiber have been 
proposed, however none of them have been clinically approved yet.  
 
This work presents the possibility of designing a packed bed reactor with poly-L-
lysine/alginate beads. The poly-L-lysine/alginate beads have been used widely in 
fields of microencapsulation of cells and can be made using techniques such as the 
Initech encapsulation and layer by layer approach. In some cases ginipin has been 
used for microcapsule preparations to provide stronger cross linking. In this study, the 
poly-L-lysine beads are made using the encapsulation procedure patented by Chang18 
(1992).  Batch experiments, using saline, fetal calf serum and blood were performed 
to investigate the efficiency of the beads. The absorption of heparin was determined to 
be a first order absorption process and fits the Freundlich Isotherm. The beads were 
determined to be relatively safe in blood. The absorption of heparin was linked to the 
poly-L-lysine content in the membrane. Thus the rate of the amount of heparin 
absorbed could be increased by increasing the membrane thickness or by increasing 
the number of poly-L-lysine/alginate beads. The results were used to investigate the 
feasibility of using a packed bed reactor for the absorption process by adjusting the 
specifications of the reactor and analysing simple flow models.  
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CHAPTER 1: INTRODUCTION 
 
1.1. INTRODUCTION 
Exposure of blood to foreign objects in extracorporeal devices such as the kidney 
dialyser usually leads to the formation of clots. Anticoagulants such as heparin are 
injected into the patients’ blood during such procedures to prevent clotting. 
Heparinisation is a major problem as under-coagulation may result in clotting while 
over-heparinisation increases the risk of haemorrhage. This problem arises from the 
difficulty of monitoring the adequacy of anticoagulation during the short period of 
hemodialysis. Approximately 20 million extracorporeal procedures are performed 
each year, of which between 8 to 30% of bleeding complications arises due to 
systematic heparinisation.  
 
Heparin is not prescribed to patients with low platelet numbers or with bleeding 
disorders. Patients with some source of bleeding such as recent surgery, injury or 
ulcer are also in danger of excess bleeding when administered with heparin. Side 
effects of heparin include unusual bleeding or bruising, blood in urine or stools, 
abdominal or back pain, heavy menses and skin irritation. Alternate modalities, 
instead of the standard heparin anticoagulation, are used; however all of them have 
disadvantages and complications. It would be useful to have a system that would 
eliminate heparin after the standard anticoagulation procedure is administered. 
Various reactor designs including the use of heparinase and poly-L-lysine.HBr hollow 
fiber have been proposed, however none of them have been clinically approved yet.  
1.2. AIM OF PROJECT 
The aim of this project is to perform experiments for the development of a reactor that 
would permit full heparinisation of blood entering any extracorporeal device, but 
enable the elimination of the heparin before the blood returned to the patient 
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This work presents the possibility of designing a packed bed reactor with poly-L-
lysine/alginate beads. Batch experiments, using saline, fetal calf serum and blood 
were performed to investigate the efficiency of the beads.  
1.3. THESIS CONTENTS 
The thesis comprises of three articles. Each chapter (article) comprises of a literature 
review, an introduction, apparatus and methods, results, discussion and a conclusion. 
 
Chapter 3 (Article 1) investigates the possibility of using poly-L-lysine/alginate beads 
to extract heparin from saline solution. Chapter 3 presents the results and discussions 
of mass transfer experiments that were performed to test the feasibility of using poly-
L-lysine/alginate beads to remove heparin. The experimental data was fit to a first 
order absorption model. The experiments were repeated several times and the average 
standard deviation of the results were less than 2%. 
 
Chapter 4 (Article 2) investigates ways of optimizing the absorption procedure. 
Chapter 4 presents the results and discussion of experiments where the physical 
parameters, like the number of the beads, volume, surface area and the size of the 
beads were varied. The findings were related to the membrane thickness of the beads. 
Methods of increasing the membrane thickness and thereby optimizing the process 
were investigated. 
 
Chapter 5 (Article 3) explores the feasibility of the proposed reactor by utilizing 
theoretical models for the flow process and the results obtained from the previous 
chapters. Various feasible reactor options are investigated for optimum heparin 
removal. 
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CHAPTER 2: APPARATUS AND METHODS 
 
 
2.1. INTRODUCTION 
The apparatus used for the project can be divided into three main categories: 
calibration, formation of poly-L-lysine/alginate beads and the mass transfer 
experiments. All the experiments were performed in the chemical pathology lab at the 
University of Witwatersrand Medical School. The required chemicals were supplied 
by Sigma. The concentration range of heparin used in the experiments varied from 
0U/mL to 3U/mL, which is higher than the expected clinical values. Heparin was 
supplied by the renal unit of Johannesburg General Hospital.  
2.2. CALIBRATION 
The concentration of unfractionated heparin in saline and fetal calf serum was 
determined by using the calibration method of Ameer et al26. A spectrometer 
(Figure 2.1) was used to obtain the absorbency of a required sample of heparin at a 
particular wavelength. The absorbance of unfractionated heparin corresponding to the 
concentration ranges of 0U/mL to 3U/mL is linear (Ameer et al26., 1999). 
Figure 2.1  Cintra 5 UV-VIS Double Beam Spectrometer 
Computer
Spectrometer
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1 mL quartz cuvettes were used to obtain a 1cm path length. Two of these cuvettes 
were used for the duration of all the experiment to minimize the variables. One of the 
cuvette was used as a blank, while the other was used to obtain the required 
absorbance. 
2.2.1 Method for calibration 
Standard solutions of 3U/mL, 1.5U/mL and 0.75 U/mL of unfractionated heparin 
were prepared in 100mM MOPS and 5mM-calcium acetate (pH of 7.4) saline 
solution.  A solution of 0.01mg/mL of Azure II dye was also prepared using distilled 
water (Figure 2.2). 900 µL of Azure II dye was mixed with 100 µL of the heparin 
sample solution in a 1 mL quartz cuvette (path length of 1cm). The mixture was 
incubated at room temperature for 1 minute. The absorbance of the mixture was then 
measured using the spectrometer at the selected wavelength. The known 
concentrations of heparin were plotted against the obtained values of the absorbance 
(Figure 2.3) to obtain the expected linear plot.  
 
 
Figure 2.2  A beaker containing 0.01 mg/mL of Azure II dye solution 
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Figure 2.3  Calibration Curve of unfractionated heparin in saline 
 
Refer to Appendix A1 for the tabulated values of the above calibration curve. 
2.2.2. Determination of the required wavelength 
A sample of known concentration of heparin was mixed with azure II dye as 
described previously in section 2.2.1. The wavescan of the sample was obtained using 
the spectrometer. The wavescans obtained for 0U/mL, 1.5 U/mL and 3U/mL are 
illustrated in Figure 2.4. 
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Figure 2.4  Wavescans of 0U/mL, 1.5 U/mL and 3 U/mL of unfractionated heparin 
in Saline 
 
From Figure 2.4, a wavelength of 520 nm was selected to measure the absorbance of 
the heparin samples.  
 
Plastic cuvettes could be used for analysis, because the selected wavelength is in the 
visible range; however these cuvettes were easily scratched and damaged causing 
drastic changes to the absorbance values. Quartz cuvettes were used to avoid these 
problems and for consistency. 
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2.2.3. Timescan of unfractionated heparin in saline 
A timescan for a known concentration of heparin was performed to observe whether 
the absorbance was time dependent. The timescan was done for a period of 0 to 300 
seconds 
 
Figure 2.5  Timescan of a sample of unfractionated heparin in saline 
 
The absorbance of the mixture of heparin and Azure II dye was determined to be 
independent of time from the above time scan. 
2.3 FORMATION OF POLY-L-LYSINE/ ALGINATE BEADS 
The standard encapsulation procedure patented by Chang29 in 1992 was used to 
produce poly-L-lysine/alginate beads. The apparatus used is illustrated in Figure 2.6. 
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Figure 2.6  The apparatus used to produce the poly-l-lysine/alginate beads 
 
Flow of air from the air cylinder was controlled by a manifold dial, and was measured 
in L/min using a rotameter. Air flowed into the droplet generator through tube A. 
Sodium alginate was pumped by the syringe infusion pump through tube B to the 
droplet generator. The droplet generator allowed contact of air with sodium alginate 
solution and produced beads in spherical form.  
 
 
 
 
Air cylinder
Knob
Rotameter
Droplet Generator
Tube A
Tube B
Beaker
Syringe Infusion
Pump
Stirrer
Pressure gauge
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Figure 2.7 Droplet generator  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8  Front view of the syringe infusion pump 
 
2.3.1 Method to form poly-L-lysine/alginate beads (Chang29., 1992) 
Equal amounts of saline and 4% sodium alginate (Appendix A2) solution were mixed 
in a 10mL syringe. The solution was extruded with the syringe infusion pump through 
the droplet generator. The flowrate of the alginate solution was in a range of 
0.1mL/min to 0.4mL/min, while the air from the cylinder was between 0.5L/min and 
4L/min, depending on the bead size that was required. The droplets of beads were 
Syringe 
Tube B 
Flowrate 
Solution inlet
(connects to Tube B)
Air inlet
(connects to Tube A)
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allowed to fall into 300 mL of 100mM calcium chloride solution (Appendix A2), 
where calcium alginate, a spherical gel-like substance, was formed. The beads were 
then left in the calcium chloride solution for 15 min with continuous stirring. The 
beads were strained and washed with saline, and placed in 80 mL poly-L-lysine 
solution (Appendix A2) for 20 min. This was the stage where the membrane of the 
beads was formed. The beads were then strained and washed and placed in 200 mL of 
0.2% sodium alginate solution (Appendix A2)   for 5 min to form cross-links with the 
poly-L-lysine membrane. The beads were strained and washed and placed in 200mL 
of 50mM sodium citrate solution (Appendix A2) for 6 min to remove the gel like 
substance (Calcium alginate) from the beads, thereby producing “empty” poly-L-
lysine/alginate beads.  
 
The beads were then stored in saline solution until they were used in experiments. If 
the beads were required to encapsulate an enzyme, the initial stage of mixing was 
altered by the addition of 4% sodium alginate solution to an equal amount of the 
enzyme solution (instead of the saline solution). The size and number of beads can be 
altered by changing the air and solution flow rates. The number of beads was 
estimated by counting the droplets that fell out of the droplet generator, while the size 
of the bead was measured using a light microscope, fitted with a ruler. 
 
 
 
Figure 2.9 Poly-L-lysine/alginate beads in a drop of saline solution. 
 
The beads formed were spherical with a uniform size distribution. 
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2.4. BATCH MASS TRANSFER EXPERIMENTS 
Mass transfer experiments were performed on a batch of beads using the following 
apparatus. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Schematic Diagram of the apparatus used for mass transfer 
experiments 
 
 
 
 
 
 
 
 
Figure 2.11 Schematic diagram of the microspin filter and the receiving 
(centrifuge) tube 
 
 
 
 
Beaker 
Beads in suspension 
Stirrer 
Solution with heparin 
Supernatant solution 
with no bead fragments 
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microspin filter 
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2.4.1. Method for the mass transfer experiments 
A known volume of saline or blood solution containing heparin was added to a known 
volume of uniformly sized beads. The contents in the beaker were then stirred to 
ensure that the beads were in suspension and to maintain uniform exposure of heparin 
to the beads. Samples of 300 µL of the supernatant solution were taken out at time 
intervals from 0 seconds to 1.5 hours, using a pipette. The samples were placed in 
centrifuge tubes containing 0.45µm microspin filters. These samples were centrifuged 
at 4000 rpm at 25OC for 5 min to filter out the fragments of beads from the 
supernatant solution. The samples were then analyzed using the spectrometer. 
Absorbencies obtained from the spectrometer were used to obtain the concentration of 
heparin in the samples from the calibration curve (Figure 2.3). 
 
The calibration curve was analyzed and plotted prior to all the experiments to check 
for variances. 
2.4.2. Efficiency of pipettes 
An experiment to check the accuracy of the pipettes was performed. Ten samples of 
900 µL of water were taken out using the 900 µL pipette. These samples were then 
weighed. The expected mass was 900g since the density of water is 1000kg/m3. A 
curve of the expected mass versus the mass obtained was plotted as shown in 
Figure 2.12. 
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Figure 2.12 A curve of the expected mass of water versus the weighed mass of 
water for a 900 µL pipette 
 
Refer to Appendix A3 for the tabulated values of the above curve. 
 
From the above curve, it is evident that the 900 µL pipette is accurate. The standard 
deviation for the above values is approximately 0.13%. 
 
Similarly a curve for the 100 µL pipette was obtained using the same procedure 
described above. (Appendix A4). The standard deviations for the 100 mL pipette were 
0.025%. 
 
The pipettes were therefore reliable and accurate. 
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2.5. CONCLUSION 
 
The above analytical techniques and the technique used to form the poly-L-
lysine/alginate beads were followed throughout the duration of this project. 
Repeatability and reliability of the techniques was good.  
 
It is recommended that the apparatus used to form the beads must be improved as a 
slight change in the position of the droplet generator; or the flowrates of the solution 
and air changed the shape and size of the beads. The beads’ size was obtained using a 
microscope after the beads were formed. If the beads were not of the required size, the 
entire procedure had to be repeated. It would be beneficial to design an apparatus to 
produce a constant amount of beads with the required size automatically. 
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CHAPTER 3:  EFFICIENCY OF POLYMER BEADS IN THE 
REMOVAL OF HEPARIN 
 
 
The following article has been submitted to the Journal: “Artificial Cells, Blood 
Substitutes and Biotechnology” and is currently being reviewed. This paper focuses 
on the possibility of using poly-L-lysine/alginate beads to remove heparin. The 
experiments were performed to measure the removal rates of heparin, test the 
efficiency of the beads, determine the repeatability and to identify the factors that 
could influence the removal rate of heparin. 
 
EFFICIENCY OF POLYMER BEADS IN THE REMOVAL OF HEPARIN: 
TOWARD THE DEVELOPMENT OF A NOVEL REACTOR 
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3.1. ABSTRACT 
Administration of heparin during extracorporeal procedures increases the risk of 
haemorrhage. Various reactor designs, including the use of heparinase and poly-L-
lysine.HBr hollow fiber have been investigated for the removal of heparin prior to the 
blood being returned to the patient; however none of them have been implemented 
clinically. In this paper it is proposed that beads made from poly-L-lysine/alginate can 
be used to remove the heparin. The aim of this work is to perform the necessary 
experiments in order to get the information required to design a heparin removal 
reactor which uses these beads. The experiments are aimed at measuring the removal 
rates of heparin by the beads, testing the efficiency of the beads to remove heparin, 
determining repeatability and identifying factors that could influence the removal rate. 
Batch rate experiments using poly-L-lysine/alginate beads in saline solutions were 
performed to investigate the removal rate of heparin. The results, which indicate that 
heparin is efficiently removed, may lead to improved bioreactor designs.  
3.2.  INTRODUCTION 
Heparin is introduced into the blood during the use of extracorporeal devices such as 
renal dialysis, to prevent clotting resulting from the blood contacting foreign surfaces 
such as the dialyser membrane. However, hheparinisation during extracorporeal 
procedures is a challenging problem since under-coagulation may result in clotting 
within the extracorporeal circuit, while over-heparinisation exposes the patient to risks 
of prolonged bleeding (Swartz1.,  1990). 
 
Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides 
called glycosaminoglycans having anticoagulant properties.  
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The main sugars occurring in heparin are (Elkins Sinn 2.,2004): 
• α-L-iduronic acid 2-sulphate, 
• 2-deoxy-2-sulphamino-α-D-glucose 6-sulphate, 
• β-D-glucuronic acid, 
• 2-acetamido-2-deoxy-α-D-glucose, and 
• α-L-iduronic acid.  
 
Heparin is strongly acidic because of its content of covalently linked sulphate and 
carboxylic acid groups.       
       
       COO    
    H           H           H    O3   SOCH2  H 
     
            H  
           OH      OH             H 
            
        
          H            OSO3      H           HNSO3                  
  
   
Figure 3.1: Chemical structure of a single unit of unfractionated heparin  
  (adapted from Quader et al3., 2002) 
 
Heparin is heterogeneous with respect to molecular size, anticoagulant activity and 
pharmacokinetic properties. The molecular weight of heparin ranges from 3000 to 
30000. The anticoagulant activity of heparin is heterogeneous because only one third 
of the heparin molecules administered to the patients have an anticoagulant profile 
(Hirsh et al 4., 2001). 
 
Heparin administration is the standard therapy for the treatment of deep vein thrombi 
(Hemostasis & Thrombosis Center5., 2002).  
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The main clinical uses of heparin (Rxmed 6., 2004) are: 
• Acute phase myocardial infarction; 
• Prevention and treatment of venous and arterial thrombosis; 
• Treatment of  pulmonary embolism; 
• Prevention of pulmonary embolism and deep vein thrombosis in pregnancy; 
• Management of complications of arterial diseases such as atherosclerosis; 
• Extra-corporeal therapies, such as heart-lung oxygenation and  renal dialysis; 
• Open heart surgery; 
• Deep phlebitis (inflammation of the walls of the vein); 
• Vitreoretinal surgery; 
• Topical application in pruritus (itching); and 
• Topical application for leg ulcers. 
 
The basic analytical method to measure heparin in saline was demonstrated by Jaques 
et al7. A 2mL aliquot of saline, 2mL of phosphate buffer (pH 7.3) and 1 mL of Azure 
A solution (100mg% Azure A diluted to 1:8.5) was added to a given volume of 
heparin solution. The solution was mixed and transferred to a glass cell. The colour of 
the cell solution was matched immediately in a lovibond tintometer using the red and 
blue glasses. A lovibond tintometer is a colorimeter, which uses colour measurement 
for analysis of substances. The heparin content of the sample was determined from 
the red reading to provide a standard curve of the following shape. 
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   Heparin (mg of free acid) 
 
Figure 3.2: Schematic diagram of the standard curve obtained from Jaques7 
 
A modification of the above method was developed by Ameer et al8 in 1999 to 
measure the concentrations of unfractionated heparin in saline. A 4.5 mL volume of 
Azure II dye solution (0.01mg/mL) was added to 0.5 mL of the heparin solution to be 
tested. The azure II dye measures the negative sites of heparin. The sample was mixed 
and incubated at room temperature for 1 min before measuring the absorbance at 
500nm. A standard curve for this assay was prepared by using solutions of known 
heparin concentrations ranging from 0 to 3 U/mL. The standard curve was linear in 
the above range. 
 
Attempted solutions to anticoagulation during hemodialysis include systemic 
heparinisation, regional heparinisation, low-dose heparinisation, heparin-free 
hemodialysis in patients with high risks of bleeding, (Swartz1., 1990), administering 
protamine to neutralize heparin and administering antithrombic drugs other than 
heparin (Langer et al9., 1982). However the safety and efficiency of these methods 
Lovibond red 
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remain debatable. One of the major barriers to the optimal dosing of heparin arises 
from the difficulty of monitoring the adequacy of anticoagulation during the short 
(usually three-to-four hour session) period of hemodialysis. (Low et al10., 1996) The 
use of heparin and its antagonist protamine has been associated with potentially fatal 
complications in high-risk patients such as those suffering from acute renal failure or 
those who have undergone recent surgery. (Broyer et al11., 1986) 
 
The development of a safe and efficient bioreactor design for heparin removal has 
remained a challenge. Such a reactor would permit full heparinisation of blood 
entering any extracorporeal device but would enable the elimination of the heparin 
before the blood returned to the patient (Langer et al9., 1982). Immobilized heparinase 
I specifically degrades heparin resulting in non-toxic products (Larsen et al12., 1986). 
Another alternative is to bound protein to the walls of a hollow fiber dialyser to 
enhance the whole blood compatibility of the system, but the surface area 
requirements remain impractical (Vallar et al13., 1996). Porous particles such as 
agarose or cellulose beads have been proposed as a way to optimize the protein or 
absorbent loading per volume of device (Gejyo et al14., 1993; Langer et al9., 1982). 
Heparin can also be neutralised by addition of polyanions, enzymes or resins to 
clinical samples (Wenz et al15., 1991). Immobilised protamine (Yang et al16) and poly-
L-lysine ligand coupled to agarose substrate (Rodger et.al17., 1994) are other methods 
employed to remove heparin from blood. However according to the authors, 
additional research is required to use these methods for clinical purposes.  
 
In order to expand on the above possibilities, it is proposed to use poly-L-lysine beads 
to remove heparin from saline solutions. The poly-L-lysine beads are made using the 
encapsulation procedure patented by Chang18 (1992), and utilized by Vally et al19 
(2005) in South Africa to encapsulate liver cells. Batch rate experiments using the 
poly-L-lysine/alginate beads will be performed to obtain the necessary parameters 
required for the design of the reactor. The experiments in this article are designed to 
test issues like the efficiency of the beads to remove heparin, repeatability and some 
of the factors that could influence the rate. 
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3.3. APPARATUS AND METHODS 
 
3.3.1 Calibration 
Concentration of unfractionated heparin was determined using an Azure II dye assay 
as described by Ameer et al8., 1999a. A cintra 5 UV-VIS double beam spectrometer 
was used to measure the absorbency of heparin. A mixture of 900µL of Azure II dye 
(0.01mg/mL) and 100µL of the heparin solution under test was placed in a 1mL-
quartz cuvette. The absorbency was then measured at a wavelength of 520 nm. A 
standard curve for this assay was prepared by using solutions of known heparin 
concentrations ranging from 0 to 3U/mL. The standard curve was linear for this 
concentration range. 
3.3.2 Formation of poly-L-lysine/alginate beads 
The standard encapsulation procedure patented by Chang18 in 1992 was used to 
produce poly-L-lysine/alginate beads.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Droplet Generator  
 
The droplet generator (Figure 3.3) allowed contact of air with sodium alginate 
solution and produced beads in spherical form.  
 
 
Sodium alginate solution (26-gauge 
Air (16 gauge 
Bead
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Equal amounts of saline and 4% sodium alginate solution were mixed in a 10mL 
syringe. The solution was extruded from the syringe by a syringe infusion pump 
(Harvard apparatus; Millis, Mass) and pumped through the 26-gauge needle of the 
droplet generator. Air was allowed to flow through the 16-guage needle of the droplet 
generator. The flowrate of the alginate solution was in a range of 0.1mL/min to 
0.4mL/min, while the air from the cylinder was between 0.5L/min and 4L/min, 
depending on the required bead size. The droplets were allowed to fall into 300 mL of 
100mM calcium chloride solution and cured in the calcium chloride solution for 15 
min. The beads were strained using a 0.45 µm mesh filter, washed and placed in 80-
mL poly-L-lysine solution for 20 min. The beads were then strained and washed and 
placed in 200 mL of 0.2% sodium alginate solution for 5 min. The beads were 
strained and washed for a final time and placed in 200mL of 50mM sodium citrate 
solution for 6 min. The beads were then stored in saline solution until they were used 
in experiments. 
3.3.3 Batch rate experiments 
The aim of the rate experiments is to illustrate the efficiency of the poly-L-lysine 
beads and to fit a model to obtain the intrinsic rate. Although the rate limiting step 
cannot be identified, it could be expected that the magnitudes of rates measured in the 
batch experiments would be achieved in a well designed reactor. The rate will depend 
on parameters such as concentration of heparin in the solution, time and the number of 
beads or the ratio of the volume of beads to the volume of solution. The experimental 
apparatus will be designed to reduce, and if possible eliminate, the mass transfer 
limitations between the beads and the solution by stirring the solutions. In this way the 
intrinsic removal rate that will be achieved in a reactor can be measured.  
 
Saline solution containing a known concentration of heparin was added to a known 
volume of uniformly sized beads. The contents in the beaker were then stirred to 
ensure that the beads were in suspension and to maintain uniform exposure of heparin 
to the beads. Samples of 300µL of the supernatant solution were taken out at time 
intervals from 0 seconds to 1.5 hours. The samples were centrifuged to separate the 
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fragments of beads from the supernatant solution. The supernatant samples were then 
analyzed using the spectrometer.  
 
As the experiments are aimed at measuring data that would be needed for the reactor 
design, the experimental programme is set up so that the measurements, analysis and 
interpretation are iterative. This approach is called process synthesis and the 
advantage of it is that one can gain relevant data for the design more quickly and 
efficiently. 
 
3.4. RESULTS 
 
3.4.1 Initial Measurement of Rate of Removal of Heparin 
A fixed number of beads were used in a fixed volume of saline containing heparin. 
The aim of this experiment was to get an estimate of the magnitude of the removal 
rate of heparin by the beads and thereby establish whether the beads can be used for 
the purpose of removing heparin from a reactor. Approximately 8000 + 1000 poly-L-
lysine/alginate beads of size 900µm + 100µm were placed in 40-mL saline solution 
with a heparin concentration of 3 U/mL, which was stirred continuously at room 
temperature. Aliquots of 300 µL of the heparin solution were pipetted out at intervals 
from zero seconds to one and half hours. The absorbency of the samples was analyzed 
at a wavelength of 520 nm using the spectrometer. The results obtained from this 
experiment are shown in Figure 3.4 and tabulated in Appendix B1.  
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Figure 3.4: Graph of heparin concentrations during the rate experiment using 8000 
beads and 40 ml of 3U/mL heparin solution. 
 
The results indicate that the beads can efficiently remove the heparin from the saline 
solution. The concentration of heparin in solution was reduced by half in about 100 
seconds which implies that the removal rate is fast enough for a practical design.  
Equilibrium was attained after approximately 1000 seconds. The average standard 
deviation for the results obtained was less than 2%. 
 
The next set of experiments were performed to test the consistency of the results The 
rate experiments were repeated using constant variables, such as the number of beads 
(850 + 100  beads), volume of the heparin solution (23-mL), concentration of the 
heparin in the solution (3U/mL) and the size of the beads (900µm + 100µm). The 
number of beads used in this set of experiments was decreased from 8000 (used in the 
previous experiment) to 850 in order to try and saturate the beads. The experiments 
were repeated at room temperature. The results (Appendix B2) are shown in 
Figure 3.5. 
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Figure 3.5: Repeat experiments for 850 beads of 900 υm diameter and 23 mL of 
3U/mL of heparin solution. 
 
Figure 3.5 indicated that the results were consistent and repeatable. The standard 
deviation for the results was less than 2%, which was similar to the previous 
experiment.  
 
A control experiment to prove that heparin was not absorbed onto the glass surface of 
the cuvettes and the beakers was performed. A saline solution of 40 mL with 3U/mL 
of heparin, containing no beads, was stirred for 30 minutes. Samples of 300 µL of the 
solution were pipetted out from the stirring solution at different time intervals. The 
samples were then centrifuged as before and analyzed at 520 nm using the 
spectrometer (Figure 3.6 and Appendix B3). 
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Figure 3.6 Concentration of heparin in saline solution containing no beads  
 
The results obtained from this experiment indicated that a negligible amount of 
heparin was absorbed onto the glass surface. The results therefore indicate that the 
heparin is removed by the beads only and the rates measured are the rates of the 
absorption rate of heparin on the beads.  
 
The next experiment was performed to check if any of the heparin was released back 
into the solution after some time. Poly-L-lysine/alginate beads that had been loaded 
with heparin were incubated in saline for one week at room temperature to determine 
if the absorbed heparin was released back into the solution. Samples of the saline 
solution were taken out every day and analyzed to measure the concentration of 
heparin. 
 
After analysis, no heparin was found in any of the samples, which implies that the 
absorbance of heparin on to the beads is an irreversible process.  
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3.4.2 Estimation of the order of the absorption process 
In order to fit a model to the rate process, as a first approximation, assume that the 
rate can be described by a simple first order absorption model. 
 
For a first order absorption process: 
 
)( exxKdt
dx
−=  ……………………..……..………………………Equation 3.1 
 
where: 
 x is the concentration of heparin in solution (liquid phase) in U/mL; 
 t is the time in seconds; 
 K is the rate coefficient in seconds-1; 
 xe is the concentration of heparin in U/ml in solution (liquid phase) at infinite 
time (equilibrium concentration)  
 
Equation 3.1 can be integrated and rearranged to give a linear equation. 
 
)ln()ln( eoe xxKtxx −+=−   ……..…………………………….Equation 3.2 
 
where 
 xo is the initial concentration of heparin in the solution in U/mL 
 
Since the concentration of heparin towards the end of the experiment decreased very 
slowly, the final concentration was assumed to be the concentration of heparin at 
infinite time or the equilibrium concentration, which was obtained from the 
experiment. The initial concentration of heparin was 3U/mL. 
 
The curve of ln { x – xe } versus time t, was plotted using the data given in Figure 3.4 
and is shown in Figure 3.7. (Appendix B4) The resultant straight line curve implies 
that the rate model is a simple first order absorption process and the rate constant   
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K =  0.0039 s-1.. The data measured for the 800 beads (Figure 3.5) is also plotted in 
Figure 3.7. It can be seen that this data too follows a straight line, but the rate constant 
K has a value of -0.002 s-1 which is different to that for the large number of beads.  
This is not that surprising and the next step is the need to investigate the relationship 
between the number of beads and the rate constant.  
8000 beads: y = -0.0039x + 1.0638
R2 = 0.9881
850 beads: y = -0.002x - 0.434
R2 = 0.9951
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Figure 3.7:  Experimental data fitted to a first order absorption process 
3.4.3 Relation of absorption rate to the number of beads 
In order to design a reactor, it is essential to know the impact that the quantity of the 
beads would have on the absorption process. It would be useful if a correlation could 
be obtained between the number of beads and the amount of heparin that can be 
absorbed by the beads. 
 
Rate experiments in saline solution were performed by varying the number of beads. 
The previous results together with the new data are presented in Figure 3.8 
(Appendix B5). 
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Figure 3.8: Comparison of rate experiments for different number of beads at 25OC. 
 
The final concentration obtained was assumed to be the concentration at the infinite 
time or the equilibrium concentration since very little change was observed between 
the last two points. It can be seen that the initial slope depends on the number of beads 
and hence the rate constant K depends, as observed previously, on the number of 
beads.  The data shown in Figure 3.8 was fitted to equation 3.2 and all the data sets 
fitted the first order rate model. The rate constants for experiments at 25 OC and 37 OC 
are plotted versus the number of beads in Figure 3.9 (Appendix B6).  
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Figure 3.9: Correlation of K-values to the number of beads 
 
It can be seen that the rate of absorption of heparin by the beads is linearly dependent 
on the number of beads.  
3.4.4 Fitting an isotherm to the equilibrium concentration data points 
A classical isotherm for a heterogeneous flat surface is the Freundlich Isotherm, 
which is defined as follows: 
 
mi
eii xkq =   ……………………………………………………Equation 3.3 
 
where: 
 mi is a constant which is positive and generally not an integer; 
 ki is a constant; 
xe is the fluid phase concentration at equilibrium (concentration of heparin in 
saline solution at infinite time) in U/ml; 
qi is the absorbed phase concentration in U/mL; 
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qi =  Amount of heparin absorbed by the beads…………Equation 3.4 
   Total volume of the beads 
 
The amount of heparin absorbed by the beads is equal to the initial amount of heparin 
in saline solution minus the final amount of heparin in the saline solution 
 
The assumptions for these equations are: 
• The volume of saline solution removed during the rate experiments is less than 
10% of the initial volume of saline solution and is therefore assumed to be 
negligible. The final volume of the saline solution is thus approximately equal to 
the initial volume, which is equal to 40 mL 
• The membrane thickness of the beads is negligible when compared to the radius of 
the beads (450 nm) and can therefore be ignored.  
 
Equation 3.3 therefore becomes: 
 
)
3
4(
)40(403
3
rN
mLxmL
mL
U
q
b
e
i
pi
−
= ……………………………………………Equation 3.5 
where: 
 Nb is the number of beads 
 r is the radius of the beads in m 
 
Equation 3.5 can be rearranged as follows: 
 
)ln()ln()ln( eiii xmkq +=   ……………………………………..Equation 3.6 
 
The data points were used to obtain the values of qi and the results were plotted on the 
graph in Figure 3.10 (Appendix B7). 
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Figure 3.10: Data points obtained from the rate experiments fitted to Freundlich 
Isotherm 
 
The results indicate that the equilibrium data points obtained from the rate 
experiments can be modeled using the Freundlich Isotherm. The gradient (mi) is 
positive and not an integer; however the values differ for the different temperatures. 
This difference could be attributed to experimental error. The Freundlich Isotherm can 
therefore be used to predict the equilibrium parameters that are essential for the 
reactor design. 
3.5. DISCUSSION 
The results indicate that heparin can be efficiently removed using poly-L-
lysine/alginate beads with no heparinase. Figure 3.5 illustrated that the results 
obtained from the experiments were consistent and repeatable. The experiment 
performed in the absence of beads demonstrated that very little of the heparin was 
absorbed onto the glass surface (Figure 3.6). Results from the incubation experiment 
indicated that heparin absorbed by the beads was not released back into the solution. 
If heparin removal were a diffusion process only, heparin would have been released 
into the saline solution to attain a new equilibrium concentration. Therefore, it was 
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concluded that the removal was an absorption process. The data obtained from the 
rate experiments showed an excellent fit to the first order absorption model 
(Figure 3.7). Increasing the number of beads, as illustrated in Figure 3.8 increased the 
amount of heparin removed from the saline solution, while the rate constants 
decreased (Figure 3.9). The results obtained from Figure 3.10 indicated that the 
Freundlich Isotherm could be used to correlate the data for the equilibrium 
concentrations. 
3.6. CONCLUSION 
The present study demonstrates that heparin can be efficiently removed from a saline 
solution using poly-L-lysine/alginate beads. The removal of heparin from these 
solutions is a first order absorption process and depends on the number of beads. The 
rate is fast enough, as the half life is approximately 100 seconds for the initial 
experiments, thus this method appears to be a feasible method that can be used to 
remove heparin. The absorption process at a particular temperature can be predicted 
using the Freundlich Isotherm. These results will ultimately provide some of the 
required parameters for the bioreactor design using poly-L-lysine/alginate beads. 
Further research is required to study the effect of these beads on the constituents of 
blood, the correlation between the volume and size of the beads and the absorption 
rate. 
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CHAPTER 4: INVESTIGATING ABSORPTION IN SALINE, 
FETAL CALF SERUM AND BLOOD 
 
 
The following article will be submitted to the Journal: “Artificial Cells, Blood 
Substitutes and Biotechnology” and is currently being reviewed. This paper 
investigates the absorption in saline, fetal calf serum and blood. Ways of optimizing 
the absorption process are explored by performing rate experiments to vary the 
physical parameters of the beads. All the experiments are designed to obtain the 
required parameters for the reactor design. 
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4.1. ABSTRACT 
During extracorporeal procedures like hemodialysis, heparin is administered to 
patients to prevent clotting. Unfractionated heparin has side effects such as excessive 
bleeding. It would be advantageous if the blood could be deheparinased before it 
returns to the patient. Previous work has indicated that poly-L-lysine/alginate beads 
can efficiently remove heparin from saline solutions (Varghese et al1., 2006). Heparin 
is irreversibly absorbed onto the beads. This article explores ways of optimizing the 
absorption process by performing rate experiments varying the physical parameters of 
the beads. Fetal calf serum and blood are also used in experiments to investigate the 
possibility of designing a safe and efficient reactor to absorb heparin. All the 
experiments are designed to obtain the required parameters for the reactor design. The 
results indicate that the absorption could be optimized by controlling the membrane 
thickness of the beads. The beads also showed efficient removal of heparin in blood. 
4.2. INTRODUCTION 
Heparin has been the basis of initial anticoagulation therapy for more than 80 years 
(Nielsen2., 2003) Heparin reduces clotting during extracorporeal procedures such as 
hemodialysis. Heparin does not block the platelets from attaching to the foreign 
objects, but it blocks the cascade of proteins that work with the platelets to form the 
clot. It does not dissolve the clots but limits or slows clotting by binding and 
enhancing the activity of a protein called antithrombin III (Patients3., 2002). The 
complex formed with antithrombin III inhibits several activated blood coagulation 
factors: XIIa, XIa, IXa, Xa and thrombin (Heparin in children4., 2002). 
 
Anticoagulation in routine hemodialysis consists of a standard dose of heparin given 
as a bolus at the start of dialysis treatment with a mid-treatment dose to maintain 
suitable anticoagulation. Alternatively, heparin modeling can be performed using an 
initial bolus followed by a constant fixed infusion of heparin, as mentioned above, to 
maintain an activated clotting time of 200 to 250 seconds (the normal activated 
clotting time is in the range of 90 to 140 seconds). Activated clotting time is a 
  
Chapter 4 Article 2  38 
  
measure of the anticoagulation effects of heparin in blood. This therapy ensures 
systematic anticoagulation throughout the dialysis treatment. It is reliable and requires 
minimal staff intervention after a patient’s heparin dose is determined. (Kovalik5., 
2000) 
 
However, side effects of heparin include excessive bleeding or bruising, blood in 
urine or stools, abdominal or back pain, heavy menses and skin irritation. 
(Patients3.,2002). Heparin is not prescribed to patients with low platelet counts or with 
bleeding disorders. Patients with some source of bleeding such as recent surgery, 
injury or ulcer are also in danger of excess bleeding when heparin is administered. 
Osteoporosis is another serious but uncommon side effect associated with high dose 
heparin administration over a prolonged period. (Heparin in children4., 2002). Various 
alternative anticoagulation substitutes have been used including extreme 
hemodilution, low molecular weight heparins, danaparoid, ancrod, r-hirudin, 
abciximab, tirofiban, argatoban and others. In the presence of heparin-induced 
thrombocytopenia (HIT) and thrombosis, the use of r-hirudin appears to be an 
acceptable solution which has been well studied. The main issue with r-hirudin is the 
difficulty in monitoring its activity (Von Segesser6., 2001). 
 
Some of the alternatives for patients with a high risk of bleeding are (Heparin in 
children4., 2002): 
 
• Minimum dose heparin 
Minimum dose heparin involves boluses of 500 units of heparin every 30 minutes to 
keep the activated clotting time greater than 150 seconds but less than 200 seconds. 
An alternate way is to have a continuous infusion of heparin with frequent activated 
clotting time monitoring. No additional equipment is required in the dialysis circuit, 
however a minimal degree of anticoagulation still occurs. 
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• Regional anticoagulation with protamine reversal 
Regional anticoagulation with protamine reversal involves constant infusion of 
heparin into the dialyser inlet line and simultaneous constant infusion of protamine 
prior to blood returning to the patient (protamine binds to heparin and eliminates its 
anticoagulant activity). The infusion pump rates are adjusted to keep the activated 
clotting time in the dialyser at 250 seconds. The protamine dosage required to 
neutralise the heparin can be determined by a protamine titration test. Protamine 
reversal has been largely abandoned due to technical difficulties and due to problems 
with rebound bleeding two to four hours after the end of dialysis as free heparin is 
released from the protamine-heparin complex back into the general circulation.  
 
• Heparin free hemodialysis 
Heparin free hemodialysis is administered to patients with a high risk of bleeding. 
Both the dialyser and the blood lines are pre-treated with 2000 to 5000 units of 
heparin contained in a litre of normal saline prior to the start of the dialysis treatment 
so that heparin is not administered to the patient. The blood flowrates are in the range 
of 250 to 500 mL/min and 25 to 30 mL saline flushes are administered every 15 to 30 
min into the arterial (pre-dialyser) limb to minimise hemoconcentration and to wash 
fibrin strands from the kidney. This volume of saline must be removed during dialysis 
to prevent hypervolemia. Careful monitoring of the arterial and venous pressure 
alarms is required to detect early clotting. The above method is used in approximately 
90% of Intensive Care Unit patients with temporary venous access, with only a 2% 
clotting rate in the extracorporeal circuit. However, close nursing observation is 
required, as it may be necessary to convert to minimum dose heparin or stop treatment 
in 5% of the cases.  
 
• Low molecular weight heparin 
The two main types of heparin are unfractionated and fractionated low molecular 
weight heparin. The molecular weight range of low molecular weight heparin is from 
1000 to 10000, while unfractionated heparin is from 3000 to 30000. Low molecular 
weight heparin is given in a fixed dosage and does not require dose adjustment. 
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Coagulation assays to monitor its activity are unnecessary. Low molecular weight 
heparin requires less frequent dosing because of its longer half-life. The risk of 
osteoporosis is less with prolonged administration of low molecular weight heparin 
than with unfractionated heparin. However low molecular weight heparin is very 
expensive. 
 
All of the above alternate modalities have disadvantages and complications. It would 
therefore be useful to have a system that would eliminate unfractionated heparin after 
the standard anticoagulation procedure is administered. 
 
It was demonstrated in the earlier article that poly-L-lysine/alginate beads can 
efficiently remove heparin from saline solutions (Varghese et al1., 2006). The 
absorption process was a first order process and the Freundlich isotherm best fitted the 
experimental data. This article explores methods of optimizing the conditions to 
design an efficient reactor. 
4.3. APPARATUS AND METHODS 
 
4.3.1 Calibration 
Concentration of unfractionated heparin was determined using an Azure II dye assay 
as described by Ameer et al7., 1999a. A cintra 5 UV-VIS double beam spectrometer 
was used to measure the absorbency of heparin. A standard linear curve for this assay 
was prepared by using solutions of known heparin concentrations ranging from 0 to 
3U/mL.  
 
 
 
 
 
  
Chapter 4 Article 2  41 
  
4.3.2 Formation of poly-L-lysine/alginate beads 
The standard encapsulation procedure patented by Chang8 in 1992 was used to 
produce poly-L-lysine/alginate beads (Varghese et al1., 2006) 
 
Standard poly-L-lysine/alginate beads were formed using a 26-gauge needle of the 
droplet generator. The beads were then stored in saline solution until they were used 
in experiments. 
4.3.3 Batch rate experiments 
Previous work ((Varghese et al1., 2006) has indicated that the extraction of heparin 
from the saline solution by the poly-L-lysine/alginate beads is a irreversible first order 
absorption process and the equilibrium data can be modeled by using a Freundlich 
isotherm. For the reactor design, it is essential to determine the absorption capacity of 
the beads and whether the saline results are representative of the blood results. The 
aim of this article is to determine whether the absorption process is rate controlling, to 
determine the rate controlling step, the absorption capacity of the beads and the 
absorption process in fetal calf serum and in blood. 
 
The batch rate experiments were performed using a saline solution containing a 
known concentration of heparin was added to a known volume of uniformly sized 
beads. The contents in the beaker were then stirred to ensure that the beads were in 
suspension and to maintain uniform exposure of heparin to the beads. Samples of 
300µL of the supernatant solution were taken out at time intervals from 0 seconds to 
1.5 hours. The samples were centrifuged to separate the fragments of beads from the 
supernatant solution. The supernatant samples were then analyzed using the 
spectrometer.  
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4.4. RESULTS 
The first step in the process of determining the absorption capacity of the beads is to 
determine what characteristics of the beads the absorption process depends on. 
Experiments were planned to identify whether the absorption process was influenced 
by the ratio of the volume of the beads to the solution, the surface area of the beads or 
the membrane volume.  
4.4.1 Absorption Dependence on Total Volume Ratio of beads to 
solution 
This experiment was performed to check whether the total volume ratio of beads to 
solution had an effect on the absorption process. Two batch rate experiments were 
performed by ensuring that the total volume ratio of the beads to the solution was kept 
constant. If the absorption process is affected by the total volume ratio of the beads to 
the solution then the results of both the experiments would be similar to each other.  
 
Poly-L-lysine/alginate beads were placed in a fixed volume of saline solution with a 
heparin concentration of 3 U/mL, which was stirred continuously at room 
temperature. The beads of approximate diameters of size 900µm + 100µm and 2mm + 
100µm were used. The number of beads and the volume of the solution used were 
adjusted such that the total surface volume ratio of beads to solution was kept 
constant. Aliquots of 300 µL of the heparin solution were pipetted out at different 
time intervals from zero seconds to one and half-hours. The absorbance of the 
samples was analyzed at a wavelength of 520 nm using the UV-VIS spectrometer.  
 
Since the membrane thickness was so small when compared to the diameter of the 
bead, it was neglected:  
 
  Volume of one bead  = 3
3
4
rpi   …...Equation 4.1 
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Total volume of beads = )
3
4( 3rN pi  …… Equation 4.2 
where: 
 N is the total number of beads used for the experiment; 
 r is the radius of the beads; 
For the total surface volume ratio of beads to solution to be constant: 
 
1
3
222
3
11 )3
4()
3
4( VrNVrN pipi =                 ……………Equation 4.3 
 
where: 
 N1 is the number of beads used in the 900 µm beads experiment = 8000; 
 r1 is the radius of beads in the 900 µm beads experiment = 450 µm; 
V1 is the total volume of 3 U/mL heparin solution in mL used for the 900 µm 
beads experiment; 
 N2 is the number of beads used in the 2 mm beads experiment = 848; 
 r2 is the radius of beads in the 2 mm beads experiment = 1 mm; 
V2 is the total volume of 3 U/mL heparin solution in mL used for the 2 mm 
beads experiment. 
 
8000 + 1000 beads (diameter 900 µm) were made. A batch rate experiment was 
performed to obtain the absorption results using 40 mL of saline.  Equation 4.3 was 
then used to obtain the number of 2mm beads and the volume of saline that was 
required such that the total surface volume ratio remained constant. The obtained 
values are tabulated in Table 4.1. 
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Table 4.1 Parameters of beads and solutions used in the total volume ratio 
experiments. 
V1 N1 r1 V2 N2 r2 
40 mL 8000 450*10-6 m 46 mL 848 1*10-3 m 
 
A rate experiment was performed to obtain the absorption results using the 2 mm 
beads and the obtained results were plotted on the same axes for purposes of 
comparison in Figure 4.1 (Appendix C1). 
 
Figure 4.1. Comparison of rate with constant total surface volume ratio of beads to 
solution 
 
The results clearly indicate that the ratio of the total volume of beads to the solution 
does not influence the absorption rate.  
4.4.2 Absorption Dependence on Total Surface Area of beads  
This experiment was performed to check whether the ratio of the total surface area of 
beads to the volume of solution had an effect on the absorption process. Two batch 
rate experiments were performed by ensuring that the ratio of the total surface area of 
beads to the volume of solution was kept constant. If the absorption process is 
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affected by the ratio of the total surface area of the beads to the volume of the solution 
then the results of both the experiments would be similar to each other.  
 
The rate experiments were performed for 900 µm beads and 2mm beads. The number 
of beads and the volume of the solution used were adjusted such that the surface area 
ratio of the beads to volume the solution was kept constant. 
 
Neglecting the membrane dimension:  
 
Surface area of one bead  =        24 rpi        ... Equation 4.4 
 
  Total surface area of beads  =    )4( 2rN pi          ...Equation 4.5 
 
For the surface area ratio to be constant: 
 
1
2
222
2
11 )4()4( VrNVrN pipi =     …………………….Equation 4.6 
 
3650 beads of diameter 900 µm were made. A batch rate experiment was performed 
using 40 mL of saline.  Equation 4.6 was then used to obtain the number of 2mm 
beads and the volume of saline that was required such that the total surface area ratio 
of beads to the volume of solution remained constant. The obtained values are 
tabulated in Table 4.2. 
 
Table 4.2 Parameters of beads and solutions used in the surface area ratio 
experiments. 
V1 N1 r1 V2 N2 r2 
40 mL 3650 450*10-6 m 46 mL 848 1*10-3 m 
 
The results obtained from the rate experiments were plotted on the same axes for 
purposes of comparison (Appendix C2). 
  
Chapter 4 Article 2  46 
  
Figure 4.2. Comparison of rate with constant total surface area ratio of beads  
 
The results clearly indicate that the surface area of the beads does not influence the 
absorption rate. 
4.4.3 Effects of the bead membrane on the absorption of heparin 
The above experiments have indicated that the absorption process does not depend on 
the volume or surface area of the beads.  Previous research has proved that poly-L-
lysine can absorb heparin (Rodger et.al7., 1994). During the formation of beads, the 
poly-L-lysine is contained in the membrane of the beads. The following set of 
experiments were planned to check if the membrane of the beads had an influence on 
the absorption process. 
 
It is essential to determine whether if any of the other constituents of the membrane 
apart from poly-L-lysine affects the absorption process. The following experiment 
was planned to confirm that the sodium alginate in the membrane had no effect on the 
absorption process. The sodium alginate used initially to form the beads was expected 
to have no part in the absorption, as it diffuses out in the final stage of the bead 
formation (Chang5., 1992). A rate experiment involving a variation of the sodium 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0 1000 2000 3000 4000 5000 6000 7000
Time (sec)
Co
n
c
e
n
tr
a
tio
n
 
o
f h
e
pa
rin
 
(U
/m
l)
3650 (0.9 mm) beads
848 (2 mm) beads
  
Chapter 4 Article 2  47 
  
alginate concentration was performed to investigate the effect of sodium alginate on 
the absorption process. 
 
Two sets of poly-L-lysine/alginate beads (8000 beads) of size 900 µm were made 
using the procedure described above. One set of beads was produced using a 
concentration of sodium alginate of 5%, while the other set was made using 2.5% 
sodium alginate. Rate experiments were performed for both sets of beads. The results 
obtained from the experiments are presented in Figure. 4.3 (Appendix C3). 
Figure 4.3. Comparison of the absorption of heparin by varying the concentration 
of sodium alginate  
 
The results clearly indicate that sodium alginate has no effect on the absorption 
process, as varying the concentration of the sodium alginate does not alter the 
absorption process. 
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The following experiment was planned to confirm whether the membrane (poly-L-
lysine) was the only factor to consider when determining the absorption capacity of 
the beads. Beads with no membrane were used in a rate experiment to determine the 
effect on the absorption process. 
 
Approximately 8000 beads of size 900 µm were produced. Equal amounts of saline 
and 5% sodium alginate were mixed in a syringe. The droplets were allowed to fall 
into the calcium chloride solution, thereby forming beads with calcium alginate (gel 
structure with no membrane). All the other stages were excluded from the formation 
of the beads. A rate experiment was performed using these beads with no membrane. 
 
The results obtained from the experiment are shown in Figure 4.4 (Appendix C4). 
Figure 4.4. Absorption of heparin by beads with no membrane 
 
The results indicate that some of the heparin can be taken by the calcium alginate; 
however, some of it is released back into the solution to obtain a new equilibrium 
concentration of 2.66 U/mL, which is much higher than 0.028 U/mL obtained using 
beads with a membrane. This leads to the conclusion that although calcium alginate 
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absorbs heparin, the majority of the absorption is due to the poly-L-lysine content in 
the beads. 
 
As part of the experiments, it was vital to check if the membrane of the smaller beads 
was different from that of the larger beads and what effects, if any, the difference in 
membrane thickness would have on the absorption process and ultimately lead to the 
parameters essential for the reactor design. 
 
Upon microscopic observation, the smaller beads were found to have a thicker 
membrane than the larger beads (Figure 4.5). The ratio of the dimensions of the 
membrane thickness was estimated using the programme Scion Image. The thickness 
of the 2 mm beads was estimated to be 0.006 mm, while the thickness of the 900 µm 
beads was 0.014 mm. 
 
 
 
 
 
 
 
 
 
Figure 4.5. Microscopic photo of the 900 µm and 2 mm beads illustrating the  
  different membrane thickness 
 
After observing the noticeable difference in the membrane thickness, batch rate 
experiments were planned to check if the volume of the membrane of the beads 
influenced the absorption process. 
 
 
 
900 µm 2 mm 
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The ratio of the membrane thickness of the beads is as follows:  
 
43.0
1
2
=δ
δ
                                                ………………………………… Equation 4.7 
 
where: 
 δ2 is the membrane thickness of the 2 mm beads in mm; 
 δ1 is the membrane thickness of the 900 µm beads in mm. 
 
Volume of membrane of one bead = δpi 24 r       … Equation 4.8 
  
Total membrane volume of beads = )4( 2δpirN     Equation 4.9 
 
For the  ratio of the total volume of the bead membrane to be constant: 
 
)4()4( 22221211 δpiδpi rNrN =       ..................Equation 4.10 
 
The above equation was used to obtain the following parameters that were used for 
the rate experiments at 37OC (normal human body temperature), such that the 
membrane volume ratio of the beads remained the same. 
 
Table 4.3 Parameters used in the bead membrane volume ratio experiments. 
N1 r1 N2 r2 δ2/δ1 
1800 450*10-6 m 850 1*10-3 m 0.43 
 
The results obtained from the rate experiment are illustrated in Figure 4.6 
(Appendix C5). 
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Figure 4.6. Comparison of the rate experiments with constant membrane volume 
ratio of beads 
 
The above results clearly indicate that the absorption process is dependent on the 
volume of the membrane of the beads. The absorption capacity of the beads thus 
depends on the volume of the membrane, which implies that the reactor design must 
be based on the volume of the membrane of the beads and not on the volume or the 
surface area of the beads. Previously, the experimental data was fitted to a first order 
absorption model and the Freundlich Isotherm, however, the volume of the membrane 
of the beads were neglected. From the above process, it is evident that the membrane 
of the beads influences the absorption process, thus this parameter cannot be ignored. 
The effect of the volume of the membrane of the beads needs to be incorporated into 
both the constants for the First order model and the Freundlich Isotherm. It is essential 
to check if the models fit the above results in order to obtain a method of determining 
the constants irrespective of the conditions under which the experiments were 
performed. This would be beneficial for the reactor design as the value of the 
constants for a particular number of beads can be easily estimated. 
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From the previous article (Varghese et al., 2006), the experimental data fitted the 
following first order absorption model: 
 
)( inflnln CCKdt
dC
so
so
−=    .................................................................Equation 4.11 
where: 
 Csoln is the concentration of heparin in solution in U/mL; 
 t is the time in seconds; 
 K is the rate coefficient in seconds-1; 
 Cinf is the concentration of heparin U/ml at infinite time (equilibrium  
concentration)  
 
The curve of ln {Csoln – Cinf } versus time t, was plotted using the data points obtained 
from the rate control experiment in saline solution and a straight line was obtained. 
The gradient of the graph yielded the value of K. The data points from above 
experiment for both the 900 µm and 2mm beads were used to obtain the values of K. 
These values were then plotted together with the previous values obtained from the 
previous article (Varghese et al., 2006) against the volume of the membrane of the 
beads as shown in Figure 4.7 (Appendix C6): 
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Figure 4.7. K-values for varying volume of membrane of the beads 
 
From Figure 4.7, the K value obtained from the 2mm and the 900µm beads is directly 
proportional to the volume of the membrane of the beads. Therefore if the volume of 
the membrane of the beads is known, the value of K can be obtained, irrespective of 
the size of the beads. 
 
The Freundlich Isotherm in the previous article was obtained using the volume of the 
beads. The Freundlich isotherm is as follows: 
mi
eqmii Ckq =                       .………………………………………………..Equation 4.12 
 
where: 
 mi is a constant which is positive and generally not an integer; 
 Ki is a constant; 
Ceqm is the fluid phase concentration at equilibrium (concentration of heparin 
in saline solution at infinite time) in U/ml; 
qi is the absorbed phase concentration in U/mL; 
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The above equation can be rearranged to: 
 
)ln()ln()ln( eqmiii Cmkq +=   ……………………………………Equation 4.13 
 
The absorbed phase concentrations were calculated in the previous article using the 
volume of the beads. These values are corrected for the volume of the membrane of 
the beads, and the following graph (Appendix C7) is obtained: 
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Figure 4.8. Data points fitted to Freundlich Isotherm using the volume of 
membrane of the beads  
 
The above graph indicates that the data obtained still follows the Freundlich isotherm, 
and the gradient remains the same as that obtained in Article 1. 
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4.4.4 Relation of absorption rate to the membrane thickness of the 
beads 
Since poly-L-Lysine is known to absorb heparin (Rodger et.al18., 1994) and since the 
absorption of heparin is directly related to the membrane volume of the beads 
(Figure 4.6), it would be beneficial if the membrane thickness of the beads could be 
controlled in order to obtain the optimum absorption conditions. Three sets of 2mm 
beads were produced, and the membrane thickness was altered by changing the time 
that the beads were kept in the poly-L-lysine solution. The first set of beads was 
produced by placing them for the usual 20 minutes in the poly-L-lysine solution. 40 
minutes was used for the second set, while 60 minutes was used for the third set. The 
membrane thickness of the beads was then compared under light microscopy and 
photographed. 
 
 
 
 
 
 
 
Figure 4.9. Microscopic photo of 2 mm beads placed in poly-L-lysine solution for 
20 minutes and 40 minutes 
 
 
 
 
 
 
 
 
Figure 4.10. Microscopic photo of 2 mm beads placed in poly-L-lysine solution for 
20 minutes and 60 minutes 
20 min 40 min 
20 min 60 min 
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The ratio of the membrane thickness of the beads was determined, using the 
programme Scion Image, to be approximately  
 
 20δ  : 40δ  : 60δ    = 1  :  3  :  5  …………….…… Equation 4.14 
 
where the subscript of δ represents the time in minutes that the beads were placed in 
the poly-L-lysine solution. 
4.4.5 Rate Experiment for beads with more Poly-L-Lysine content than 
the standard beads 
Since poly-L-lysine is the main constituent that affects the absorption process, it 
would be beneficial to know if the content of poly-L-lysine were to be increased with 
the aim of producing solid poly-L-lysine beads, what the effects would be on the 
absorption process. 
 
850 beads of size 900 µm were produced using Chang’s procedure, however the last 
two steps were omitted in order to produce beads with a poly-L-lysine coating. Three 
sets of beads were produced. One set was incubated in saline overnight, one set was 
incubated in poly-L-lysine solution overnight, while the remaining set of beads were 
used immediately for a rate experiment. Another set of standard beads (containing 
poly-L-lysine membrane) were made by using the full procedure as described by 
Chang. The incubated beads were used for rate experiments using 23 mL of saline 
solution with 3U/mL of heparin. The results (Appendix C8) are as shown in 
Figure 4.11. 
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Figure 4.11. Comparison of the rate of heparin using beads with varying poly-L-
lysine content 
 
The rate coefficients for the first order model for the above data points are tabulated in 
Table 4.4. 
 
Table 4.4  Rate coefficients for the beads with varying poly-L-lysine (PLL) 
content 
Beads Rate coefficients (K) in sec-1 
Standard beads -0.001 
PLL beads incubated in PLL -0.0057 
PLL beads incubated in saline -0.0012 
PLL beads with no incubation -0.0009 
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The results clearly indicate that increasing the poly-L-lysine content of the beads 
increases the amount of heparin absorbed. This finding creates the possibility of using 
solid poly-L-lysine beads to improve the efficiency of the reactor. 
4.4.6 Heparin absorption in fetal calf serum (FCS) using beads 
The above experiments have indicated that the beads can efficiently absorb heparin 
from saline solutions. However the use of the beads in extracorporeal procedures, 
where human blood is used, the feasibility of the beads have to tested. As an initial 
test, fetal calf serum was used. The properties of fetal calf serum are similar to that of 
blood, thus a rate experiment using the beads in heparinised fetal calf serum would 
give a clear indication as to whether the beads are feasible or not. 
 
Rate experiments were performed in fetal calf serum to verify the efficiency of the 
beads at absorbing heparin. Two sets of approximately 1700 beads of size 900 µm 
were produced. One set was used in a rate experiment using fetal calf serum. The 
other set was incubated in fetal calf serum for a day, and a rate experiment was 
performed in the same volume of saline solution. Another experiment was performed 
with no beads to determine whether any of the heparin was absorbed by FCS. The 
results (Appendix C9) are presented in Figure 4.12: 
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Figure 4.12. Comparison of the rate of heparin in fetal calf serum (FCS) 
 
The rate coefficient for the first order model for the beads in FCS is -0.0011 sec-1. 
 
The results indicate that the beads are more efficient in fetal calf serum.  
4.4.7 Heparin absorption in human blood using beads 
Since the beads have been tested to be efficient in fetal calf serum, the next step 
would be to test the feasibility of using the beads in human blood. The efficiency of 
the beads in blood was tested by performing a rate experiment in blood. Fresh samples 
of blood (kindly donated by co-authors/supervisors) in citrate tubes were mixed and 
utilised. The samples, taken at time intervals ranging from 0 to 5400 seconds, were 
centrifuged for 20 minutes to separate the blood. The plasma was then centrifuged as 
before to remove the fragments from the samples. The results (Appendix C10) are 
shown in Figure 4.13: 
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Figure 4.13. Comparison of the rate of heparin absorption in blood, Fetal calf serum 
and saline 
 
The rate coefficients for the first order model for the above data points are tabulated in 
Table 4.5. 
 
Table 4.5  Rate coefficients for blood, FCS and saline 
Beads Rate coefficients (K) in sec-1 
Beads in saline -0.001 
Beads in FCS -0.0014 
Beads in Blood -0.0027 
 
The results seem to indicate that the beads are more efficient in blood and follow the 
same trend as the absorption process in saline. 
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4.4.8 Effect of pH on the absorption process 
The above results indicate that the absorption process in blood is more efficient. One 
of the reasons could be pH. This experiment was performed to obtain the trends, if 
any, when the pH value is changed. 
 
The effects of pH were observed by performing rate experiments using solutions with 
varying pH. The volume of the beads and solution were kept constant. The results 
obtained from the experiments are illustrated in Figure 4.14 (Appendix C11).  
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Figure 4.14. Comparison of the rate of heparin using different pH solutions 
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The rate coefficients for the first order model for the above data points are tabulated in 
Table 4.6. 
 
Table 4.6 Rate Coefficients for the first order absorption model 
Beads Rate coefficients (K) in sec-1 
Saline -0.001 
Blood -0.0027 
FCS -0.0014 
pH = 7.5 -0.0012 
pH = 7.92 -0.0023 
 
The results indicate that the pH has an effect on the absorption process and cannot be 
ignored. In the final design of the reactor, one would need to determine the optimum 
pH for the blood in order to ensure efficient absorption of heparin. 
4.4.9 Effect of beads on the normal constituents of blood  
To help assess the safety of the beads, the beads were incubated in whole blood for 5 
hours. The blood was added to a tube containing a little heparin tp prevent clotting. 
Measurements of various constituents in blood were taken before and after the 
incubation, to see if any of the important constituents of the blood were affected by 
the beads. The results obtained from the measurements are tabulated in Table 4.7. 
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Table 4.7 Effects of beads on the blood constituents  
CONSTITUENTS READINGS 
BEFORE 
EXPT 
READINGS 
AFTER 
EXPT 
% 
REDUCED 
Serum proteins 63 61 3.17% 
Serum Albumin 40 38 5.00% 
Serum Calcium 2.04 1.89 7.35% 
Serum Cholesterol 3.32 3.26 1.80% 
Serum Creatine 90 85 5.56% 
Serum Urea 5.47 5.26 3.84% 
Serum direct 
bilirubin 
2 2 0.00% 
Serum iron 16.1 15.7 2.48% 
Serum total 
bilirubin 
8 8 0.00% 
Serum HDL 
cholesterol 
1.07 1.06 0.93% 
Serum magnesium 1.31 1.1 16.00% 
Serum 
triglycerides 
0.46 0.44 4.35% 
Serum transferin 1.9 1.82 4.21% 
Serum uric acid 0.17 0.16 5.88% 
CRP 0 0.1 10.0 % 
increase 
Serum phosphate 0.7 0.64 8.57% 
Serum ferritin 58 56 3.45% 
Serum sodium* 163 155 4.91% 
Serum potassium 3.71 3.4 8.36% 
Serum chloride 82 82 0.00% 
Serum glucose 3.1 2.8 9.68% 
*
The amount of sodium in the sample is higher than the normal range due to the sodium heparin present in the sample.  
#
The units of the constituents were not listed on the table since only the relative percentage change was considered to determine 
the effect of the beads on the blood. 
 
The results indicated that there was no significant decrease on any of the important 
constituents of blood. Although, this experiment proves that the beads have no 
influence on the constituents of blood, it is essential that all the necessary safety test 
are performed for the final design of the reactor to ensure that the blood is safe.  
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4.5. DISCUSSION 
The absorption of heparin is not dependent on the total volume (Figure 4.1) or on the 
total surface area (Figure 4.2) of the beads. Figure 4.1 indicated that fewer larger sized 
beads absorbed less heparin than the smaller sized beads. The concentration of sodium 
aliginate did not have an effect on the absorption rate as illustrated in Figure 4.3. 
Beads with no membrane or poly-L-lysine absorbed heparin initially. However the 
heparin was released back into the solution until an equilibrium concentration of 
heparin was attained. The equilibrium concentration of heparin, 2.66 U/mL 
(Figure 4.4), is much higher than 0.028 U/mL obtained using beads with a membrane.  
 
Large beads have thinner membranes, while the small beads have thicker membranes 
(Figure 4.5). The results obtained from the rate experiments implied that the 
absorption of heparin was affected by the membrane thickness (Figure 4.6). The 
absorption of heparin is solely dependent on the poly-l-Lysine content in the beads. 
 
If the volume of the membrane of the beads is known, the value of the rate coefficient 
for a first order absorption model can be estimated using Figure 4.7. The Freundlich 
Isotherm model (Figure 4.8) can also be used to estimate the amount of heparin that 
can be absorbed from the solution. 
 
The membrane thickness definitely increased as the time of exposure of the beads in 
poly-L-lysine solution was increased (Figures 4.9 and 4.10). The results obtained 
from this experiment implied that the thickness of the membrane is directly related to 
the poly-L-lysine and can therefore be controlled by varying the time in which the 
beads are kept in the poly-L-lysine solution. 
 
The results from Figure 4.11 indicated that the beads with more poly-L-lysine coating 
absorbed more heparin than the standard beads. The Poly-L-Lysine coated beads that 
were incubated in saline and the beads with no incubation absorbed almost the same 
amount of heparin. The beads that were incubated in poly-L-lysine removed much 
more heparin, in comparison to the other sets of beads. Controlling the amount of 
  
Chapter 4 Article 2  65 
  
poly-L-lysine in the beads can optimize the absorption of heparin from the saline 
solution. Therefore the membrane thickness of the beads can be altered to absorb 
more heparin. 
 
The beads are efficient at removing heparin from both FCS and human blood 
(Figures 4.12 and 4.13). More heparin is absorbed in blood when compared to saline 
using the same number and volume of beads. The absorption rate is affected by pH 
(Figure 4.14), and there seems to be an optimum pH, however this value has not been 
identified. Table 4.7 indicates that there is no significant decrease in the important 
constituents of blood, which would be an important safety consideration. 
4.6. CONCLUSION 
Poly-L-lysine/alginate beads can efficiently absorb heparin from saline, fetal calf 
serum and blood. The beads also have minimal effects in blood, as the amount of the 
constituents in the blood is not significantly affected. The thickness of the membrane 
of the beads can be adjusted to optimise the absorption process. Heparin absorbs onto 
the poly-L-lysine in the membrane of the beads, therefore increasing the poly-L-lysine 
content in the beads will improve the amount of absorption. Smaller sized beads have 
thicker membranes and therefore absorb more heparin than the larger sized beads. 
Poly-L-lysine/alginate beads can therefore be used in a reactor to absorb heparin 
during extracorporeal procedures. The findings of this article will be highly beneficial 
for the design of the reactor.  
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CHAPTER 5: INVESTIGATION OF THE USE OF POLY-l-
LYSINE/ALGINATE BEADS IN A PACKED BED 
CONFIGURATION FOR REMOVING HEPARIN.  
 
 
The following article will be submitted to the Journal: “Artificial Cells, Blood 
Substitutes and Biotechnology” and is currently being reviewed. This paper 
investigates the feasibility of using poly-l-lysine/alginate beads in a packed bed 
reactor configuration using results obtained from previous batch experiments. 
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5.1. ABSTRACT 
Bioreactor designs that can eliminate heparin during extracorporeal procedures have 
remained a challenge. Reactors developed thus far, including an immobilized 
heparinase I reactor and poly-L-lysine.HBr hollow fiber reactors are not appropriate 
for clinical purposes. Previous work has proved that poly-l-lysine/alginate beads could 
efficiently remove heparin from saline and blood. Necessary batch rate experiments 
were performed in both saline and blood to obtain the information required to design a 
heparin removal reactor using poly-L-lysine/alginate beads. The results are used to 
investigate the feasibility of using a packed bed reactor for the absorption process by 
adjusting the specifications of the reactor and analysing simple flow models.  
 
5.2 INTRODUCTION 
Approximately 20 million extracorporeal blood procedures are performed each year, 
of which between 8 to 30% of bleeding complications arises due to systematic 
heparinisation (University of Michigan1., 2001). Various methods to remove the 
heparin have been explored including the investigation of using various reactors to 
treat the blood prior to returning to the patient. The bioreactor designs can be divided 
into two categories: membrane-based devices, such as hollow fiber cartridges, and 
porous particle devices in the form of packed columns or fluidized beds (Ameer et 
al2., 1999a). Several investigators have bound the protein of interest to the walls of a 
hollow fiber dialyser to enhance the whole blood compatibility of the system, but in 
many cases the surface area requirements remain impractical (Vallar et al3., 1996). 
Others have suggested the use of porous particles such as agarose or cellulose beads, 
in either the packed bed or fluidised bed mode as a way to optimize the protein or 
absorbent loading per volume of device (Gejyo et al4., 1993; Langer et al5., 1982) 
 
The reactors proposed thus far include the following: 
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5.2.1 Immobilized heparinase system 
A novel approach to enable enzymatic elimination of heparin before the blood 
returned to the patient was introduced by Langer et al5., 1982. This approach 
consisted of placing a blood filter containing immobilized heparinase at the stream 
exiting from the extracorporeal device.  
 
 
Figure 5.1: Diagram of the immobilized heparinase system 
  (adapted from Langer et al., 19826) 
 
Fresh blood from dogs was heparinised and passed through the filter at a rate of 
50 mL/min. The filter was placed between two 1-liter blood transfer packs. After the 
entire blood volume from one pack had passed through the filter into the other pack 
(one pass), the packs were disconnected and their positions with respect to the filter 
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were switched. Six passes of the blood were performed and heparin concentrations 
were analysed. There was an 80% loss of heparin after the first pass. After two passes 
90% loss of heparin occurred. According to the author, the heparin products were 
observed to be non-toxic; however there was a 30% decrease in the white blood cells 
count and a 70% decrease in the platelet count. This system therefore required 
modifications to be utilized in clinical processes because of the damage to the blood 
cells. 
5.2.2 Vortex flow fluidised bed reactor (VFFBR) 
Ameer et al., 1999a2 investigated the use of a whole blood fluidised bed Taylor-
Couette flow device for enzymatic heparin neutralization using immobilised 
heparinase. Taylor –Couette flow is the resulting fluid flow found in the gap between 
two infinitely long concentric cylinders, one or both of which are rotating along their 
common axis. Heparinase was immobilised using agarose gel beads (200µm average 
diameter). Immobilization increased the stability of heparinase. 
 
 
Figure 5.2: Diagram of the vortex flow fluidised bed reactor (VFFBR) 
  (adapted from Ameer et al.,1999a2) 
Heparinised blood In  
Heparinised 
blood Out  
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Whole blood entered and exited the device while the agarose was continuously 
recirculated. Taylor-Couette flow together with a “flow induced” recirculation was 
used as a reactor system to fluidise the agarose immobilized heparinase at high flow 
rates. The selected tangential location of the recirculation ports allowed continuous 
flow and fluidisation of the beads without the aid of an external pump. Ninety percent 
of the heparin was removed within 3 min of operation at a flow rate of 100 mL/min. 
However extensive damage to the red cells, white cells and platelets was caused by 
the Taylor vortices. The red cells were ruptured and hemoglobin was released into the 
plasma. Two steps were taken to reduce the damage. The gap width was increased 
(design 2) and the rotation rate was reduced to 200 rpm. Eighty percent of the heparin 
was removed in 3 min and the red cell hemolysis rate was reduced. However for 
clinical blood flowrates, the rotation rates required to maintain good fluidization was 
higher than 200 rpm, which lead to extensive damage to the blood cells. The authors 
felt that the VFFBR required further investigation due to the hemolysis, even though 
the percentage of heparin degradation was high. Their studies suggested that when 
Taylor-Couette flow is combined with macroscopic solid particles such as agarose 
beads, lysis of the red cells becomes an important issue. Further investigations were 
therefore required to eliminate the hemolysis problem. 
5.2.3 Vortex flow plasmapheretic reactor (VFPR) 
A device that simultaneously effected plasma separation and enzymatic reaction to 
minimize blood damage was designed by Ameer et al., 19996. 
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Figure 5.3: Diagram of the vortex-flow Plasmapheretic Reactor (VFPR) 
  (adapted from Ameer et al.,19997) 
 
The reactor consisted of two concentric cylinders and a microporous membrane to 
separate the blood cells from the agarose immobilized heparinase. The outer 
stationary cylinder was counter-bored to accommodate an unsupported microporous 
membrane along the circumference of its inner surface. This set-up created a separate 
annular compartment (reactive chamber) for the agarose immobilized enzyme. A 
second, smaller compartment (plasma-collection chamber) was counter-bored into the 
outer cylinder to accommodate the agarose cylindrical 15-µm-polyester mesh to 
prevent the agarose beads from escaping the device and to minimize the pressure drop 
across the beads in the reactive chamber. A plasma pump was used to force 
convective flow of heparin through the membrane to improve the heparin mass 
transfer from the main annulus into the reactive chamber. The reacted solution was 
recombined into the main annulus of the VFPR. 
 
A 500mL volume of the feed solution, heated to 32OC, was recirculated through the 
circuit at 120 mL/min with the plasma pump adjusted to 60mL/min. The rotation rate 
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of the inner cylinder was set to 1200 rpm. Approximately 20 mL of the immobilized 
heparinase was injected into the reactive chamber of the VFPR and was fluidized. The 
infusion of the heparin pre-reactor was adjusted to achieve clinically relevant heparin-
plasma concentrations (5-12µg heparin/mL plasma). Heparin concentrations were 
measured at the inlet and outlet of the reactor. A mean heparin conversion of 34% in 
blood was observed. According to the authors, a minimum of 40 to 50% conversion of 
heparin is required for a reactor to be efficient, therefore the conversion did not fall 
within the target range; however the data demonstrated the feasibility of using the 
novel design to achieve regional heparinisation with negligible damage to the blood. 
5.2.4 Immobilized Protamine Reactor  
A reactor containing immobilized protamine was developed by Yang et al7 (1991) that 
provided simultaneous extracorporeal heparin removal and protamine treatment. In 
vivo studies indicated that the reactor removed about 50% of the heparin in 10 
minutes. Hemolysis complements were reduced by approximately 10 to 20% while 
there was a significant decrease in platelet and white blood cell counts. 
5.2.5 Hollow Fiber Reactor 
Based on the negative charge density characteristics of heparin, an affinity absorption 
technique was developed for the removal of heparin using poly-L-lysine.HBr that was 
immobilized onto a hollow fiber (Xinghang et al8., 1992). The activity of heparin 
decreased by 85% in 25 minutes and no adverse effects on the blood was observed. 
Clotting was observed to occur within the hollow fibers at low heparin concentrations.  
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The design criteria required for a reactor to remove heparin are as follows: (Ameer et 
al., 19996) 
1. Efficacy:  The average steady state single pass conversion of heparin must be 40  
to 50%. 
2. Safety: There must be no significant effect on whole blood cells such as  
hemolysis, rapid cell and platelet-count reduction, or excessive white 
cell or platelet activation.  
3. Stability: There must be stable operations at flow rates of up to 300 mL/min. 
4. Simplicity: A simple and low cost reactor would be preferred. 
 
The reactors described above do not meet all of the four criteria mentioned above. The 
immobilised heparinase system and the VFFBR had high heparin degradation rates 
but caused damage to the blood cells at high flowrates. The VFPR met the safety 
criteria as very little damage to the blood cells was observed. However the VFPR had 
a low conversion of 34% of heparin. The immobilized protamine reactor had 
significant damage to the white blood cell counts and the platelets. The hollow fiber 
reactor had clotting complications. In order to expand all the above studies and based 
on the batch experiments, it is proposed that the feasibility of using a reactor packed 
with poly-L-lysine beads is investigated.  
 
Previous work has indicated that poly-L-lysine /alginate beads can efficiently remove 
heparin from blood (Varghese et al9., 2006). Furthermore the spherical beads not only 
provide a larger surface area to volume ratio for removing heparin, but also provides 
three-dimensional stability with respect to mechanical stresses (Vally et al10., 2005). 
The beads are also relatively simple to produce at a relatively low cost. A fluidised 
bed or a packed bed reactor would be ideal for the absorption process, as the beads 
would have direct contact with the blood. The use of a fluidised bed reactor was 
investigated for the design of a hybrid liver using the poly-L-lysine/alginate beads 
(Vally et al11., 2005). The fluidized bed reactor was determined not to be feasible as 
the density of the beads was similar to the density of blood thereby providing 
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problems to the fluid flow and resulting in inhomogeneous concentrations through the 
reactor. 
 
This article provides the design of a simple packed bed reactor. Previous work 
indicated that the absorption was a first order process and fitted the Freundlich 
Isotherm (Varghese et al9., 2006). The absorption process depended on the membrane 
thickness and the poly-L-lysine content of the beads (Varghese et al11.,2006). The 
results are used to investigate the feasibility of using a packed bed reactor for the 
absorption process by using simple flow models and fundamental rate based  models 
that can be used on both batch and flow systems.  
 
5.3. REACTOR DESIGN MODELS 
Various models were used previously (Varghese et. al9., 2006 and Varghese et. al11., 
2006) to fit the batch experimental data. As will be discussed below, these models are 
not suitable for use in design of processes in flow reactors. Thus more fundamental 
models are used to analyze the batch data. These models are discussed in Section 
5.3.2.  
 
5.3.1 Models used for the Batch Processes 
Varghese et. al9., 2006 fitted the Freundlich Isotherm to the equilibrium data that was 
obtained from the batch experiments. The Freundlich Isotherm is of form: 
 
mi
eii xkq = ………………………………………………………………Equation 5.1 
where: 
 mi is a constant which is positive and generally not an integer; 
 ki is a constant; 
xe is the fluid phase concentration at equilibrium (concentration of heparin in 
saline solution at infinite time) in U/ml; 
qi is the absorbed phase concentration in U/mL; 
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The Freundlich Isotherm is a commonly used model for analyzing batch data and in 
particular for relating the equilibrium concentrations xe to system parameters. 
However its use for modeling more complex  processes, such as occurs in flow 
systems,  is very limited as in these situations the equilibrium concentration xe is not 
well defined. In a typical system the solid may be in batch mode while the fluid flows 
continuously over the solid. In this case the parameter xe would depend on the history 
of the solid that the fluid is in contact with and would change with time and position 
in the reactor. 
 
Varghese et. al9., 2006 also analysed the time dependent behaviour by fitting the 
experimental data to a simple first order process namely: 
 
)( exxKdt
dx
−=     ………………………………..Equation 5.2 
where: 
 t is the time in seconds; 
 K is the rate coefficient in seconds-1; 
x is the concentration of heparin in the liquid phase in U/mL; 
 
This model was shown to fit the batch data (Varghese et. al9., 2006). Although this 
appears at first glance to be a fairly fundamental model, it is found that different 
experiments were fitted with different values of the rate coefficient K. It was further 
shown that K is proportional to the number of beads and to the total volume of the 
membrane of the beads (Varghese et. al11., 2006). This means that this model is again 
not useful in more complex flow situations as the value of the rate coefficient K as 
well as the equilibrium concentration xe is again not well defined in these situations. 
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5.3.2 Fundamental Models for both Batch and Continuous Absorption 
Processes 
Fundamental rate based absorption models were developed that are applicable in both 
batch and continuous flow systems. The model used is fundamental and is a simple 
rate based model which assumes that the absorption process is reversible. The rate of 
absorption onto the solid is assumed to be proportional to the fluid phase 
concentration and the number of available sites in the solid. The desorption from the 
solid to the fluid phase is assumed to be proportional to the concentration of the solid 
phase. Using this model, one can propose the following rate equation: 
 
y
V
V
kyy
V
V
xkr
x
y
x
y
21 )( −−= Θ …………..…………………………………Equation 5.3 
 
where: 
 r is the rate of reaction or absorption per volume of liquid in U/(mL sec); 
 k1 is the rate constant for the  process in mL/U sec; 
k2 is the rate constant for the desorption process in 1/sec; 
x is the concentration of heparin in the liquid phase in U/mL; 
 y is the concentration of heparin in the solid phase in U/mL; 
 yΘ is the capacity of the bead per volume of bead membrane in U/mL; 
Vx is the volume of liquid in mL; 
Vy is the volume of solid (total volume of membrane of the beads) in mL. 
 
In this model the parameter yΘ is assumed to be fixed for a given solid and hence is 
the same in both batch and continuous flow systems. The above rate equation has 
been fitted to a wide range of experimental results in other absorption processes and 
has given a good fit for both batch and continuous data (Williams, D. F. et. al15., 
1985). This model is a two-parameter model (k1 and k2) and as before the parameters 
are fitted by using the batch experimental data.  
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5.3.3 Model simplifications for Batch systems at Equilibrium (Infinite 
Time)  
The Freundlich Isotherm was previously shown (Varghese et al9., 2006) to fit the 
batch equilibrium data. It is therefore necessary that the proposed rate based model 
simplifies at equilibrium to a form that fits the batch experimental data.  
 
It was experimentally found that when beads loaded with heparin were placed in 
saline solution; the heparin concentration in the saline solution was negligible, 
implying that the heparin absorption was fairly irreversible. This implies that the 
proposed fundamental rate model can be simplified by assuming that k2 ≈0.  
 
The fundamental rate equation (equation 5.3), with the simplification of k2=0, has two 
terms that could tend to zero at equilibrium, namely x and (yΘ -y).  These two 
scenarios will be examined separately.  
i) The concentration of heparin in the liquid phase, x, becomes zero. In this case 
the equilibrium concentration of heparin in the solid phase is not equal to the 
capacity of the beads per volume of bead membrane ( Θ≠ yye ), that is the 
beads have not been fully loaded yet. 
ii) The term (yΘ -y) becomes zero.  In this case the concentration of heparin in the 
liquid phase, x, is not zero and has attained an equilibrium value ( exx = ). The 
beads are fully loaded in this situation and therefore Θ= yye . 
 
If the results obtained from the batch experiments, Figure 3.8 (Varghese et al9., 2006) 
are observed, it is clear that for the two experiments with the smaller  number of beads 
( that is 848 and 1696 beads), the liquid concentration of heparin, x,  at equilibrium is 
non zero.  Thus the liquid concentration is approaching an equilibrium value, xe≠0, 
and therefore ye can be assumed to be yΘ.  As the number of beads increases (the 
experiments with 3650 and 8000 beads), the liquid concentration of heparin, x, 
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approaches zero.  At equilibrium the beads are not fully loaded and therefore 
Θ≠ yye . 
For the smaller number of beads where the beads are fully loaded at equilibrium and 
0≠ex  the fundamental rate equation at equilibrium is: 
 
0)(1 =−Θ ee
x
y yyx
V
V
k     …………………………..…Equation 5.4 
 
which simplifies to: 
 
eyy =
Θ
     ……………………………..Equation 5.5 
 
The mass balance is: 
 
yVxxV yeox =− )(     ……………………………..Equation 5.6 
 
which simplifies at equilibrium to: 
 
)( eo
y
x
e xxV
V
yy −== Θ     ……………………………..Equation 5.7 
 
Using the results of the 848 beads and 1696 beads in Equation 5.7 the average value 
of yΘ is estimated to be 1004 U/mL, (see Table 5.1) 
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Table 5.1:  Estimated values of  yΘ from equilibrium data. 
 No of beads Equilibrium 
concentration xe 
U/mL 
Estimated yΘ 
 
U/mL 
Experiment  1 848 2.23 929 
Experiment 2 1696 1.33 1079 
Average   1004 
 
5.3.4 Model predictions of Concentration versus Time for Batch 
Systems  
A more stringent test of the proposed rate based model is to see how well it fits the 
batch data at times other than equilibrium. In order to do this the rate based model will 
be fitted to the results obtained previously by Varghese et al9., 2006 for batch 
absorption systems. 
 
Assuming that k2 is negligible, the fundamental rate equation, r, becomes: 
 
)(1 yyV
V
xkr
x
y
−=
Θ
    ……………………………..Equation 5.8 
 
Substituting the mass balance (Equation 5.6) in Equation 5.8 and simplifying: 
 
)(1 xaxkr +=      ……………………………..Equation 5.9 
 
Where 0xyV
V
a
x
y
−=
Θ
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For the batch absorption process: 
 
)(1 xaxkrdt
dx
+==     …………………………..Equation 5.10 
 
Integrating Equation 5.10 and simplifying, the following equation is obtained: 
 






+
+
−=
xxa
xxa
a
kt )(
)(ln1
0
0
   …………………………..Equation 5.11. 
 
A graph of 





+
+
−
xxa
xxa
a )(
)(ln1
0
0
 versus time, t, should yield a straight line passing 
through the origin with a slope of the rate constant, k1. 
 
The experimental results obtained previously for the batch absorption experiments 
(Varghese et al9., 2006) are fitted and shown in Figure 5.4. Since the ln term is 
sensitive at small values of the term in the parenthesises, small experimental errors in 
the value of the liquid concentration at low rates will cause a large deviation to the 
value of the ln term.  Liquid concentrations of above 70% conversions were thus not 
used in to fit the value of k1.  
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Figure 5.4 Graph to obtain k1, parameter of the fundamental rate based equation 
 
From Figure 5.4, it can be seen that all four sets of data fit the model all the data falls 
on a straight line and importantly all the data fits the same slope.  One can therefore 
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have confidence in the model and from the slope one can estimate the rate constant, 
k1, to be –0.0006 mL/U sec. 
 
5.3.5 The Effect of Blood and Fetal Calf serum (FCS) on the parameters 
of the rate equation 
The data for the absorption of heparin in FCS and blood can also be analyzed to try to 
understand how these substances affect the performance of the beads. Assuming that 
the capacity of the beads, yΘ, is the same value as that obtained for saline (yΘ = 1004 
mL/U sec) and using the results obtained from Figure 4.13(Varghese et. al11., 2006), 
the data is fitted for blood and FCS and the results are tabulated in Table xx.  
 
 
Table 5.2 Comparison of values of k1 for saline, FCS and blood 
 k (mL/Usec) 
Saline -0.0006 
FCS -0.0024 
Blood -0.0039 
 
It should be noted that the data for blood and FCS are limited as only one experiment 
was performed, however the general effect can be noted from the above results and it 
is clear that the rate constant value is the greatest for blood. The absorption rate is 
therefore sensitive to the type of fluid used and the pH as stated previously (Varghese 
et. al11., 2006).  
5.3.6 Model Testing 
One can compare the experimental data to the model by using the values of the 
parameters estimated previously in the fundamental rate model. One can compare the 
measured equilibrium concentration of heparin in the liquid phase with those 
predicted by the model. 
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Figure 5.5 Comparison of predicted and measured equilibrium concentration 
 
The results indicate that the fundamental rate model predicts the measured 
equilibrium concentration data well. 
 
The concentrations of heparin in the liquid phase at a particular time can be predicted 
by simplifying Equation 5.11 and obtaining the following equation: 
 
b
ax
x 0=       …….……………Equation 5.12 
 
where  
00 )exp()( xktaxab −−+=  and 0xyV
V
a
x
y
−=
Θ
 
The predicted results are compared with the measured results obtained previously 
from the batch experiments of saline and is shown in Figure 5.6. 
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Figure 5.6: Comparison of predicted and measured concentrations of heparin 
 
The results indicate that the fundamental rate model can be used to predict the results 
for a batch process in saline relatively well, with the exception of the 3650 beads, 
which may be attributed to experimental error and may require further investigation in 
future. 
 
5.3.7 Using the Fundamental Rate Based Model to predict the 
Performance of a Continuous Reactor 
In a batch process, all the reactants are added in the beginning, the reaction is allowed 
to proceed and samples are withdrawn to obtain the compositions that change with 
time until the reaction is completed or stopped when the required conversion has been 
reached. In a flow process, the reactants are fed into the reactor continuously and 
products are withdrawn continuously. A packed bed reactor with a reasonably low 
pressure drop would be the ideal choice for a continuous reactor as minimum damage 
is expected to the blood cells since the shear stresses would be small if pressure drop 
was low.  An added advantage is that there are no mechanical moving parts within the 
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reactor which also eliminates possible damage to the blood cells. Blood containing 
heparin can be allowed to flow through a packed bed reactor filled with poly-L-
lysine/alginate beads. It is proposed that such a reactor can be designed to achieve the 
required absorption of heparin within the reactor. 
 
The next step is therefore to predict the performance of a continuous reactor using the 
information from the batch experiments. Since the aim of this prediction is to check if 
the option of a reactor packed with beads is feasible to remove heparin in a flow 
process, one can test this theoretically by using a very simplified reactor model. A 
model is required for both the liquid and solid phases in this case. One can assume 
that the change in concentration of heparin in the solid phase is slow in comparison to 
that in the liquid. As a result of the different time constants of the two phases one can 
use a pseudo-steady state model in that one can assume that the liquid phase at any 
time is approximately at steady state, but that the concentration in the liquid phase 
will change slowly with time. 
 
 The simplest model that characterises the major features of a flow reactor is: 
• Liquid phase:  as the liquid concentration changes slowly with time, it is 
proposed that a simple CSTR model  be used  for initial screening.  Under this 
assumption, the liquid concentration in the device is uniform. Further more 
under this assumption the concentration of heparin in the liquid flowing out of 
the reactor is the same as that in the reactor. The exit concentration (and hence 
the concentration in the reactor) will change with time as the beads in the 
reactor become loaded.  
•  Solid phase: the solid is in batch mode and it is assumed that the 
concentration of the solid is uniform in the reactor. Thus the solid 
concentration is characterised by a single value that is time dependent.  
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where: 
 Q is the volumetric flow rate of liquid in mL/min and is constant; 
 x is the concentration of heparin in liquid in the reactor as well as in the exit 
stream from the reactor in U/mL. This value will change with time. 
xo is the concentration of heparin in liquid in the feed to the reactor in U/mL 
and is constant. 
Vx is the holdup or volume of liquid within the reactor  
y is the concentration of heparin in the solid phase and will change with time. 
Vy is the volume of solid (membrane) within the reactor. 
 
The mass balance for heparin in the liquid phase is as follows: 
 
xo rVQxQx =−   ……………………………………..……..Equation 5.13 
 
One can use the fundamental rate model in the continuous case and very importantly, 
the values of the parameters k1 and yΘ that was obtained by fitting batch data can be 
used in the continuous reactor model. As was stated previously, the  process is nearly 
irreversible and thus it can be assumed that k1 is much larger than k2. The fundamental 
rate model, Equation 5.2, simplifies in this case to:  
 
( )yyx
V
V
kr
x
y
−=
Θ
1 …………………………………………………….....Equation 5.14 
 
 
 
Substituting the rate model (Equation 5.14) into the liquid phase mass balance 
(Equation 5.13) gives: 
 
Vx 
Vy 
 
Qxo 
 
Vy y 
Qx 
  
Chapter 5 Article 3  88 
  
)(1 yyxkxx so −=− Θτ  ………………………………………………….Equation 5.15 
where: 
τS is a residence time like constant for the beads within the reactor and is equal 
to (Vy/Q) in sec. 
 
The mass balance of heparin in the solid phase is as follows: 
 
QxQx
dt
dyV oy −=      …………………....Equation 5.16 
 
which simplifies to 
 
)(1 xx
dt
dy
o
s
−=
τ
     …………...……….Equation 5.17 
 
The initial condition from Equation 5.17 is that at t=0, y =0. 
 
Equations 5.15 and 5.17 can be solved simultaneously to obtain the trends of the 
concentration change of heparin within the reactor. The values of k1 and yΘ used are 
those determined for saline from the batch experiments. There is only one parameter 
that the designer is free to chose, namely τs. 
 
The subsequent sections look at the sensitivity of the model to the value of the 
parameter τs and in particular investigates if there is a value of the parameter where 
the reactor can satisfy the specifications.  
 
5.3.8 Reactor Specifications 
In section 5.2.5, the following criteria were given for a reactor to remove heparin: 
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1. Efficiency: A per pass conversion of 40 to 50 % was specified. This is thus a 
criterion that can be used in sizing the reactor. Low15 et al., 1996 states that a 
40 to 70 % conversion is required; therefore a range of 40 to 70% conversion 
will be used to size the reactor. 
2. Safety: No significant effect on whole blood cells should be observed, 
therefore a simple packed bed reactor will be considered to minimize the 
damage that could be incurred on the cells by additional requirements such as 
stirring. 
3. Stability: Stable operation at flowrates up to 300 ml/min is specified. This 
flowrate can be used as a design criterion. For kidney dialysis the range of 
flowrate of blood is between 250mL/min and 500mL/min (Renal Unit, 
Johannesburg Hospital. Therefore a flowrate of 300mL/min will be considered 
as a design criterion. 
4. Simplicity: The reactor proposed is fairly simple, the most expensive part of it 
is are the beads. The proposed design is therefore believed to meet this 
criterion. 
 
From these the following specifications could be made:  
 
• It was assumed that the inlet concentration of heparin in the liquid flowing into 
the reactor was constant at 1U/mL.  
 
• The reactor must therefore be sized that the outlet concentration of heparin lies 
between 0.60 U/mL (40% conversion) and 0.40 U/mL (60% conversion). If 
necessary this criteria could be relaxed as Low15 et al.,1996 specify that the 
exit concentration of heparin in blood/saline must be in the range of 0.3U/mL 
(corresponding to 70 % conversion) to 0.6 U/mL (corresponding to 40% 
conversion) to avoid clotting within the reactor. 
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• The volume of blood in the reactor cannot exceed 150 mL as this is a clinical 
specification to minimize hemodilution of the patient. (Ameer2 et al., 1999a). 
Thus the value of Vx must be equal to or less than 150 mL. 
 
• An operating time of more than four hours is preferred for the reactor as the 
usual dialysis treatment lasts for approximately four hours. This will allow for 
simplicity of operation in that unit would not need to be changed during the 
treatment.  
 
5.3.9 Reactor Absorption Behaviour 
Equations 5.15 and 5.17 were solved using polymath and a graph of the exit liquid 
concentration x versus time for various values of the parameter τs is given in Figure 
5.7. The values of k1 = -0.0006 mL/U sec and yΘ = 1004 U/mL used are those 
determined for saline from the batch experiments. The operating range for the reactor 
to meet specifications is also shown in Figure 5.7. Thus the lines corresponding to 40 
and 70 % conversion of heparin are shown. The reactor should operate between these 
limits. The time constraint of 4 hours is also shown. Thus the curves which lie within 
this region satisfy the reactor specification. It can be seen that there is no curve which 
lies within the operating region for a full 4 hours.   
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Figure 5.7:  Reactor Absorption Behaviour for Saline 
 
It can be seen that Equation 5.15 can be used to estimate the value of τs such that the 
liquid leaving the reactor initially has a 70 % removal of heparin: 
 
 
 
 
It can be seen that the curve corresponding to  τs =3.88 sec  meets the upper limit of 
conversion at 70% and at 4963 sec, corresponding to 1.4 hours,  reaches a conversion 
of  40 % and therefore would no longer meet the design criteria. 
 
One can therefore conclude that a packed bed would meet the design specifications 
for 1.4 hours and thus if longer operating times where required, the packed bed would 
need to be replaced every one and a half hours.  To see if this is feasible, the 
following should be considered: sizing the reactor and estimating the number of beads 
required and more importantly the volume of blood in the reactor. 
 
( )
sec88.3
3.0
13.0
1
=
−
= Θykx
x
o
o
sτ
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The volume of membrane Vy required can be estimated using the volumetric flowrate 
of 300 ml/min and τs =3.88 sec from: 
QV sy τ=       …………...……….Equation 5.18 
 
The total volume of membrane that is required is 19.4 mL. 
 
 
The number of beads N required can therefore be estimated from: 
 
)(
3
4 33
inouty rrNV −= pi      …………...……….Equation 5.19 
where  
rout is the outer radius of the bead and  
rin is the inner radius of the bead. 
 
If the outer and inner radius of the beads is used as that of the batch experiments, 
rout = 0.00045m and rin = 0.000436m it can be seen that 561849 beads are required.  
 
 
The reactor volume Vr can be estimated for a packed reactor of voidage ε =0.4 from: 
)1(
)
3
4( 3
ε
pi
−
=
rN
Vr      …………...……….Equation 5.20 
 
The volume of the reactor is thus estimated to be 357 mL. The priming volume of 
blood is εVr and is in the range of 143 mL. 
 
According to Ameer2 et al., 1999a the volume of the reactor cannot exceed 150 mL to 
minimize hemodilution of the patient. Previous work indicated that as the thickness of 
the membrane of the beads is increased the amount of heparin absorbed would 
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increase. The effect of membrane thickness on the volume of the reactor can be 
investigated and this is shown in Figure 5.8. 
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Figure 5.8: Effect of membrane thickness on the reactor volume 
 
In order to satisfy the criterion of minimising hemodilution, from the graph the 
membrane thickness should be increased from 1.4*10-5m to 3.5*10-5m. The 
specifications for the proposed reactor would therefore be as in Table 5.3. 
 
Table 5.3: Proposed Reactor Specifications for Saline 
 Reactor Specifications 
Time like variable (τs) 3.88 sec 
Volume of membrane (Vy) 19.4 mL 
Number of beads (N) 235676  
Volume of Reactor (Vr) 150 mL 
Priming blood volume (Vb) 60 mL 
Operating Time 1.4 hours 
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Thus the reactor meets the specifications given previously. It should be noted that the 
values of k1 could change if the membrane of the beads is altered; therefore further 
experiments are required to determine the exact values.  
 
Using the results obtained from the blood experiment, where the values of k1 = -
0.0039 mL/Usec
 
and yΘ = 1004 U/mL, and solving Equations 5.15 and 5.17, the graph 
of the exit liquid concentration x versus time for various values of the parameter τs is 
given in Figure 5.9. The results indicate that τs must be 0.6 sec and must be replaced 
every 12 minutes in order to meet the required specifications. Therefore for the 
duration of the dialysis treatment of 4 hours, at least 20 packed bed reactors/cartridges 
would be required. The blood results were based on limited data, thus further 
experiments will be required to confirm the results, however from the experiments the 
absorption in blood appears to be a lot faster, the reactor should therefore be designed 
to meet the saline specifications. This can be easily achieved in blood by introducing 
mass transfer effects to slow down the absorption process. The beads can be coated 
with an inert substance or the membrane can be made thicker using sodium alginate to 
reduce the absorption by poly-L-Lysine. In this way the effect of the rate constant will 
be decreased and the number of cartridge changes could be limited. 
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Figure 5.9:  Reactor Absorption Behaviour for Blood 
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The final check that one can do at this stage is to estimate the pressure drop across the 
reactor.  
5.3.10 Pressure drop within the Reactor 
Another important consideration of the reactor design is the pressure drop across the 
reactor. The pressure drop must be as low as possible within the reactor to avoid 
frictional losses and hence possible damage to the blood. 
 
The pressure drop can be estimated using the Blake –Kozeny equation as follows: 
 








−
=∆ 32
2)1(150
ε
εµ
p
o
D
Lu
P    …………………..……… Equation 5.21 
 
where: 
∆P is the pressure drop in Pa. 
µ is the viscosity of blood in kg/ms. The viscosity of blood from literature is 
2.72 centipoise. 
L is the length of the reactor in m. 
uo is the velocity of the blood through the reactor (based on reactor cross 
sectional area) in m/s. 
ε is the voidage (0.4 for spherical particles). 
Dp is the diameter of the beads in m (Range between 800µm and 2000µm). 
 
The velocity of the blood through the reactor is calculated as follows:  
A
Q
uo =  …………………….……………..Equation 5.22 
 
where: 
Q is the flowrate of blood through the reactor in m3/sec.  
A is the area of the reactor in m2. 
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It is known from our previous calculations that the volume of the reactor Vr = 150 ml. 
Furthermore Vr =AL and hence the cross sectional area and length of the reactor are 
related. Equation 5.21 can thus be rewritten as follows: 
 








−
=∆ 322
2)1(150
ε
εµ
p
r
DA
QV
P     ………………………..Equation 5.23 
 
One can look at the upper and lower limits on the cross sectional area of the device 
and compute the pressure drop across the reactor for all reasonable (i.e. between the 
upper and lower limits) dimensions.  
 
 The minimum cross sectional area Amin would typically correspond to a device with a 
diameter equal to 10 particle diameters Dp, i.e. 
 
2
min )5( pDA pi=       …………………………..Equation 5.24 
  
The maximum cross sectional area Amax would roughly correspond to a unit where the 
diameter D and length were equal. Thus 
 
DDVr )4(
2pi
=       ………………………..Equation 5.25 
And  
 
)
4
(
2
max
DA pi=       ………………………..Equation 5.26 
 
The Ergun equation can be solved between these limits and the possible range of 
pressure drops in the device can be estimated. The results for saline and blood are 
indicated in Table 5.4. 
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Table 5.4: Pressure Drop Results for Saline and Blood 
 
 Volume of 
Reactor 
(mL) 
Minimum 
Area of 
Reactor 
(m2) 
Maximum 
Pressure 
(kPa) 
Maximum 
Area of 
Reactor 
(m2) 
Minimum 
Pressure 
(Pa) 
Saline 150 6.36*10-5 525 0.31 0.022 
Blood 150 6.36*10-5 193 0.041 0.44 
 
 For the estimated Vr = 150 mL, the minimum area of 6.36*10-5 m2 yields a pressure 
drop of 525 kPa, while the maximum area of 1.69 m2 yields a pressure drop of 0.022 
Pa. The typical pressure drop across a haemoperfusion device, such as a dialysis 
machine is about 13.33 kPa (100mmHg).  Therefore the reactor can be designed for a 
pressure drop of 10 kPa with an area of 4.61*10-4m2.  
 
From Equation 5.23, as the diameter of the beads increases, the pressure drop 
decreases. However increasing diameters may introduce diffusional limitations in the 
absorption process. From the batch experiments (Varghese et al11., 2006) it was 
shown that beads with the smaller diameter absorbed more heparin than the larger 
beads. It was also shown that the smaller beads had a thicker poly-L-lysine membrane 
therefore increasing the quantity of heparin absorbed. However as the bead sizes 
decrease a wider size distribution is obtained during the production. A wider 
distribution of sizes will result in an increased pressure drop across the reactor. This 
trend needs to be taken into consideration when designing the reactor and a balance 
between pressure drop and capacity will need to be made in deciding on the optimal 
bead size. 
 
The flow rate of the blood will also affect the pressure drop within the reactor. As the 
flow rate decreases the pressure drop will decrease. If this device is used in series with 
existing devices such as the dialysis machine, then the flowrate through the device 
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will be set by these and thus is not a design variable. The designer however can 
choose the diameter of the device, and hence the velocity of the liquid phases in the 
device. A larger diameter of the device will lead to the lower liquid phase velocities 
and hence lower the pressure drops across the device. Again the designer will need to 
balance reduced pressure drop against efficient solid- liquid contact when choosing a 
suitable diameter. 
5.4. CONCLUSION  
The experiments and estimations have indicated that a reactor with poly-L-lysine 
beads is a feasible option to absorb heparin from extracorporeal procedures. The 
reactor should be designed to meet the saline specifications. Using an exit stream for a 
flowrate of 300 ml/min, a voidage of 0.4 and a reactor volume of 150 mL for saline, 
235676 beads are required. The area of the reactor should be 0.31 m2 in order to limit 
the pressure drop and should be replaced every one and a half hours.  
 
A packed bed reactor would also be simple, relatively cheap and easy to operate. All 
the required specifications that are 40 to 70% conversion of heparin, safety (minimum 
damage to blood cells) stable flowrate of 300mL/min and simplicity are achieved by 
the proposed reactor configuration. The reactor should be tested experimentally in a 
flow process to determine the optimum parameter values.  
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Chapter 6: CONCLUSION 
 
 
The study indicates that heparin can be efficiently removed from saline, fetal calf 
serum and blood using poly-L-lysine/alginate beads.  
 
Article 1 indicates that the absorption process is a first order irreversible process and 
the data fits the Freundlich Isotherm. The amount of heparin absorbed can be 
increased by increasing the number of beads in a sample solution. 
 
Article 2 illustrates that the beads have minimal effect on the constituents of human 
blood. The thickness of the membrane can be adjusted to optimize the absorption 
process. The thicker the membrane, the more heparin is absorbed. The amount of 
heparin absorbed can also be increased by increasing the poly-L-lysine content of the 
beads. The smaller beads are more efficient because of their thicker membranes.  
 
Article 3 indicates that a reactor with poly-L-lysine beads is a feasible option to 
absorb heparin from extracorporeal procedures. The number of beads or reactive sites 
should be selected to ensure the adequate absorption of heparin to prevent clotting 
within the reactor but allow clotting once the blood returns back to the patient. The 
ideal configuration would be to replace a packed bed reactor/cartridge every one and a 
half hours during the dialysis process. 
 
This study indicates that poly-L-lysine/alginate beads could be used to design a novel 
reactor. The reactor and bead parameters could be altered to optimize the absorption 
process. The reactor design provides an efficient, simple and user friendly option of 
extracting heparin from extracorporeal systems. Further investigation using a flow 
process for the proposed reactor configuration, more experiments using blood and 
clinical trials are recommended to optimize the design and to limit all possible 
problems that may arise during extracorporeal procedures. 
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APPENDICES 
 
 
Appendix A  Data for Chapter 2: Apparatus and methods  
Appendix A1 Calibration 
 
 
Concentration in U/mL 
 
 
Absorbance 1 
 
Absorbance 2 
0.00 0.0000 0.0000 
0.75 0.0253 0.0254 
1.50 0.0490 0.0481 
3.00 0.0927 0.0947 
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Appendix A2 Solutions used in the formation of poly-l-Lysine/alginate beads 
 
4% Sodium alginate solution (500 mL) 
Sodium alginate  20g 
Sodium chloride  2.25g 
 
100 mM Calcium chloride solution (500 mL) 
100 mM Calcium chloride 7.35g 
10mM HEPES  1.19g 
20mM Fructose  1.8g 
 
50mg% Poly-L-Lysine solution (500mL) 
Poly-L-Lysine   0.25g 
Sodium chloride  4.25g 
10 mM HEPES  1.19g 
20mM Fructose  1.8g 
 
0.2% Sodium alginate solution (500 mL) 
Sodium alginate  1g 
Sodium chloride  4.25g 
10 mM HEPES  1.19g 
20mM Fructose  1.8g 
 
50 mM Sodium citrate solution (500mL) 
Sodium citrate  7.35g 
Sodium chloride 4.25g 
20mM Fructose 1.8g 
 
 
 
  
Appendices               104 
  
Appendix A3 Efficiency of the 900 µL pipettes 
 
Measured mass in g Expected mass in g 
0.8935 0.9 
0.8937 0.9 
0.8947 0.9 
0.8945 0.9 
0.8957 0.9 
0.8956 0.9 
0.897 0.9 
0.8968 0.9 
0.8973 0.9 
0.8957 0.9 
 
Appendix A4 Efficiency of the 100 µL pipettes 
 
Measured mass in g Expected mass in g 
0.0976 0.1 
0.0974 0.1 
0.0976 0.1 
0.0973 0.1 
0.0981 0.1 
0.0979 0.1 
0.0979 0.1 
0.0979 0.1 
0.0979 0.1 
0.0979 0.1 
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Figure A4.1 Curve of the expected mass of water versus the weighed mass of water 
for a 100 µL pipette 
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Appendix B  Data for Chapter 3: Efficiency of Polymer Beads in the 
Removal of Heparin 
Appendix B1 Figure 3.4 Results 
 
  
8000 900 µm 
beads 
  
  
Time Conc 1 Conc 2 
Ave 
Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.572 2.572 2.572 0.0000 
30 2.320 2.326 2.323 0.0042 
70 2.137 2.139 2.138 0.0014 
120 1.859 1.851 1.855 0.0057 
330 0.991 0.989 0.990 0.0014 
600 0.436 0.437 0.437 0.0007 
930 0.124 0.128 0.126 0.0028 
1200 0.058 0.058 0.058 0.0000 
5160 0.035 0.038 0.037 0.0021 
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Appendix B2 Figure 3.5 Results 
 
  Experiment 1     
Time Conc 1 Conc 2 
Ave 
Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.914 2.908 2.911 0.0042 
30 2.652 2.638 2.645 0.0099 
60 2.634 2.629 2.632 0.0035 
120 2.568 2.560 2.564 0.0057 
300 2.418 2.450 2.434 0.0226 
608 2.164 2.163 2.164 0.0007 
1210 1.694 1.711 1.703 0.0120 
1800 1.339 1.345 1.342 0.0042 
5400 1.343 1.326 1.335 0.0120 
     
  Experiment 2     
Time Conc 1 Conc 2 
Ave 
Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.915 2.907 2.911 0.0057 
30 2.653 2.649 2.651 0.0028 
60 2.613 2.635 2.624 0.0156 
120 2.555 2.558 2.557 0.0021 
300 2.468 2.473 2.471 0.0035 
608 2.168 2.109 2.139 0.0417 
1210 1.748 1.751 1.750 0.0021 
1800 1.442 1.426 1.434 0.0113 
5400 1.345 1.321 1.333 0.0170 
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  Experiment 3     
Time Conc 1 Conc 2 
Ave 
Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.824 2.818 2.821 0.0042 
30 2.826 2.814 2.820 0.0085 
60 2.741 2.726 2.734 0.0106 
120 2.634 2.630 2.632 0.0028 
300 2.438 2.449 2.444 0.0078 
608 2.025 2.022 2.024 0.0021 
1210 1.778 1.769 1.774 0.0064 
1800 1.406 1.401 1.404 0.0035 
5400 1.345 1.339 1.342 0.0042 
     
  Experiment 4     
Time Conc 1 Conc 2 
Ave 
Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.823 2.824 2.824 0.0007 
30 2.829 2.810 2.820 0.0134 
60 2.735 2.731 2.733 0.0028 
120 2.637 2.634 2.636 0.0021 
300 2.441 2.443 2.442 0.0014 
608 2.022 2.026 2.024 0.0028 
1210 1.769 1.775 1.772 0.0042 
1800 1.406 1.402 1.404 0.0028 
5400 1.349 1.343 1.346 0.0042 
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Appendix B3 Figure 3.6 Results 
 
  No Beads     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 3.000 3.000 3.000 0.000 
30 2.893 2.886 2.889 0.005 
70 2.925 2.925 2.925 0.000 
120 2.950 2.950 2.950 0.000 
330 2.943 2.943 2.943 0.000 
600 2.950 2.950 2.950 0.000 
930 2.943 2.943 2.943 0.000 
1200 2.950 2.950 2.950 0.000 
5160 2.950 2.950 2.950 0.000 
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Appendix B4 Figure 3.7 Results 
 
  8000 beads   
Time Con    
sec U/mL ln (C-Cinf) 
0 2.57 0.93 
30 2.32 0.83 
70 2.14 0.74 
120 1.86 0.60 
330 0.99 -0.05 
600 0.44 -0.92 
930 0.13 -2.42 
1200 0.06 -3.84 
5160 0.04   
   
  850 beads   
Time Conc    
sec U/mL ln (C-Cinf) 
0 2.91 -0.39 
30 2.81 -0.54 
60 2.75 -0.65 
120 2.75 -0.66 
300 2.58 -1.07 
608 2.45 -1.53 
1210 2.30 -2.71 
1800 2.25 -4.14 
5400 2.23   
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Appendix B5 Figure 3.8 Results 
 
Number of beads K-value 
848   
1696 -0.0014 
3650 -0.0023 
8000 -0.0039 
 
Appendix B6 Figure 3.9 Results 
 
Number of beads K-values 
0 0 
848 -0.002 
1696 -0.0014 
3650 -0.0023 
8000 -0.0039 
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Appendix B7 Figure 3.10 Results 
 
Data for 25oC 
 
  850 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.911 2.907 2.909 0.0028 
30 2.809 2.813 2.811 0.0028 
60 2.753 2.753 2.753 0.0000 
120 2.746 2.748 2.747 0.0014 
300 2.574 2.576 2.575 0.0014 
608 2.447 2.447 2.447 0.0000 
1210 2.295 2.300 2.298 0.0035 
1800 2.245 2.249 2.247 0.0028 
5400 2.237 2.225 2.231 0.0085 
     
  
        1700 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.911 2.909 2.910 0.0014 
30 2.665 2.635 2.650 0.0212 
60 2.625 2.614 2.620 0.0078 
120 2.561 2.559 2.560 0.0014 
300 2.470 2.470 2.470 0.0000 
600 2.138 2.141 2.140 0.0021 
1200 1.748 1.751 1.750 0.0021 
1800 1.432 1.428 1.430 0.0028 
5400 1.331 1.333 1.332 0.0014 
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  3650 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.961 2.959 2.960 0.0014 
30 2.459 2.462 2.461 0.0021 
60 2.401 2.399 2.400 0.0014 
120 2.090 2.090 2.090 0.0000 
300 1.730 1.730 1.730 0.0000 
600 1.042 1.038 1.040 0.0028 
1200 0.450 0.450 0.450 0.0000 
1800 0.270 0.270 0.270 0.0000 
3645 0.302 0.304 0.303 0.0014 
     
  8000 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.572 2.572 2.572 0.0000 
30 2.320 2.326 2.323 0.0042 
70 2.137 2.139 2.138 0.0014 
120 1.859 1.851 1.855 0.0057 
330 0.991 0.989 0.990 0.0014 
600 0.436 0.437 0.437 0.0007 
930 0.124 0.128 0.126 0.0028 
1200 0.058 0.058 0.058 0.0000 
5160 0.035 0.038 0.037 0.0021 
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Data for 37oC 
 
  700 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.750 2.758 2.754 0.0052 
30 2.743 2.739 2.741 0.0026 
60 2.294 2.291 2.293 0.0026 
150 2.181 2.181 2.181 0.0000 
300 2.032 2.035 2.034 0.0026 
600 1.729 1.696 1.713 0.0232 
1200 1.711 1.696 1.704 0.0103 
1800 1.445 1.441 1.443 0.0026 
3615 1.419 1.423 1.421 0.0026 
     
  
        1000 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.750 2.743 2.747 0.0052 
30 2.473 2.477 2.475 0.0026 
60 2.287 2.276 2.282 0.0077 
150 2.119 2.116 2.118 0.0026 
300 1.973 1.966 1.970 0.0052 
600 1.849 1.853 1.851 0.0026 
1200 1.466 1.470 1.468 0.0026 
1800 0.992 0.985 0.989 0.0052 
3615 0.956 0.999 0.978 0.0310 
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  1820 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.941 2.911 2.926 0.0208 
30 2.820 2.859 2.839 0.0278 
60 2.816 2.817 2.817 0.0000 
150 2.718 2.784 2.751 0.0462 
300 2.388 2.404 2.396 0.0116 
600 1.852 1.835 1.843 0.0116 
1200 1.155 1.174 1.165 0.0139 
1800 0.765 0.779 0.772 0.0093 
3615 0.507 0.501 0.504 0.0046 
     
  2240 beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.883 2.879 2.881 0.0029 
30 2.875 2.883 2.879 0.0057 
60 2.791 2.787 2.789 0.0029 
150 2.762 2.762 2.762 0.0000 
300 2.303 2.299 2.301 0.0029 
600 1.061 1.053 1.057 0.0057 
1200 0.746 0.754 0.750 0.0057 
1800 0.262 0.250 0.256 0.0086 
5400 0.262 0.250 0.256 0.0086 
 
  
Appendices               116 
  
Appendix C  Data for Chapter 4: Investigating Absorption in Saline, Fetal 
Calf Serum and Blood 
Appendix C1 Figure 4.1 Results 
 
  848 2mm beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.872 2.912 2.892 0.02818 
35 2.842 2.905 2.874 0.04461 
60 2.866 2.862 2.864 0.00235 
120 2.826 2.816 2.821 0.00704 
305 2.653 2.690 2.671 0.02583 
600 2.434 2.437 2.436 0.00235 
1247 1.986 1.989 1.987 0.00235 
1800 1.707 1.703 1.705 0.00235 
6120 1.478 1.471 1.474 0.00470 
     
  
8000 900 µm beads 
      
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.572 2.572 2.572 0.00000 
30 2.32 2.326 2.323 0.00420 
70 2.137 2.139 2.138 0.00140 
120 1.859 1.851 1.855 0.00570 
330 0.991 0.989 0.99 0.00140 
600 0.436 0.437 0.437 0.00070 
930 0.124 0.128 0.126 0.00280 
1200 0.058 0.058 0.058 0.00000 
5160 0.035 0.038 0.037 0.00210 
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Appendix C2 Figure 4.2 Results 
 
  
3650 900 µm 
beads       
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.919 2.957 2.938 0.0271 
30 2.488 2.459 2.474 0.0203 
60 2.389 2.396 2.393 0.0045 
120 2.131 2.086 2.109 0.0316 
300 1.723 1.732 1.727 0.0068 
600 0.995 1.043 1.019 0.0338 
1200 0.424 0.450 0.437 0.0180 
1800 0.223 0.271 0.247 0.0338 
3645 0.303 0.297 0.300 0.0045 
     
  848 2mm beads     
Time Conc 1 Conc 2 Ave Conc  Std Deviation 
sec U/mL U/mL U/mL   
0 2.886 2.902 2.894 0.0117 
35 2.876 2.869 2.872 0.0047 
60 2.849 2.842 2.846 0.0047 
120 2.826 2.806 2.816 0.0141 
305 2.700 2.643 2.671 0.0399 
600 2.434 2.437 2.436 0.0023 
1247 1.979 1.996 1.987 0.0117 
1800 1.730 1.677 1.703 0.0376 
6120 1.454 1.484 1.469 0.0211 
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Appendix C3 Figure 4.3 Results 
 
  5% Sodium alginate     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 3.001 3.011 3.006 0.007 
45 2.771 2.776 2.773 0.003 
60 2.519 2.439 2.479 0.057 
120 1.807 1.799 1.803 0.006 
330 0.996 0.954 0.975 0.029 
600 0.343 0.332 0.337 0.008 
1200 0.059 0.035 0.047 0.017 
1860 0.012 0.012 0.012 0.000 
     
  2.5% Sodium alginate     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.566 2.572 2.569 0.004 
30 2.295 2.348 2.322 0.037 
70 2.132 2.145 2.138 0.009 
120 1.846 1.865 1.855 0.013 
330 0.985 0.997 0.991 0.009 
600 0.437 0.437 0.437 0.000 
930 0.145 0.132 0.138 0.009 
1200 0.049 0.068 0.058 0.013 
5160 0.040 0.043 0.042 0.002 
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Appendix C4 Figure 4.4 Results 
 
  Beads with no membrane   
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.784 2.793 2.789 0.0066 
30 2.650 2.640 2.645 0.0066 
60 2.565 2.587 2.576 0.0155 
120 2.659 2.675 2.667 0.0110 
300 2.631 2.650 2.640 0.0133 
600 2.665 2.656 2.661 0.0066 
1200 2.653 2.659 2.656 0.0044 
1800 2.668 2.684 2.676 0.0110 
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Appendix C5 Figure 4.6 Results 
 
  
1820 900 µm 
beads     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.941 2.911 2.926 0.0208 
30 2.820 2.859 2.839 0.0278 
60 2.817 2.817 2.817 0.0000 
150 2.718 2.784 2.751 0.0463 
300 2.388 2.404 2.396 0.0116 
600 1.852 1.835 1.843 0.0116 
1200 1.155 1.174 1.165 0.0139 
1800 0.765 0.779 0.772 0.0093 
3615 0.507 0.501 0.504 0.0046 
     
  850 2mm beads     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.884 2.887 2.885 0.0021 
30 2.741 2.798 2.770 0.0399 
60 2.718 2.756 2.737 0.0273 
150 2.545 2.551 2.548 0.0042 
300 2.361 2.337 2.349 0.0168 
600 1.823 1.879 1.851 0.0399 
1200 0.922 0.892 0.907 0.0210 
1800 0.532 0.556 0.544 0.0168 
3615 0.485 0.538 0.511 0.0378 
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Appendix C6 Figure 4.7 Results 
 
Bead 
Diameter 
Number of 
beads 
Membrane 
Thickness K Vmem 
µm 
  mm   m3 
900 1800 0.014 -0.0012 6.413E-08 
2000 850 0.006 -0.0015 6.409E-08 
900 848 0.014 -0.0009 3.021E-08 
900 1696 0.014 -0.0014 6.042E-08 
900 3650 0.014 -0.0023 1.3E-07 
900 8000 0.014 -0.0039 2.85E-07 
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Appendix C7 Figure 4.8 Results 
 
      37oC       
Fluid 
phase con 
(ci) 
Absorbed 
phase con 
(ni) 
Volume of 
beads 
Volume of 
membrane 
Corrected 
ni ln Ci ln ni  
1.42 272.01 0.27 0.02 2914.43 0.35 7.98 
0.98 243.44 0.38 0.04 2608.23 -0.02 7.87 
0.54 162.89 0.69 0.06 1745.25 -0.62 7.46 
0.26 147.41 0.86 0.08 1579.42 -1.35 7.36 
       
      25oC       
Fluid 
phase con 
(ci) 
Absorbed 
phase con 
(ni) 
Volume of 
beads 
Volume of 
membrane 
Corrected 
ni ln ci ln ni 
2.23 125.96 0.32 0.03 1349.59 0.80 7.21 
1.33 123.60 0.65 0.06 1324.24 0.29 7.19 
0.3 78.04 1.39 0.13 836.09 -1.20 6.73 
0.037 38.84 3.05 0.29 416.16 -3.30 6.03 
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Appendix C8 Figure 4.11 Results 
  Beads in saline       
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation   
Sec U/mL U/mL U/mL     
0 2.915 2.907 2.911 0.0057   
30 2.653 2.649 2.651 0.0028   
60 2.613 2.635 2.624 0.0156   
120 2.555 2.558 2.557 0.0021   
300 2.468 2.473 2.471 0.0035   
608 2.168 2.109 2.139 0.0417   
1210 1.748 1.751 1.750 0.0021   
1800 1.442 1.426 1.434 0.0113   
5400 1.345 1.321 1.333 0.0170   
       
  
Poly-L-lysine Beads incubated in poly-L-
lysine     
Time Con 1 Con 2 Con 3 Con 4 
Average 
conc Std dev 
sec U/mL U/mL U/mL U/mL U/mL   
0 2.664 2.668 2.673 2.668 2.668 0.0038 
30 2.589 2.593 2.593 2.598 2.593 0.0038 
60 2.274 2.279 2.274 2.279 2.277 0.0027 
120 1.604 1.609 1.613 1.609 1.609 0.0038 
300 1.881 1.885 1.885 1.885 1.884 0.0023 
600 0.183 0.183 0.178 0.178 0.181 0.0027 
1200 0.234 0.230 0.230 0.225 0.230 0.0038 
1800 0.286 0.281 0.272 0.272 0.278 0.0070 
5400 0.455 0.455 0.455 0.455 0.455 0.0000 
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  Poly-L-lysine Beads incubated in saline     
Time Con 1 Con 2 Con 3 Con 4 
Average 
conc Std dev 
sec U/mL U/mL U/mL U/mL U/mL   
0 2.91 2.91 2.91 2.91 2.91 0.00 
30 2.78 2.78 2.78 2.79 2.78 0.00 
60 2.77 2.77 2.77 2.78 2.77 0.00 
120 2.68 2.68 2.68 2.68 2.68 0.00 
300 2.37 2.37 2.37 2.37 2.37 0.00 
600 1.94 1.94 1.94 1.93 1.94 0.00 
1200 1.40 1.40 1.40 1.40 1.40 0.00 
1800 0.95 0.95 0.95 0.95 0.95 0.00 
5400 0.92 0.92 0.92 0.92 0.92 0.00 
       
  Poly-L-lysine Beads with no incubation     
Time Con 1 Con 2 Con 3 Con 4 
Average 
conc Std dev 
sec U/mL U/mL U/mL U/mL U/mL   
0 2.879 2.879 2.879 2.879 2.879 0.0000 
30 2.836 2.836 2.836 2.840 2.837 0.0024 
60 2.719 2.719 2.724 2.724 2.721 0.0028 
120 2.651 2.646 2.646 2.651 2.648 0.0028 
300 2.471 2.466 2.466 2.466 2.467 0.0024 
600 2.150 2.145 2.150 2.150 2.149 0.0024 
1200 1.537 1.537 1.537 1.537 1.537 0.0000 
1800 0.968 0.963 0.963 0.963 0.964 0.0024 
5400 0.905 0.910 0.910 0.910 0.908 0.0024 
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Appendix C9 Figure 4.12 Results 
 
  Beads in saline      
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation  
sec U/mL U/mL U/mL    
0 2.915 2.907 2.911 0.0057  
30 2.653 2.649 2.651 0.0028  
60 2.613 2.635 2.624 0.0156  
120 2.555 2.558 2.557 0.0021  
300 2.468 2.473 2.471 0.0035  
608 2.168 2.109 2.139 0.0417  
1210 1.748 1.751 1.750 0.0021  
1800 1.442 1.426 1.434 0.0113  
5400 1.345 1.321 1.333 0.0170  
      
  Beads in FCS      
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation  
sec U/mL U/mL U/mL    
0 2.903 2.928 2.916 0.0174  
30 2.627 2.627 2.627 0.0000  
60 2.362 2.350 2.356 0.0087  
120 2.171 2.171 2.171 0.0000  
300 2.030 2.024 2.027 0.0043  
608 1.396 1.378 1.387 0.0130  
1210 0.935 0.923 0.929 0.0087  
1800 0.480 0.474 0.477 0.0043  
5400 0.301 0.301 0.301 0.0000  
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No 
beads        
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation  
sec U/mL U/mL U/mL    
0 2.985 2.985 2.985 0.0000  
300 2.977 2.985 2.981 0.0054  
600 2.985 2.992 2.989 0.0054  
1800 2.977 2.962 2.970 0.0108  
 
Appendix C10 Figure 4.13 Results 
 
  Beads in saline     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.915 2.907 2.911 0.0057 
30 2.653 2.649 2.651 0.0028 
60 2.613 2.635 2.624 0.0156 
120 2.555 2.558 2.557 0.0021 
300 2.468 2.473 2.471 0.0035 
608 2.168 2.109 2.139 0.0417 
1210 1.748 1.751 1.750 0.0021 
1800 1.442 1.426 1.434 0.0113 
5400 1.345 1.321 1.333 0.0170 
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  Beads in blood     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.909 2.949 2.929 0.0277 
120 1.998 1.940 1.969 0.0416 
300 0.999 0.960 0.980 0.0277 
600 0.500 0.490 0.495 0.0069 
1200 0.225 0.176 0.201 0.0346 
1800 0.118 0.078 0.098 0.0277 
     
  Beads in FCS     
Time Conc 1 Conc 2 
Ave 
Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.903 2.928 2.916 0.0174 
30 2.627 2.627 2.627 0.0000 
60 2.362 2.350 2.356 0.0087 
120 2.171 2.171 2.171 0.0000 
300 2.030 2.024 2.027 0.0043 
608 1.396 1.378 1.387 0.0130 
1210 0.935 0.923 0.929 0.0087 
1800 0.480 0.474 0.477 0.0043 
5400 0.301 0.301 0.301 0.0000 
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Appendix C11 Figure 4.14 Results 
  Beads in saline     
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.915 2.907 2.911 0.0057 
30 2.653 2.649 2.651 0.0028 
60 2.613 2.635 2.624 0.0156 
120 2.555 2.558 2.557 0.0021 
300 2.468 2.473 2.471 0.0035 
608 2.168 2.109 2.139 0.0417 
1210 1.748 1.751 1.750 0.0021 
1800 1.442 1.426 1.434 0.0113 
5400 1.345 1.321 1.333 0.0170 
     
  Beads in blood     
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.909 2.949 2.929 0.0277 
120 1.998 1.940 1.969 0.0416 
300 0.999 0.960 0.980 0.0277 
600 0.500 0.490 0.495 0.0069 
1200 0.225 0.176 0.201 0.0346 
1800 0.118 0.078 0.098 0.0277 
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  Beads in FCS     
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.903 2.928 2.916 0.0174 
30 2.627 2.627 2.627 0.0000 
60 2.362 2.350 2.356 0.0087 
120 2.171 2.171 2.171 0.0000 
300 2.030 2.024 2.027 0.0043 
608 1.396 1.378 1.387 0.0130 
1210 0.935 0.923 0.929 0.0087 
1800 0.480 0.474 0.477 0.0043 
5400 0.301 0.301 0.301 0.0000 
     
  Beads in pH = 7.92 solution   
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.753 2.763 2.758 0.0073 
300 2.077 2.056 2.066 0.0148 
600 1.411 1.347 1.379 0.0456 
1200 1.387 1.381 1.384 0.0042 
1800 1.390 1.378 1.384 0.0090 
2400 1.387 1.378 1.382 0.0066 
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  Beads in pH = 7.5 solution   
Time Conc 1 Conc 2 Ave Conc  
Std 
Deviation 
sec U/mL U/mL U/mL   
0 2.780 2.775 2.778 0.0035 
120 2.390 2.388 2.389 0.0014 
300 2.010 2.009 2.010 0.0007 
600 1.820 1.816 1.818 0.0028 
1200 1.340 1.349 1.345 0.0064 
1800 0.960 0.958 0.959 0.0014 
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AppendixD  Data for Chapter 5: Feasible Reactor Configuration 
Appendix D1 Figure 5.4 Results 
 
  Time (sec) Ln term 
848 beads 0 -0.000297 
  30 -0.050950 
  60 -0.085041 
  120 -0.089082 
  300 -0.224361 
  608 -0.378268 
  1210 -0.719302 
  1800 -0.960314 
1696 beads 0 0.000000 
  30 -0.070334 
  60 -0.079887 
  120 -0.100092 
  300 -0.133507 
3650 beads 0 0.000000 
  30 -0.063975 
  60 -0.073376 
8000 beads 0 0.000130 
  30 -0.014870 
  70 -0.027457 
 
Appendix D2 Figure 5.5 Results 
Number of 
beads Predicted Eqm Con (U/mL) Measured Eqm Con (U/mL) 
848 2.18 2.23 
1696 1.44 1.33 
3650 0.00 0.30 
8000 0.00 0.04 
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Appendix D3 Figure 5.6 Results 
848 beads 
 
y* 1004.000 U/mL    mem thickness   0.000014 m 
Vx 40.000 mL    r   0.00045 m 
N 848      
V of mem of one 
bead   3.45E-05 mL 
Vy 0.02928042 mL    Inside R   0.000436   
Constant: 
a 
-
2.17506138         
         
Time b 
Predicted 
Conc 
      
Sec   (U/mL) 
      
0 -2.1751 2.9100       
100 -2.2650 2.7945       
200 -2.3439 2.7004       
300 -2.4132 2.6229       
400 -2.4739 2.5584       
500 -2.5273 2.5044       
600 -2.5741 2.4589       
700 -2.6152 2.4202       
800 -2.6513 2.3873       
900 -2.6829 2.3591       
1000 -2.7107 2.3350       
1100 -2.7351 2.3142       
1200 -2.7565 2.2962       
1300 -2.7753 2.2806       
1400 -2.7918 2.2672       
1500 -2.8062 2.2555       
1600 -2.8189 2.2453       
1700 -2.8301 2.2365       
1800 -2.8398 2.2288       
1900 -2.8484 2.2221       
2000 -2.8560 2.2162       
2100 -2.8626 2.2111       
2200 -2.8684 2.2066       
2300 -2.8735 2.2027       
2400 -2.8779 2.1993       
2500 -2.8819 2.1963       
2600 -2.8853 2.1937       
2700 -2.8883 2.1914       
2800 -2.8910 2.1894       
2900 -2.8933 2.1876       
3000 -2.8953 2.1861       
3100 -2.8971 2.1847       
3200 -2.8987 2.1835       
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3300 -2.9001 2.1825       
3400 -2.9013 2.1816       
3500 -2.9024 2.1808       
3600 -2.9033 2.1801       
3700 -2.9041 2.1795       
3800 -2.9048 2.1789       
3900 -2.9055 2.1785       
4000 -2.9060 2.1780       
4100 -2.9065 2.1777       
4200 -2.9069 2.1774       
4300 -2.9073 2.1771       
4400 -2.9076 2.1768       
4500 -2.9079 2.1766       
4600 -2.9082 2.1764       
4700 -2.9084 2.1763       
4800 -2.9086 2.1761       
4900 -2.9088 2.1760       
5000 -2.9089 2.1759       
5100 -2.9091 2.1758       
5200 -2.9092 2.1757       
5300 -2.9093 2.1756       
5400 -2.9094 2.1755       
5500 -2.9094 2.1755       
5600 -2.9095 2.1754       
5700 -2.9096 2.1754       
5800 -2.9096 2.1753       
5900 -2.9097 2.1753       
6000 -2.9097 2.1753       
6100 -2.9097 2.1753       
6200 -2.9098 2.1752       
6300 -2.9098 2.1752       
6400 -2.9098 2.1752       
6500 -2.9098 2.1752       
6600 -2.9099 2.1752       
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1696 beads 
y* 1004.000 U/mL    mem thickness   0.000014 m 
Vx 40.000 mL    r   0.00045 m 
N 1696      
V of mem of one 
bead   3.45E-05 mL 
Vy 0.05856085 mL    Inside R   0.000436   
Constant: 
a 
-
1.44012276         
         
Time b 
Predicted 
Conc 
      
Sec  (U/mL) 
      
0 -1.4401 2.9100       
100 -1.5618 2.6833       
200 -1.6734 2.5043       
300 -1.7758 2.3600       
400 -1.8697 2.2415       
500 -1.9558 2.1428       
600 -2.0348 2.0596       
700 -2.1072 1.9888       
800 -2.1737 1.9280       
900 -2.2346 1.8754       
1000 -2.2905 1.8296       
1100 -2.3418 1.7895       
1200 -2.3888 1.7543       
1300 -2.4320 1.7232       
1400 -2.4716 1.6956       
1500 -2.5079 1.6711       
1600 -2.5411 1.6492       
1700 -2.5717 1.6296       
1800 -2.5997 1.6120       
1900 -2.6254 1.5963       
2000 -2.6489 1.5821       
2100 -2.6705 1.5693       
2200 -2.6904 1.5577       
2300 -2.7085 1.5472       
2400 -2.7252 1.5378       
2500 -2.7405 1.5292       
2600 -2.7545 1.5214       
2700 -2.7674 1.5143       
2800 -2.7792 1.5079       
2900 -2.7900 1.5020       
3000 -2.8000 1.4967       
3100 -2.8091 1.4919       
3200 -2.8174 1.4874       
3300 -2.8251 1.4834       
3400 -2.8321 1.4797       
3500 -2.8386 1.4764       
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3600 -2.8445 1.4733       
3700 -2.8499 1.4705       
3800 -2.8549 1.4679       
3900 -2.8594 1.4656       
4000 -2.8636 1.4634       
4100 -2.8675 1.4615       
4200 -2.8710 1.4597       
4300 -2.8742 1.4581       
4400 -2.8772 1.4565       
4500 -2.8799 1.4552       
4600 -2.8824 1.4539       
4700 -2.8847 1.4528       
4800 -2.8868 1.4517       
4900 -2.8887 1.4507       
5000 -2.8905 1.4499       
5100 -2.8921 1.4490       
5200 -2.8936 1.4483       
5300 -2.8949 1.4476       
5400 -2.8962 1.4470       
5500 -2.8973 1.4464       
5600 -2.8984 1.4459       
5700 -2.8993 1.4454       
5800 -2.9002 1.4450       
5900 -2.9010 1.4446       
6000 -2.9018 1.4442       
6100 -2.9024 1.4439       
6200 -2.9031 1.4436       
6300 -2.9036 1.4433       
6400 -2.9042 1.4430       
6500 -2.9047 1.4428       
6600 -2.9051 1.4426       
 
 
 
 
 
 
 
 
 
 
 
  
Appendices               136 
  
3650 beads 
 
y* 1004.000 U/mL    mem thickness   0.000014 m 
Vx 40.000 mL    r   0.00045 m 
N 3650      
V of mem of one 
bead   3.45E-05 mL 
Vy 0.12603012 mL    Inside R   0.000436   
Constant: 
a 0.20335609         
         
Time b 
Predicted 
Conc 
      
Sec  (U/mL) 
      
0 0.2034 2.9600       
100 0.2422 2.4854       
200 0.2815 2.1383       
300 0.3213 1.8735       
400 0.3616 1.6648       
500 0.4024 1.4960       
600 0.4436 1.3568       
700 0.4854 1.2401       
800 0.5277 1.1407       
900 0.5705 1.0551       
1000 0.6139 0.9806       
1100 0.6577 0.9152       
1200 0.7021 0.8573       
1300 0.7471 0.8057       
1400 0.7926 0.7594       
1500 0.8387 0.7177       
1600 0.8853 0.6799       
1700 0.9325 0.6455       
1800 0.9803 0.6140       
1900 1.0287 0.5852       
2000 1.0776 0.5586       
2100 1.1272 0.5340       
2200 1.1774 0.5112       
2300 1.2282 0.4901       
2400 1.2796 0.4704       
2500 1.3316 0.4520       
2600 1.3843 0.4348       
2700 1.4377 0.4187       
2800 1.4916 0.4035       
2900 1.5463 0.3893       
3000 1.6016 0.3758       
3100 1.6576 0.3631       
3200 1.7143 0.3511       
3300 1.7717 0.3398       
3400 1.8298 0.3290       
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3500 1.8886 0.3187       
3600 1.9481 0.3090       
3700 2.0083 0.2997       
3800 2.0693 0.2909       
3900 2.1311 0.2825       
4000 2.1936 0.2744       
4100 2.2568 0.2667       
4200 2.3209 0.2594       
4300 2.3857 0.2523       
4400 2.4513 0.2456       
4500 2.5178 0.2391       
4600 2.5850 0.2329       
4700 2.6531 0.2269       
4800 2.7220 0.2211       
4900 2.7917 0.2156       
5000 2.8623 0.2103       
5100 2.9338 0.2052       
5200 3.0062 0.2002       
5300 3.0794 0.1955       
5400 3.1535 0.1909       
5500 3.2286 0.1864       
5600 3.3046 0.1822       
5700 3.3815 0.1780       
5800 3.4593 0.1740       
5900 3.5381 0.1701       
6000 3.6179 0.1664       
6100 3.6987 0.1627       
6200 3.7804 0.1592       
6300 3.8631 0.1558       
6400 3.9469 0.1525       
6500 4.0317 0.1493       
6600 4.1175 0.1462       
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8000 beads 
 
y* 1004.000 U/mL    mem thickness   0.000014 m 
Vx 40.000 mL    r   0.00045 m 
N 8000      
V of mem of one 
bead   3.45E-05 mL 
Vy 0.276230407 mL    Inside R   0.000436   
Constant: 
a 4.363383209         
         
Time b 
Predicted 
Conc 
      
Sec  (U/mL) 
      
0.0000 4.3634 2.5700       
100.0000 6.4383 1.7417       
200.0000 9.1343 1.2277       
300.0000 12.6370 0.8874       
400.0000 17.1880 0.6524       
500.0000 23.1010 0.4854       
600.0000 30.7836 0.3643       
700.0000 40.7654 0.2751       
800.0000 53.7344 0.2087       
900.0000 70.5846 0.1589       
1000.0000 92.4776 0.1213       
1100.0000 120.9225 0.0927       
1200.0000 157.8802 0.0710       
1300.0000 205.8983 0.0545       
1400.0000 268.2867 0.0418       
1500.0000 349.3461 0.0321       
1600.0000 454.6642 0.0247       
1700.0000 591.5010 0.0190       
1800.0000 769.2889 0.0146       
1900.0000 1000.2835 0.0112       
2000.0000 1300.4081 0.0086       
2100.0000 1690.3510 0.0066       
2200.0000 2196.9924 0.0051       
2300.0000 2855.2567 0.0039       
2400.0000 3710.5201 0.0030       
2500.0000 4821.7386 0.0023       
2600.0000 6265.5121 0.0018       
2700.0000 8141.3645 0.0014       
2800.0000 10578.6042 0.0011       
2900.0000 13745.2381 0.0008       
3000.0000 17859.5521 0.0006       
3100.0000 23205.1593 0.0005       
3200.0000 30150.5492 0.0004       
3300.0000 39174.4898 0.0003       
3400.0000 50899.0301 0.0002       
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3500.0000 66132.3801 0.0002       
3600.0000 85924.6230 0.0001       
3700.0000 111640.1015 0.0001       
3800.0000 145051.4653 0.0001       
3900.0000 188461.8664 0.0001       
4000.0000 244863.7222 0.0000       
4100.0000 318144.9924 0.0000       
4200.0000 413357.1888 0.0000       
4300.0000 537063.5917 0.0000       
4400.0000 697791.6780 0.0000       
4500.0000 906620.9472 0.0000       
4600.0000 1177946.6670 0.0000       
4700.0000 1530472.1845 0.0000       
4800.0000 1988498.2080 0.0000       
4900.0000 2583597.9320 0.0000       
5000.0000 3356793.4785 0.0000       
5100.0000 4361383.6824 0.0000       
5200.0000 5666618.1504 0.0000       
5300.0000 7362470.8571 0.0000       
5400.0000 9565842.3383 0.0000       
5500.0000 12428618.0172 0.0000       
5600.0000 16148138.1517 0.0000       
5700.0000 20980801.1273 0.0000       
5800.0000 27259737.8156 0.0000       
5900.0000 35417775.3479 0.0000       
6000.0000 46017273.2697 0.0000       
6100.0000 59788888.7776 0.0000       
6200.0000 77681943.2503 0.0000       
6300.0000 100929861.9988 0.0000       
6400.0000 131135198.2066 0.0000       
6500.0000 170380102.0323 0.0000       
6600.0000 221369849.8599 0.0000       
         
         
         
         
         
 
 
 
 
 
 
 
 
  
Appendices               140 
  
 
Appendix D4 Figure 5.7 Results 
 
τs = 1     τs = 3.88     τs = 5     
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
0.00 0.00 0.62 0.00 0.00 0.30 0.00 0.00 0.25 
49.68 18.55 0.63 146.90 26.39 0.31 184.34 27.57 0.25 
107.93 40.01 0.63 336.71 60.18 0.31 417.90 62.21 0.26 
171.80 63.21 0.64 533.66 94.83 0.32 661.99 98.07 0.27 
247.15 90.11 0.65 735.67 129.94 0.33 913.45 134.60 0.28 
323.69 116.91 0.65 941.14 165.18 0.34 1170.94 171.58 0.29 
401.25 143.55 0.66 1149.13 200.35 0.35 1350.00 197.02 0.29 
479.72 169.95 0.67 1350.00 233.80 0.36 1609.16 233.43 0.30 
558.98 196.06 0.67 1556.47 267.66 0.37 1867.84 269.25 0.31 
638.94 221.84 0.68 1761.79 300.76 0.38 2125.30 304.37 0.32 
719.53 247.25 0.69 1965.57 333.04 0.39 2380.90 338.68 0.33 
800.67 272.25 0.70 2167.48 364.43 0.40 2632.39 371.87 0.35 
882.31 296.82 0.70 2367.26 394.89 0.41 2700.00 380.69 0.35 
964.41 320.93 0.71 2563.07 424.15 0.43 2941.34 411.82 0.36 
1046.92 344.57 0.72 2700.00 444.24 0.44 3179.13 441.93 0.37 
1129.81 367.71 0.72 2885.85 471.01 0.45 3413.17 470.98 0.39 
1213.04 390.36 0.73 3068.99 496.81 0.46 3643.28 498.96 0.40 
1296.51 412.47 0.74 3249.38 521.65 0.47 3866.51 525.52 0.41 
1350.00 426.32 0.74 3427.02 545.53 0.48 4050.00 546.91 0.42 
1432.32 447.17 0.75 3601.93 568.46 0.50 4258.97 570.76 0.44 
1514.83 467.49 0.76 3774.14 590.47 0.51 4463.96 593.61 0.45 
1597.55 487.29 0.76 3942.11 611.37 0.52 4665.03 615.48 0.46 
1680.47 506.58 0.77 4050.00 624.50 0.53 4862.23 636.39 0.48 
1763.60 525.34 0.78 4207.58 643.24 0.54 5055.64 656.35 0.49 
1846.94 543.60 0.78 4362.88 661.20 0.56 5242.98 675.16 0.50 
1930.50 561.35 0.79 4515.98 678.41 0.57 5400.00 690.52 0.52 
2014.29 578.59 0.80 4666.98 694.88 0.58 5574.11 707.11 0.53 
2098.32 595.34 0.80 4815.97 710.64 0.60 5745.19 722.94 0.54 
2182.59 611.60 0.81 4963.04 725.72 0.61 5913.36 738.03 0.56 
2267.12 627.38 0.82 5108.28 740.14 0.62 6078.75 752.42 0.57 
2351.93 642.68 0.82 5254.14 754.13 0.63 6241.50 766.14 0.59 
2437.02 657.52 0.83 5400.00 767.65 0.65 6401.74 779.20 0.60 
2522.42 671.89 0.83 5533.28 779.57 0.66 6575.87 792.88 0.61 
2611.21 686.30 0.84 5665.33 790.98 0.67 6730.25 804.58 0.63 
2700.00 700.17 0.85 5796.23 801.90 0.68 6750.00 806.04 0.63 
2783.53 712.75 0.85 5926.07 812.34 0.69 6895.15 816.61 0.64 
2867.43 724.93 0.86 6054.93 822.32 0.71 7038.64 826.68 0.66 
2951.73 736.73 0.86 6182.90 831.86 0.72 7180.57 836.29 0.67 
3036.44 748.14 0.87 6310.06 840.98 0.73 7321.06 845.44 0.68 
3121.58 759.18 0.87 6436.48 849.69 0.74 7460.23 854.16 0.69 
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3207.16 769.85 0.88 6562.26 858.00 0.75 7598.18 862.47 0.70 
3293.22 780.17 0.88 6686.63 865.88 0.76 7735.02 870.38 0.72 
3379.76 790.13 0.89 6750.00 869.77 0.76 7870.86 877.91 0.73 
3466.82 799.75 0.89 6868.58 876.81 0.77 8004.66 885.02 0.74 
3554.41 809.03 0.90 6986.92 883.55 0.78 8100.00 889.89 0.75 
3642.56 817.99 0.90 7105.09 889.99 0.79 8227.06 896.15 0.76 
3731.28 826.62 0.90 7223.15 896.14 0.80 8353.68 902.12 0.77 
3820.62 834.94 0.91 7341.16 902.02 0.81 8479.92 907.82 0.78 
3910.59 842.96 0.91 7459.20 907.63 0.82 8605.87 913.24 0.79 
4000.91 850.65 0.92 7577.32 912.99 0.83 8731.62 918.40 0.80 
4050.00 854.69 0.92 7695.59 918.09 0.84 8857.24 923.32 0.81 
4138.66 861.73 0.92 7814.08 922.96 0.84 8982.82 928.00 0.82 
4228.03 868.51 0.93 7932.85 927.60 0.85 9108.43 932.45 0.83 
4318.14 875.04 0.93 8051.34 931.99 0.86 9234.15 936.68 0.84 
4409.01 881.32 0.93 8100.00 933.73 0.86 9359.18 940.67 0.84 
4500.67 887.36 0.94 8214.71 937.68 0.87 9450.00 943.44 0.85 
4593.16 893.17 0.94 8329.99 941.45 0.88 9570.97 946.96 0.86 
4686.49 898.75 0.94 8445.89 945.04 0.88 9692.43 950.31 0.87 
4780.70 904.11 0.94 8562.47 948.47 0.89 9814.46 953.50 0.87 
4875.82 909.26 0.95 8679.79 951.73 0.90 9937.11 956.53 0.88 
4971.88 914.19 0.95 8797.92 954.83 0.90 10060.47 959.41 0.89 
5068.92 918.92 0.95 8916.90 957.77 0.91 10184.59 962.14 0.89 
5166.97 923.46 0.95 9036.82 960.58 0.91 10309.57 964.73 0.90 
5266.07 927.80 0.96 9157.73 963.23 0.92 10435.46 967.19 0.91 
5365.95 931.94 0.96 9279.71 965.76 0.92 10562.35 969.51 0.91 
5400.00 933.30 0.96 9402.25 968.14 0.93 10689.46 971.70 0.92 
5498.55 937.10 0.96 9450.00 969.03 0.93 10800.00 973.49 0.92 
5598.22 940.73 0.96 9570.30 971.17 0.93 10925.35 975.40 0.93 
5699.06 944.21 0.97 9691.88 973.20 0.94 11052.01 977.22 0.93 
5801.09 947.53 0.97 9814.81 975.13 0.94 11180.05 978.93 0.94 
5904.37 950.71 0.97 9939.17 976.96 0.94 11309.54 980.55 0.94 
6008.93 953.74 0.97 10065.02 978.68 0.95 11440.57 982.08 0.94 
6114.81 956.63 0.97 10192.44 980.32 0.95 11573.22 983.53 0.95 
6222.07 959.39 0.98 10321.51 981.86 0.96 11707.59 984.89 0.95 
6330.75 962.01 0.98 10452.31 983.32 0.96 11843.76 986.17 0.95 
6440.90 964.52 0.98 10584.92 984.69 0.96 11996.88 987.50 0.96 
6552.58 966.90 0.98 10718.74 985.98 0.96 12150.00 988.72 0.96 
6665.33 969.15 0.98 10800.00 986.72 0.97 12287.98 989.74 0.96 
6750.00 970.74 0.98 10933.35 987.85 0.97 12428.10 990.70 0.97 
6862.73 972.75 0.98 11068.76 988.92 0.97 12570.47 991.60 0.97 
6977.10 974.66 0.98 11206.33 989.93 0.97 12715.20 992.44 0.97 
7093.16 976.47 0.98 11346.14 990.88 0.97 12862.41 993.22 0.97 
7210.99 978.19 0.99 11488.32 991.77 0.98 13012.22 993.96 0.98 
7330.64 979.82 0.99 11632.96 992.60 0.98 13164.75 994.65 0.98 
7452.18 981.36 0.99 11780.20 993.38 0.98 13332.38 995.34 0.98 
7575.69 982.82 0.99 11930.15 994.11 0.98 13500.00 995.96 0.98 
7701.23 984.19 0.99 12082.18 994.78 0.98 13657.17 996.50 0.98 
7828.89 985.49 0.99 12150.00 995.07 0.98 13817.49 997.00 0.99 
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7964.45 986.77 0.99 12302.45 995.66 0.99 13981.15 997.46 0.99 
8100.00 987.95 0.99 12457.91 996.22 0.99 14148.29 997.89 0.99 
8230.86 989.00 0.99 12616.52 996.74 0.99 14319.12 998.28 0.99 
8364.05 990.00 0.99 12778.45 997.22 0.99 14493.82 998.65 0.99 
8499.65 990.93 0.99 12943.86 997.67 0.99 14671.91 998.99 0.99 
8637.76 991.80 0.99 13112.92 998.08 0.99 14850.00 999.29 0.99 
8778.50 992.62 0.99 13285.85 998.47 0.99 15032.11 999.57 0.99 
8921.96 993.39 0.99 13461.99 998.82 0.99 15218.72 999.82 0.99 
9068.28 994.11 1.00 13500.00 998.89 0.99 15410.08 1000.06 0.99 
9217.58 994.79 1.00 13676.95 999.20 0.99 15606.47 1000.27 0.99 
9369.22 995.41 1.00 13858.17 999.49 0.99 15808.18 1000.47 1.00 
9450.00 995.72 1.00 14043.88 999.75 0.99 16013.82 1000.65 1.00 
9602.98 996.27 1.00 14234.34 999.99 1.00 16200.00 1000.79 1.00 
9759.21 996.78 1.00 14429.84 1000.21 1.00 16412.72 1000.93 1.00 
9918.84 997.26 1.00 14639.92 1000.42 1.00 16631.75 1001.06 1.00 
10082.03 997.70 1.00 14850.00 1000.61 1.00 16857.48 1001.18 1.00 
10248.96 998.11 1.00 15056.86 1000.77 1.00 17090.38 1001.29 1.00 
10419.81 998.49 1.00 15269.68 1000.92 1.00 17328.64 1001.38 1.00 
10609.91 998.86 1.00 15488.85 1001.05 1.00 17550.00 1001.46 1.00 
10800.00 999.20 1.00 15714.78 1001.17 1.00 17799.39 1001.53 1.00 
10979.41 999.49 1.00 15957.39 1001.28 1.00 18057.56 1001.60 1.00 
11163.35 999.75 1.00 16200.00 1001.38 1.00 18325.17 1001.66 1.00 
11352.05 999.99 1.00 16442.60 1001.46 1.00 18612.59 1001.71 1.00 
11545.79 1000.21 1.00 16693.50 1001.54 1.00 18900.00 1001.76 1.00 
11744.85 1000.41 1.00 16953.33 1001.61 1.00 19192.86 1001.80 1.00 
11947.43 1000.59 1.00 17251.67 1001.67 1.00 19497.92 1001.83 1.00 
12150.00 1000.75 1.00 17550.00 1001.72 1.00 19816.28 1001.86 1.00 
12360.72 1000.90 1.00 17834.93 1001.77 1.00 20146.21 1001.89 1.00 
12577.72 1001.04 1.00 18131.40 1001.81 1.00 20250.00 1001.89 1.00 
12801.39 1001.16 1.00 18440.43 1001.84 1.00 20594.16 1001.91 1.00 
13032.20 1001.27 1.00 18760.11 1001.87 1.00 20955.26 1001.93 1.00 
13266.10 1001.36 1.00 18900.00 1001.88 1.00 21330.20 1001.94 1.00 
13500.00 1001.45 1.00 19234.86 1001.90 1.00 21600.00 1001.95 1.00 
13747.65 1001.52 1.00 19585.76 1001.92 1.00 22004.58 1001.96 1.00 
14004.01 1001.59 1.00 19949.44 1001.93 1.00 22477.29 1001.97 1.00 
14269.74 1001.65 1.00 20250.00 1001.95 1.00 22950.00 1001.98 1.00 
14559.87 1001.71 1.00 20643.66 1001.96 1.00 23425.67 1001.98 1.00 
14850.00 1001.75 1.00 21059.60 1001.97 1.00 23925.44 1001.99 1.00 
15141.13 1001.79 1.00 21495.71 1001.97 1.00 24300.00 1001.99 1.00 
15444.35 1001.83 1.00 21600.00 1001.98 1.00 24859.29 1001.99 1.00 
15760.75 1001.86 1.00 22062.84 1001.98 1.00 25454.74 1002.00 1.00 
16088.56 1001.88 1.00 22548.15 1001.99 1.00 25650.00 1002.00 1.00 
16200.00 1001.89 1.00 22950.00 1001.99 1.00 26325.00 1002.00 1.00 
16542.30 1001.91 1.00 23494.21 1001.99 1.00 27000.00 1002.00 1.00 
16901.37 1001.93 1.00 24072.22 1001.99 1.00 27675.00 1002.00 1.00 
17274.10 1001.94 1.00 24300.00 1002.00 1.00 28350.00 1002.00 1.00 
17550.00 1001.95 1.00 24975.00 1002.00 1.00 29025.00 1002.00 1.00 
17952.47 1001.96 1.00 25650.00 1002.00 1.00 29700.00 1002.00 1.00 
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18378.26 1001.97 1.00 26325.00 1002.00 1.00 30375.00 1002.00 1.00 
18825.49 1001.98 1.00 27000.00 1002.00 1.00 31050.00 1002.00 1.00 
18900.00 1001.98 1.00 27675.00 1002.00 1.00 31725.00 1002.00 1.00 
19373.24 1001.98 1.00 28350.00 1002.00 1.00 32400.00 1002.00 1.00 
19870.28 1001.99 1.00 29025.00 1002.00 1.00 33075.00 1002.00 1.00 
20250.00 1001.99 1.00 29700.00 1002.00 1.00 33750.00 1002.00 1.00 
20806.46 1001.99 1.00 30375.00 1002.00 1.00 34425.00 1002.00 1.00 
21398.63 1002.00 1.00 31050.00 1002.00 1.00 35100.00 1002.00 1.00 
21600.00 1002.00 1.00 31725.00 1002.00 1.00 35775.00 1002.00 1.00 
22275.00 1002.00 1.00 32400.00 1002.00 1.00 36450.00 1002.00 1.00 
22950.00 1002.00 1.00 33075.00 1002.00 1.00 37125.00 1002.00 1.00 
23625.00 1002.00 1.00 33750.00 1002.00 1.00 37800.00 1002.00 1.00 
24300.00 1002.00 1.00 34425.00 1002.00 1.00 38475.00 1002.00 1.00 
24975.00 1002.00 1.00 35100.00 1002.00 1.00 39150.00 1002.00 1.00 
25650.00 1002.00 1.00 35775.00 1002.00 1.00 39825.00 1002.00 1.00 
26325.00 1002.00 1.00 36450.00 1002.00 1.00 40500.00 1002.00 1.00 
27000.00 1002.00 1.00 37125.00 1002.00 1.00 41175.00 1002.00 1.00 
27675.00 1002.00 1.00 37800.00 1002.00 1.00 41850.00 1002.00 1.00 
28350.00 1002.00 1.00 38475.00 1002.00 1.00 42525.00 1002.00 1.00 
29025.00 1002.00 1.00 39150.00 1002.00 1.00 43200.00 1002.00 1.00 
29700.00 1002.00 1.00 39825.00 1002.00 1.00 43875.00 1002.00 1.00 
30375.00 1002.00 1.00 40500.00 1002.00 1.00 44550.00 1002.00 1.00 
31050.00 1002.00 1.00 41175.00 1002.00 1.00 45225.00 1002.00 1.00 
31725.00 1002.00 1.00 41850.00 1002.00 1.00 45900.00 1002.00 1.00 
32400.00 1002.00 1.00 42525.00 1002.00 1.00 46575.00 1002.00 1.00 
33075.00 1002.00 1.00 43200.00 1002.00 1.00 47250.00 1002.00 1.00 
33750.00 1002.00 1.00 43875.00 1002.00 1.00 47925.00 1002.00 1.00 
34425.00 1002.00 1.00 44550.00 1002.00 1.00 48600.00 1002.00 1.00 
35100.00 1002.00 1.00 45225.00 1002.00 1.00 49275.00 1002.00 1.00 
35775.00 1002.00 1.00 45900.00 1002.00 1.00 49950.00 1002.00 1.00 
36450.00 1002.00 1.00 46575.00 1002.00 1.00 50625.00 1002.00 1.00 
37125.00 1002.00 1.00 47250.00 1002.00 1.00 51300.00 1002.00 1.00 
37800.00 1002.00 1.00 47925.00 1002.00 1.00 51975.00 1002.00 1.00 
38475.00 1002.00 1.00 48600.00 1002.00 1.00 52650.00 1002.00 1.00 
39150.00 1002.00 1.00 49275.00 1002.00 1.00 53325.00 1002.00 1.00 
39825.00 1002.00 1.00 49950.00 1002.00 1.00 54000.00 1002.00 1.00 
40500.00 1002.00 1.00 50625.00 1002.00 1.00    
41175.00 1002.00 1.00 51300.00 1002.00 1.00    
41850.00 1002.00 1.00 51975.00 1002.00 1.00    
42525.00 1002.00 1.00 52650.00 1002.00 1.00    
43200.00 1002.00 1.00 53325.00 1002.00 1.00    
43875.00 1002.00 1.00 54000.00 1002.00 1.00    
44550.00 1002.00 1.00       
45225.00 1002.00 1.00       
45900.00 1002.00 1.00       
46575.00 1002.00 1.00       
47250.00 1002.00 1.00       
47925.00 1002.00 1.00       
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48600.00 1002.00 1.00       
49275.00 1002.00 1.00       
49950.00 1002.00 1.00       
50625.00 1002.00 1.00       
51300.00 1002.00 1.00       
51975.00 1002.00 1.00       
52650.00 1002.00 1.00       
53325.00 1002.00 1.00       
54000.00 1002.00 1.00       
         
 
 
Appendix D5 Figure 5.8 Results 
 
Membrane thickness 
(m) Reactor Volume (mL) 
0.0000050 981 
0.0000120 415 
0.0000140 357 
0.0000200 254 
0.0000400 133 
0.0000600 93 
0.0001000 61 
0.0005000 32 
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Appendix D6 Figure 5.9 Results 
τs = 0.1     τs =0.6     τs = 1     
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
0.00 0.00 0.72 0.00 0.00 0.30 0.00 0.00 0.20 
6.03 16.84 0.72 22.45 26.12 0.30 38.95 30.91 0.21 
13.13 36.41 0.73 50.96 59.00 0.31 83.07 65.69 0.21 
20.95 57.64 0.73 81.11 93.38 0.32 130.23 102.55 0.22 
29.31 79.94 0.74 112.30 128.51 0.33 179.22 140.49 0.23 
38.83 104.87 0.74 144.11 163.87 0.34 229.26 178.84 0.24 
48.56 129.82 0.75 176.24 199.08 0.35 285.29 221.30 0.25 
58.46 154.69 0.75 208.47 233.87 0.36 338.53 261.12 0.26 
68.52 179.40 0.76 240.62 268.02 0.37 389.10 298.44 0.27 
78.72 203.89 0.76 272.56 301.37 0.38 437.15 333.41 0.28 
89.05 228.11 0.77 304.18 333.82 0.39 482.79 366.17 0.29 
99.49 252.02 0.77 335.41 365.26 0.40 526.15 396.85 0.30 
110.03 275.58 0.78 366.17 395.64 0.41 567.34 425.57 0.31 
120.66 298.76 0.78 396.44 424.92 0.43 607.65 453.26 0.32 
131.38 321.54 0.79 426.16 453.08 0.44 647.22 480.01 0.33 
142.18 343.89 0.80 455.33 480.11 0.45 686.03 505.82 0.34 
153.06 365.81 0.80 483.92 506.02 0.46 724.09 530.69 0.35 
164.00 387.27 0.81 511.94 530.81 0.48 761.37 554.62 0.36 
175.01 408.27 0.81 539.39 554.50 0.49 797.88 577.60 0.38 
186.09 428.80 0.82 566.26 577.13 0.50 833.61 599.65 0.39 
197.22 448.85 0.82 592.59 598.71 0.51 868.57 620.78 0.40 
208.42 468.42 0.83 618.36 619.29 0.53 902.77 641.01 0.42 
219.67 487.51 0.83 643.62 638.90 0.54 936.23 660.34 0.43 
230.97 506.11 0.84 668.36 657.58 0.55 968.94 678.81 0.44 
242.33 524.24 0.84 692.62 675.35 0.57 1000.94 696.43 0.46 
253.75 541.88 0.85 716.40 692.27 0.58 1032.24 713.23 0.47 
265.21 559.05 0.85 739.75 708.37 0.59 1062.87 729.24 0.48 
276.74 575.75 0.86 762.66 723.68 0.61 1092.85 744.48 0.50 
288.31 591.98 0.86 785.18 738.24 0.62 1122.21 758.98 0.51 
299.94 607.74 0.87 807.31 752.09 0.63 1150.97 772.76 0.53 
311.63 623.05 0.87 829.09 765.25 0.64 1179.16 785.87 0.54 
323.37 637.91 0.88 850.53 777.77 0.66 1206.81 798.31 0.56 
335.16 652.32 0.88 871.65 789.67 0.67 1233.95 810.13 0.57 
347.02 666.29 0.88 892.47 800.98 0.68 1260.61 821.34 0.59 
358.93 679.84 0.89 913.02 811.73 0.69 1286.81 831.98 0.60 
370.91 692.96 0.89 934.87 822.72 0.70 1312.58 842.07 0.62 
382.94 705.67 0.90 955.63 832.74 0.72 1337.70 851.54 0.63 
395.05 717.97 0.90 975.35 841.88 0.73 1350.00 856.04 0.64 
407.21 729.87 0.90 994.08 850.23 0.74 1373.97 864.57 0.65 
419.45 741.38 0.91 1012.00 857.91 0.75 1397.50 872.62 0.66 
431.75 752.51 0.91 1029.88 865.27 0.76 1420.63 880.23 0.68 
444.12 763.27 0.91 1047.71 872.33 0.77 1443.39 887.40 0.69 
456.57 773.66 0.92 1065.51 879.10 0.78 1465.80 894.18 0.70 
469.10 783.69 0.92 1083.28 885.58 0.79 1487.90 900.59 0.72 
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481.70 793.38 0.92 1101.04 891.78 0.79 1509.72 906.63 0.73 
494.38 802.72 0.93 1118.79 897.72 0.80 1531.28 912.35 0.74 
507.15 811.73 0.93 1136.55 903.39 0.81 1552.60 917.75 0.75 
520.00 820.42 0.93 1154.32 908.82 0.82 1573.72 922.85 0.76 
532.94 828.79 0.94 1172.11 914.01 0.83 1594.65 927.67 0.78 
545.98 836.86 0.94 1189.94 918.96 0.84 1615.41 932.22 0.79 
559.10 844.62 0.94 1207.81 923.69 0.85 1636.03 936.52 0.80 
572.33 852.10 0.94 1225.72 928.20 0.85 1656.53 940.59 0.81 
585.65 859.29 0.95 1243.70 932.50 0.86 1676.93 944.43 0.82 
599.08 866.20 0.95 1261.74 936.60 0.87 1697.24 948.06 0.83 
612.61 872.85 0.95 1279.87 940.50 0.87 1717.48 951.48 0.84 
626.25 879.23 0.95 1298.08 944.22 0.88 1737.68 954.72 0.84 
640.00 885.37 0.96 1316.39 947.75 0.89 1757.84 957.77 0.85 
653.88 891.26 0.96 1334.69 951.09 0.89 1778.00 960.65 0.86 
667.87 896.90 0.96 1350.00 953.74 0.90 1798.15 963.37 0.87 
681.98 902.32 0.96 1368.17 956.73 0.90 1818.32 965.93 0.88 
696.22 907.52 0.96 1386.43 959.56 0.91 1838.52 968.35 0.88 
710.59 912.49 0.97 1404.78 962.24 0.91 1858.78 970.63 0.89 
725.09 917.26 0.97 1423.23 964.78 0.92 1879.10 972.77 0.90 
739.74 921.82 0.97 1441.79 967.19 0.92 1899.49 974.79 0.90 
754.53 926.18 0.97 1460.48 969.46 0.93 1919.99 976.70 0.91 
769.46 930.36 0.97 1479.30 971.61 0.93 1940.59 978.49 0.92 
784.54 934.34 0.97 1498.27 973.64 0.94 1961.31 980.17 0.92 
799.78 938.15 0.98 1517.39 975.56 0.94 1982.17 981.75 0.93 
815.18 941.79 0.98 1536.68 977.37 0.95 2003.19 983.24 0.93 
830.75 945.26 0.98 1556.14 979.08 0.95 2024.38 984.63 0.94 
846.48 948.57 0.98 1575.79 980.69 0.95 2045.74 985.94 0.94 
862.40 951.72 0.98 1595.64 982.21 0.96 2067.31 987.16 0.95 
878.49 954.72 0.98 1615.70 983.64 0.96 2089.09 988.31 0.95 
894.76 957.58 0.98 1635.98 984.98 0.96 2111.10 989.38 0.95 
911.23 960.30 0.98 1656.49 986.24 0.96 2133.35 990.39 0.96 
927.89 962.89 0.98 1677.25 987.43 0.97 2155.86 991.32 0.96 
944.76 965.34 0.99 1698.26 988.54 0.97 2178.65 992.20 0.96 
961.84 967.67 0.99 1719.55 989.58 0.97 2201.74 993.01 0.97 
979.13 969.88 0.99 1741.12 990.56 0.97 2226.65 993.82 0.97 
997.67 972.10 0.99 1762.98 991.47 0.98 2250.32 994.52 0.97 
1015.29 974.06 0.99 1785.16 992.32 0.98 2272.97 995.14 0.97 
1032.56 975.86 0.99 1807.67 993.12 0.98 2296.03 995.71 0.98 
1050.10 977.57 0.99 1830.51 993.86 0.98 2319.53 996.25 0.98 
1067.90 979.20 0.99 1853.71 994.56 0.98 2343.48 996.75 0.98 
1085.98 980.74 0.99 1877.29 995.20 0.98 2367.90 997.22 0.98 
1104.35 982.20 0.99 1901.25 995.80 0.99 2392.82 997.66 0.98 
1123.02 983.58 0.99 1925.62 996.35 0.99 2418.25 998.06 0.98 
1141.99 984.88 0.99 1950.42 996.87 0.99 2444.23 998.44 0.99 
1161.29 986.12 0.99 1975.67 997.34 0.99 2470.78 998.78 0.99 
1180.92 987.28 0.99 2001.38 997.78 0.99 2497.93 999.10 0.99 
1200.89 988.38 0.99 2027.58 998.19 0.99 2525.71 999.40 0.99 
1221.23 989.41 1.00 2054.30 998.56 0.99 2554.17 999.67 0.99 
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1241.93 990.38 1.00 2081.55 998.91 0.99 2583.32 999.92 0.99 
1263.02 991.30 1.00 2109.36 999.22 0.99 2613.23 1000.14 0.99 
1284.51 992.15 1.00 2138.89 999.52 0.99 2643.93 1000.35 0.99 
1306.43 992.96 1.00 2166.95 999.78 0.99 2675.22 1000.54 0.99 
1328.65 993.71 1.00 2194.86 1000.01 1.00 2700.00 1000.67 0.99 
1350.00 994.37 1.00 2223.46 1000.22 1.00 2732.52 1000.83 1.00 
1372.82 995.01 1.00 2252.78 1000.41 1.00 2765.86 1000.97 1.00 
1396.05 995.62 1.00 2282.87 1000.58 1.00 2800.07 1001.10 1.00 
1419.71 996.18 1.00 2313.77 1000.74 1.00 2835.19 1001.22 1.00 
1443.81 996.70 1.00 2345.53 1000.89 1.00 2871.28 1001.32 1.00 
1468.37 997.18 1.00 2378.19 1001.02 1.00 2908.39 1001.41 1.00 
1493.41 997.63 1.00 2411.81 1001.14 1.00 2946.59 1001.49 1.00 
1518.94 998.04 1.00 2446.45 1001.25 1.00 2985.95 1001.56 1.00 
1545.00 998.43 1.00 2482.19 1001.35 1.00 3026.53 1001.63 1.00 
1571.59 998.78 1.00 2519.08 1001.44 1.00 3068.43 1001.68 1.00 
1598.75 999.10 1.00 2557.23 1001.51 1.00 3111.74 1001.73 1.00 
1626.49 999.40 1.00 2596.71 1001.58 1.00 3158.65 1001.78 1.00 
1654.85 999.67 1.00 2637.64 1001.64 1.00 3203.22 1001.81 1.00 
1683.84 999.92 1.00 2679.76 1001.70 1.00 3247.42 1001.84 1.00 
1713.51 1000.15 1.00 2700.00 1001.72 1.00 3293.37 1001.87 1.00 
1743.89 1000.35 1.00 2744.15 1001.77 1.00 3341.21 1001.89 1.00 
1775.00 1000.54 1.00 2789.86 1001.80 1.00 3391.08 1001.91 1.00 
1806.89 1000.71 1.00 2837.26 1001.84 1.00 3443.20 1001.93 1.00 
1839.59 1000.87 1.00 2886.46 1001.87 1.00 3497.75 1001.94 1.00 
1873.15 1001.01 1.00 2937.62 1001.89 1.00 3555.00 1001.95 1.00 
1907.62 1001.13 1.00 2993.24 1001.91 1.00 3615.22 1001.96 1.00 
1943.03 1001.24 1.00 3046.08 1001.93 1.00 3678.76 1001.97 1.00 
1980.88 1001.35 1.00 3098.81 1001.94 1.00 3746.00 1001.98 1.00 
2016.84 1001.43 1.00 3153.99 1001.95 1.00 3817.42 1001.98 1.00 
2052.80 1001.51 1.00 3211.89 1001.96 1.00 3893.59 1001.99 1.00 
2089.91 1001.57 1.00 3272.78 1001.97 1.00 3971.80 1001.99 1.00 
2128.25 1001.63 1.00 3336.99 1001.98 1.00 4050.00 1001.99 1.00 
2167.91 1001.68 1.00 3404.91 1001.98 1.00 4132.13 1002.00 1.00 
2208.99 1001.73 1.00 3477.00 1001.99 1.00 4220.24 1002.00 1.00 
2251.59 1001.77 1.00 3553.82 1001.99 1.00 4315.26 1002.00 1.00 
2295.84 1001.81 1.00 3636.05 1001.99 1.00 4418.37 1002.00 1.00 
2341.86 1001.84 1.00 3724.51 1001.99 1.00 4531.09 1002.00 1.00 
2389.82 1001.87 1.00 3820.27 1002.00 1.00 4655.38 1002.00 1.00 
2439.89 1001.89 1.00 3935.14 1002.00 1.00 4793.90 1002.00 1.00 
2492.27 1001.91 1.00 4050.00 1002.00 1.00 4950.33 1002.00 1.00 
2547.19 1001.93 1.00 4162.28 1002.00 1.00 5130.01 1002.00 1.00 
2604.92 1001.94 1.00 4285.88 1002.00 1.00 5334.74 1002.00 1.00 
2665.02 1001.95 1.00 4423.32 1002.00 1.00 5400.00 1002.00 1.00 
2700.00 1001.96 1.00 4578.07 1002.00 1.00 5635.46 1002.00 1.00 
2767.50 1001.97 1.00 4755.07 1002.00 1.00 5923.64 1002.00 1.00 
2831.63 1001.98 1.00 4961.74 1002.00 1.00 6293.79 1002.00 1.00 
2896.43 1001.98 1.00 5180.87 1002.00 1.00 6750.00 1002.00 1.00 
2964.94 1001.99 1.00 5400.00 1002.00 1.00 7425.00 1002.00 1.00 
  
Appendices               148 
  
3037.62 1001.99 1.00 5721.97 1002.00 1.00 8100.00 1002.00 1.00 
3114.99 1001.99 1.00 6147.25 1002.00 1.00 8775.00 1002.00 1.00 
3197.73 1001.99 1.00 6750.00 1002.00 1.00 9450.00 1002.00 1.00 
3286.62 1002.00 1.00 7425.00 1002.00 1.00 10125.00 1002.00 1.00 
3382.69 1002.00 1.00 8100.00 1002.00 1.00 10800.00 1002.00 1.00 
3487.19 1002.00 1.00 8775.00 1002.00 1.00 11475.00 1002.00 1.00 
3601.76 1002.00 1.00 9450.00 1002.00 1.00 12150.00 1002.00 1.00 
3728.59 1002.00 1.00 10800.00 1002.00 1.00 13500.00 1002.00 1.00 
3870.65 1002.00 1.00 12150.00 1002.00 1.00 14850.00 1002.00 1.00 
4028.66 1002.00 1.00 13500.00 1002.00 1.00 16200.00 1002.00 1.00 
4050.00 1002.00 1.00 14850.00 1002.00 1.00 17550.00 1002.00 1.00 
4215.98 1002.00 1.00 16200.00 1002.00 1.00 18900.00 1002.00 1.00 
4407.29 1002.00 1.00 17550.00 1002.00 1.00 20250.00 1002.00 1.00 
4632.90 1002.00 1.00 18900.00 1002.00 1.00 21600.00 1002.00 1.00 
4907.42 1002.00 1.00 20250.00 1002.00 1.00 22950.00 1002.00 1.00 
5241.16 1002.00 1.00 21600.00 1002.00 1.00 24300.00 1002.00 1.00 
5400.00 1002.00 1.00 22950.00 1002.00 1.00 25650.00 1002.00 1.00 
5877.33 1002.00 1.00 24300.00 1002.00 1.00 27000.00 1002.00 1.00 
6575.88 1002.00 1.00 25650.00 1002.00 1.00 28350.00 1002.00 1.00 
6750.00 1002.00 1.00 27000.00 1002.00 1.00 29700.00 1002.00 1.00 
7425.00 1002.00 1.00 28350.00 1002.00 1.00 31050.00 1002.00 1.00 
8100.00 1002.00 1.00 29700.00 1002.00 1.00 32400.00 1002.00 1.00 
 
τs = 5     τs = 8     τs =10     
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
0.00 0.00 0.05 0.00 0.00 0.03 0.00 0.00 0.02 
189.87 36.09 0.05 356.81 43.19 0.03 445.63 43.43 0.03 
424.01 80.51 0.05 745.03 90.11 0.03 897.82 87.44 0.03 
665.41 126.18 0.06 1153.76 139.42 0.04 1350.00 131.40 0.03 
910.49 172.41 0.06 1350.00 163.06 0.04 1882.59 183.09 0.03 
1154.70 218.34 0.06 1761.71 212.57 0.04 2410.15 234.19 0.03 
1350.00 254.94 0.06 2170.12 261.57 0.04 2700.00 262.22 0.03 
1581.33 298.15 0.07 2567.32 309.09 0.04 3209.89 311.44 0.04 
1808.14 340.34 0.07 2700.00 324.94 0.05 3696.85 358.34 0.04 
2029.90 381.41 0.08 3074.99 369.62 0.05 4050.00 392.26 0.04 
2246.24 421.27 0.08 3439.50 412.91 0.05 4503.68 435.74 0.04 
2473.12 462.84 0.09 3783.35 453.60 0.06 4926.24 476.09 0.05 
2674.03 499.42 0.09 4050.00 485.04 0.06 5340.44 515.52 0.05 
2700.00 504.13 0.09 4360.00 521.45 0.06 5400.00 521.17 0.05 
2875.58 535.87 0.10 4658.43 556.34 0.07 5779.28 557.11 0.05 
3045.39 566.36 0.11 4945.38 589.71 0.07 6142.87 591.41 0.06 
3209.50 595.62 0.11 5212.31 620.58 0.08 6478.79 622.95 0.06 
3368.01 623.66 0.12 5400.00 642.18 0.08 6750.00 648.30 0.07 
3521.05 650.49 0.13 5630.13 668.51 0.09 7043.37 675.58 0.07 
3668.73 676.14 0.14 5850.59 693.56 0.09 7323.47 701.47 0.08 
3811.19 700.63 0.15 6061.72 717.38 0.10 7590.78 726.02 0.09 
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3944.09 723.21 0.16 6263.86 739.99 0.11 7834.40 748.23 0.09 
4050.00 741.01 0.16 6457.34 761.44 0.12 8072.24 769.74 0.10 
4152.33 758.02 0.17 6636.22 781.07 0.13 8100.00 772.24 0.10 
4251.00 774.23 0.18 6750.00 793.44 0.13 8300.42 790.19 0.11 
4346.14 789.66 0.19 6892.51 808.81 0.14 8491.52 807.16 0.12 
4437.86 804.33 0.21 7028.96 823.35 0.15 8673.77 823.19 0.13 
4526.28 818.27 0.22 7159.62 837.12 0.16 8847.58 838.30 0.14 
4611.51 831.48 0.23 7284.75 850.12 0.17 9013.37 852.55 0.15 
4693.63 844.00 0.25 7404.58 862.40 0.19 9171.53 865.95 0.16 
4772.72 855.83 0.26 7519.36 873.97 0.20 9315.85 878.01 0.17 
4848.87 866.99 0.28 7629.26 884.86 0.21 9450.00 889.03 0.18 
4922.14 877.49 0.29 7734.48 895.09 0.23 9555.96 897.61 0.20 
4992.58 887.35 0.31 7835.16 904.66 0.25 9657.36 905.68 0.21 
5060.27 896.58 0.33 7931.44 913.61 0.27 9754.43 913.28 0.22 
5125.26 905.20 0.35 8019.93 921.62 0.29 9847.33 920.42 0.24 
5187.63 913.23 0.37 8100.00 928.69 0.30 9936.26 927.12 0.26 
5247.47 920.70 0.39 8167.50 934.48 0.32 10021.34 933.38 0.27 
5304.86 927.61 0.41 8231.63 939.85 0.34 10102.71 939.24 0.29 
5358.50 933.85 0.43 8292.54 944.80 0.36 10180.50 944.69 0.31 
5400.00 938.52 0.45 8350.42 949.37 0.38 10254.80 949.75 0.33 
5449.36 943.87 0.47 8405.40 953.57 0.40 10325.75 954.43 0.35 
5496.28 948.75 0.49 8457.63 957.43 0.42 10393.45 958.76 0.37 
5540.97 953.21 0.51 8507.24 960.98 0.44 10458.05 962.74 0.40 
5583.64 957.28 0.53 8554.38 964.23 0.46 10519.68 966.40 0.42 
5624.48 961.00 0.56 8599.16 967.20 0.48 10578.52 969.75 0.44 
5663.68 964.40 0.58 8641.71 969.91 0.50 10634.75 972.81 0.47 
5701.40 967.51 0.60 8682.12 972.39 0.52 10688.54 975.61 0.49 
5737.79 970.36 0.62 8720.51 974.65 0.54 10744.27 978.36 0.52 
5772.99 972.98 0.64 8757.26 976.72 0.56 10792.84 980.63 0.55 
5807.13 975.38 0.66 8793.04 978.65 0.58 10800.00 980.95 0.55 
5840.32 977.58 0.68 8827.95 980.44 0.60 10845.49 982.95 0.57 
5872.68 979.61 0.70 8862.07 982.12 0.62 10888.96 984.75 0.60 
5904.29 981.47 0.71 8895.50 983.68 0.64 10930.65 986.38 0.62 
5935.25 983.19 0.73 8928.30 985.13 0.66 10970.78 987.85 0.64 
5965.65 984.77 0.75 8960.56 986.48 0.67 11009.54 989.18 0.67 
5995.56 986.22 0.76 8992.35 987.74 0.69 11047.11 990.39 0.69 
6025.05 987.57 0.78 9023.74 988.92 0.71 11083.63 991.49 0.71 
6054.18 988.80 0.80 9054.78 990.01 0.73 11119.26 992.49 0.73 
6083.02 989.94 0.81 9085.54 991.02 0.74 11154.12 993.40 0.75 
6111.64 990.99 0.82 9116.08 991.96 0.76 11188.33 994.23 0.77 
6140.07 991.96 0.84 9146.44 992.84 0.78 11222.00 994.98 0.79 
6170.57 992.92 0.85 9176.69 993.65 0.79 11255.23 995.67 0.80 
6199.54 993.75 0.86 9206.87 994.40 0.81 11288.10 996.29 0.82 
6227.06 994.49 0.87 9237.03 995.09 0.82 11320.71 996.86 0.83 
6253.21 995.13 0.88 9267.22 995.74 0.84 11353.14 997.38 0.85 
6278.77 995.71 0.89 9297.49 996.33 0.85 11385.45 997.85 0.86 
6304.64 996.25 0.90 9327.87 996.88 0.86 11417.72 998.28 0.87 
6330.83 996.76 0.91 9358.43 997.38 0.87 11450.03 998.67 0.89 
6357.38 997.23 0.91 9389.21 997.84 0.89 11485.03 999.05 0.90 
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6384.30 997.67 0.92 9419.86 998.26 0.90 11518.28 999.38 0.91 
6411.63 998.08 0.93 9450.00 998.64 0.91 11549.86 999.66 0.92 
6439.40 998.45 0.94 9480.89 998.99 0.91 11579.87 999.90 0.92 
6467.63 998.80 0.94 9512.03 999.31 0.92 11609.98 1000.11 0.93 
6496.35 999.12 0.95 9543.49 999.60 0.93 11640.71 1000.31 0.94 
6525.61 999.42 0.95 9575.29 999.86 0.94 11672.09 1000.50 0.94 
6555.45 999.69 0.96 9607.51 1000.10 0.94 11704.17 1000.66 0.95 
6585.89 999.94 0.96 9640.18 1000.31 0.95 11736.99 1000.82 0.96 
6616.99 1000.17 0.97 9673.37 1000.51 0.96 11770.59 1000.96 0.96 
6648.79 1000.37 0.97 9707.12 1000.69 0.96 11805.03 1001.08 0.97 
6681.34 1000.56 0.97 9741.50 1000.84 0.97 11840.37 1001.20 0.97 
6715.67 1000.74 0.98 9776.55 1000.99 0.97 11876.67 1001.30 0.97 
6750.00 1000.89 0.98 9812.33 1001.12 0.97 11914.00 1001.39 0.98 
6784.49 1001.03 0.98 9848.92 1001.23 0.98 11952.44 1001.48 0.98 
6819.80 1001.15 0.98 9886.38 1001.33 0.98 11992.09 1001.55 0.98 
6855.97 1001.26 0.99 9924.77 1001.42 0.98 12033.03 1001.62 0.99 
6893.07 1001.36 0.99 9968.53 1001.51 0.99 12075.38 1001.67 0.99 
6931.16 1001.45 0.99 10010.10 1001.59 0.99 12118.80 1001.72 0.99 
6970.32 1001.53 0.99 10049.60 1001.64 0.99 12150.00 1001.76 0.99 
7010.61 1001.59 0.99 10088.94 1001.69 0.99 12195.88 1001.79 0.99 
7052.13 1001.65 0.99 10129.68 1001.74 0.99 12243.35 1001.83 0.99 
7094.96 1001.71 0.99 10171.91 1001.78 0.99 12292.53 1001.86 0.99 
7139.20 1001.75 1.00 10215.73 1001.81 0.99 12343.58 1001.88 1.00 
7187.24 1001.80 1.00 10261.26 1001.84 1.00 12401.40 1001.91 1.00 
7232.88 1001.83 1.00 10308.64 1001.87 1.00 12456.33 1001.93 1.00 
7277.76 1001.86 1.00 10358.04 1001.89 1.00 12508.51 1001.94 1.00 
7324.45 1001.88 1.00 10409.62 1001.91 1.00 12563.05 1001.95 1.00 
7373.09 1001.90 1.00 10463.60 1001.93 1.00 12620.26 1001.96 1.00 
7423.86 1001.92 1.00 10520.23 1001.94 1.00 12680.43 1001.97 1.00 
7476.94 1001.93 1.00 10579.79 1001.95 1.00 12743.84 1001.98 1.00 
7532.56 1001.95 1.00 10642.62 1001.96 1.00 12810.88 1001.98 1.00 
7590.97 1001.96 1.00 10709.11 1001.97 1.00 12881.98 1001.99 1.00 
7652.47 1001.97 1.00 10778.88 1001.98 1.00 12957.66 1001.99 1.00 
7717.42 1001.97 1.00 10800.00 1001.98 1.00 13038.57 1001.99 1.00 
7786.24 1001.98 1.00 10867.50 1001.99 1.00 13125.49 1001.99 1.00 
7859.42 1001.99 1.00 10938.23 1001.99 1.00 13219.41 1002.00 1.00 
7937.59 1001.99 1.00 11013.42 1001.99 1.00 13321.59 1002.00 1.00 
8018.80 1001.99 1.00 11093.65 1001.99 1.00 13431.24 1002.00 1.00 
8100.00 1001.99 1.00 11179.64 1002.00 1.00 13500.00 1002.00 1.00 
8184.84 1002.00 1.00 11272.27 1002.00 1.00 13615.03 1002.00 1.00 
8276.08 1002.00 1.00 11372.65 1002.00 1.00 13741.96 1002.00 1.00 
8374.75 1002.00 1.00 11482.22 1002.00 1.00 13883.53 1002.00 1.00 
8482.17 1002.00 1.00 11602.81 1002.00 1.00 14043.49 1002.00 1.00 
8600.04 1002.00 1.00 11736.93 1002.00 1.00 14227.31 1002.00 1.00 
8730.60 1002.00 1.00 11888.02 1002.00 1.00 14443.26 1002.00 1.00 
8876.93 1002.00 1.00 12055.97 1002.00 1.00 14694.22 1002.00 1.00 
9043.35 1002.00 1.00 12150.00 1002.00 1.00 14850.00 1002.00 1.00 
9246.68 1002.00 1.00 12341.62 1002.00 1.00 15179.95 1002.00 1.00 
  
Appendices               151 
  
9450.00 1002.00 1.00 12567.43 1002.00 1.00 15618.92 1002.00 1.00 
9693.32 1002.00 1.00 12841.86 1002.00 1.00 16200.00 1002.00 1.00 
9993.14 1002.00 1.00 13170.93 1002.00 1.00 16875.00 1002.00 1.00 
10396.57 1002.00 1.00 13500.00 1002.00 1.00 17550.00 1002.00 1.00 
10800.00 1002.00 1.00 14052.17 1002.00 1.00 18225.00 1002.00 1.00 
11475.00 1002.00 1.00 14850.00 1002.00 1.00 18900.00 1002.00 1.00 
12150.00 1002.00 1.00 15525.00 1002.00 1.00 19575.00 1002.00 1.00 
12825.00 1002.00 1.00 16200.00 1002.00 1.00 20250.00 1002.00 1.00 
13500.00 1002.00 1.00 16875.00 1002.00 1.00 21600.00 1002.00 1.00 
14175.00 1002.00 1.00 17550.00 1002.00 1.00 22950.00 1002.00 1.00 
14850.00 1002.00 1.00 18225.00 1002.00 1.00 24300.00 1002.00 1.00 
15525.00 1002.00 1.00 18900.00 1002.00 1.00 25650.00 1002.00 1.00 
16200.00 1002.00 1.00 20250.00 1002.00 1.00 27000.00 1002.00 1.00 
16875.00 1002.00 1.00 21600.00 1002.00 1.00 28350.00 1002.00 1.00 
17550.00 1002.00 1.00 22950.00 1002.00 1.00 29700.00 1002.00 1.00 
18225.00 1002.00 1.00 24300.00 1002.00 1.00 31050.00 1002.00 1.00 
18900.00 1002.00 1.00 25650.00 1002.00 1.00 32400.00 1002.00 1.00 
19575.00 1002.00 1.00 27000.00 1002.00 1.00 33750.00 1002.00 1.00 
20250.00 1002.00 1.00 28350.00 1002.00 1.00 35100.00 1002.00 1.00 
20925.00 1002.00 1.00 29700.00 1002.00 1.00 36450.00 1002.00 1.00 
21600.00 1002.00 1.00 31050.00 1002.00 1.00 37800.00 1002.00 1.00 
22275.00 1002.00 1.00 32400.00 1002.00 1.00 39150.00 1002.00 1.00 
22950.00 1002.00 1.00 33750.00 1002.00 1.00 40500.00 1002.00 1.00 
23625.00 1002.00 1.00 35100.00 1002.00 1.00 41850.00 1002.00 1.00 
24300.00 1002.00 1.00 36450.00 1002.00 1.00 43200.00 1002.00 1.00 
24975.00 1002.00 1.00 37800.00 1002.00 1.00 44550.00 1002.00 1.00 
25650.00 1002.00 1.00 39150.00 1002.00 1.00 45900.00 1002.00 1.00 
26325.00 1002.00 1.00 40500.00 1002.00 1.00 47250.00 1002.00 1.00 
27000.00 1002.00 1.00 41850.00 1002.00 1.00 48600.00 1002.00 1.00 
27675.00 1002.00 1.00 43200.00 1002.00 1.00 49950.00 1002.00 1.00 
28350.00 1002.00 1.00 44550.00 1002.00 1.00 51300.00 1002.00 1.00 
29025.00 1002.00 1.00 45900.00 1002.00 1.00 52650.00 1002.00 1.00 
29700.00 1002.00 1.00 47250.00 1002.00 1.00 54000.00 1002.00 1.00 
30375.00 1002.00 1.00 48600.00 1002.00 1.00    
31050.00 1002.00 1.00 49950.00 1002.00 1.00    
31725.00 1002.00 1.00 51300.00 1002.00 1.00    
32400.00 1002.00 1.00 52650.00 1002.00 1.00    
33075.00 1002.00 1.00 54000.00 1002.00 1.00    
33750.00 1002.00 1.00       
34425.00 1002.00 1.00       
35100.00 1002.00 1.00       
35775.00 1002.00 1.00       
36450.00 1002.00 1.00       
37125.00 1002.00 1.00       
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τs = 20     
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
0.00 0.00 0.01 
675.00 33.32 0.01 
1350.00 66.62 0.01 
2025.00 99.90 0.01 
2700.00 133.17 0.01 
3375.00 166.42 0.02 
4050.00 199.65 0.02 
4725.00 232.86 0.02 
5400.00 266.04 0.02 
6075.00 299.20 0.02 
6750.00 332.33 0.02 
7425.00 365.43 0.02 
8100.00 398.50 0.02 
8775.00 431.53 0.02 
9450.00 464.51 0.02 
10125.00 497.45 0.02 
10800.00 530.34 0.03 
11475.00 563.17 0.03 
12150.00 595.92 0.03 
12825.00 628.60 0.03 
13500.00 661.17 0.04 
14175.00 693.64 0.04 
14758.92 721.62 0.04 
14850.00 725.97 0.04 
15378.65 751.18 0.05 
15855.70 773.82 0.05 
16200.00 790.08 0.06 
16615.46 809.62 0.06 
17006.72 827.90 0.07 
17360.51 844.32 0.08 
17550.00 853.06 0.08 
17849.91 866.81 0.09 
18132.48 879.66 0.09 
18398.77 891.65 0.10 
18635.76 902.21 0.11 
18865.97 912.35 0.13 
18900.00 913.84 0.13 
19084.43 921.84 0.14 
19258.75 929.30 0.15 
19423.60 936.26 0.16 
19579.57 942.73 0.18 
19727.18 948.74 0.19 
19866.90 954.31 0.21 
19999.12 959.45 0.23 
20117.50 963.94 0.25 
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20232.60 968.18 0.27 
20250.00 968.81 0.28 
20328.00 971.59 0.30 
20402.48 974.18 0.32 
20473.57 976.58 0.34 
20541.38 978.79 0.36 
20606.05 980.84 0.38 
20667.72 982.73 0.40 
20726.54 984.46 0.42 
20782.69 986.05 0.45 
20836.37 987.51 0.47 
20887.77 988.84 0.49 
20937.09 990.06 0.52 
20984.54 991.18 0.54 
21030.31 992.20 0.57 
21074.59 993.13 0.59 
21117.55 993.98 0.62 
21159.36 994.76 0.64 
21200.17 995.47 0.66 
21240.12 996.12 0.69 
21279.35 996.72 0.71 
21317.99 997.26 0.73 
21356.14 997.76 0.75 
21393.91 998.21 0.77 
21431.41 998.62 0.79 
21468.73 998.99 0.81 
21505.97 999.33 0.83 
21543.22 999.63 0.84 
21580.11 999.90 0.86 
21600.00 1000.04 0.87 
21636.62 1000.27 0.88 
21673.35 1000.48 0.89 
21710.27 1000.66 0.91 
21747.47 1000.83 0.92 
21785.06 1000.98 0.93 
21823.11 1001.11 0.93 
21861.71 1001.23 0.94 
21900.95 1001.33 0.95 
21940.93 1001.42 0.96 
21981.73 1001.50 0.96 
22023.46 1001.58 0.97 
22069.79 1001.64 0.97 
22113.80 1001.70 0.98 
22155.61 1001.74 0.98 
22197.47 1001.78 0.98 
22240.94 1001.82 0.99 
22286.12 1001.84 0.99 
22333.12 1001.87 0.99 
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22382.09 1001.89 0.99 
22433.20 1001.91 0.99 
22486.63 1001.93 0.99 
22542.61 1001.94 1.00 
22601.40 1001.95 1.00 
22663.30 1001.96 1.00 
22728.70 1001.97 1.00 
22798.03 1001.98 1.00 
22874.01 1001.98 1.00 
22950.00 1001.99 1.00 
23023.52 1001.99 1.00 
23101.92 1001.99 1.00 
23185.82 1002.00 1.00 
23276.05 1002.00 1.00 
23373.61 1002.00 1.00 
23479.78 1002.00 1.00 
23596.22 1002.00 1.00 
23725.13 1002.00 1.00 
23869.53 1002.00 1.00 
24033.66 1002.00 1.00 
24218.16 1002.00 1.00 
24300.00 1002.00 1.00 
24511.42 1002.00 1.00 
24764.84 1002.00 1.00 
25080.42 1002.00 1.00 
25476.20 1002.00 1.00 
25650.00 1002.00 1.00 
26325.00 1002.00 1.00 
27000.00 1002.00 1.00 
27675.00 1002.00 1.00 
28350.00 1002.00 1.00 
29025.00 1002.00 1.00 
29700.00 1002.00 1.00 
30375.00 1002.00 1.00 
31050.00 1002.00 1.00 
31725.00 1002.00 1.00 
32400.00 1002.00 1.00 
33075.00 1002.00 1.00 
33750.00 1002.00 1.00 
34425.00 1002.00 1.00 
35100.00 1002.00 1.00 
35775.00 1002.00 1.00 
36450.00 1002.00 1.00 
37125.00 1002.00 1.00 
37800.00 1002.00 1.00 
38475.00 1002.00 1.00 
39150.00 1002.00 1.00 
39825.00 1002.00 1.00 
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40500.00 1002.00 1.00 
41175.00 1002.00 1.00 
41850.00 1002.00 1.00 
42525.00 1002.00 1.00 
43200.00 1002.00 1.00 
43875.00 1002.00 1.00 
44550.00 1002.00 1.00 
45225.00 1002.00 1.00 
45900.00 1002.00 1.00 
46575.00 1002.00 1.00 
47250.00 1002.00 1.00 
47925.00 1002.00 1.00 
48600.00 1002.00 1.00 
49275.00 1002.00 1.00 
49950.00 1002.00 1.00 
50625.00 1002.00 1.00 
51300.00 1002.00 1.00 
51975.00 1002.00 1.00 
52650.00 1002.00 1.00 
53325.00 1002.00 1.00 
54000.00 1002.00 1.00 
22950.00 1002.00 1.00 
24300.00 1002.00 1.00 
25650.00 1002.00 1.00 
27000.00 1002.00 1.00 
28350.00 1002.00 1.00 
29700.00 1002.00 1.00 
31050.00 1002.00 1.00 
32400.00 1002.00 1.00 
33750.00 1002.00 1.00 
35100.00 1002.00 1.00 
36450.00 1002.00 1.00 
37800.00 1002.00 1.00 
39150.00 1002.00 1.00 
40500.00 1002.00 1.00 
41850.00 1002.00 1.00 
43200.00 1002.00 1.00 
44550.00 1002.00 1.00 
45900.00 1002.00 1.00 
47250.00 1002.00 1.00 
48600.00 1002.00 1.00 
49950.00 1002.00 1.00 
51300.00 1002.00 1.00 
52650.00 1002.00 1.00 
54000.00 1002.00 1.00 
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τs = 8     τs = 10     τs = 20     
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
Time 
(sec) 
y 
(U/mL) 
x 
(U/mL) 
0.00 0.00 0.17 0.00 0.00 0.14 0.00 0.00 0.08 
282.06 29.11 0.18 382.45 32.71 0.15 675.00 31.12 0.08 
628.28 64.64 0.18 806.21 68.77 0.15 1350.00 62.16 0.08 
989.14 101.41 0.19 1263.08 107.41 0.16 2025.00 93.12 0.08 
1350.00 137.90 0.19 1350.00 114.73 0.16 2700.00 123.99 0.09 
1742.01 177.21 0.20 1826.95 154.74 0.16 3375.00 154.77 0.09 
2137.40 216.47 0.21 2309.78 194.92 0.17 4050.00 185.45 0.09 
2532.09 255.26 0.22 2700.00 227.15 0.18 4725.00 216.02 0.10 
2700.00 271.63 0.22 3182.76 266.70 0.18 5400.00 246.47 0.10 
3088.43 309.18 0.23 3657.80 305.23 0.19 6075.00 276.81 0.10 
3473.76 345.98 0.24 4050.00 336.74 0.20 6750.00 307.01 0.11 
3850.65 381.49 0.25 4512.71 373.53 0.21 7425.00 337.08 0.11 
4050.00 400.08 0.26 4961.02 408.75 0.22 8100.00 366.99 0.12 
4412.29 433.47 0.27 5400.00 442.79 0.23 8775.00 396.74 0.12 
4768.62 465.81 0.28 5828.88 475.60 0.24 9450.00 426.32 0.13 
5112.55 496.52 0.29 6289.44 510.30 0.25 10125.00 455.70 0.13 
5400.00 521.77 0.30 6695.74 540.40 0.27 10800.00 484.88 0.14 
5724.08 549.77 0.32 6750.00 544.38 0.27 11475.00 513.83 0.15 
6041.04 576.63 0.33 7136.09 572.44 0.28 12150.00 542.53 0.15 
6350.72 602.35 0.34 7513.16 599.36 0.29 12825.00 570.95 0.16 
6649.00 626.59 0.36 7874.21 624.66 0.31 13500.00 599.08 0.17 
6750.00 634.68 0.36 8100.00 640.22 0.32 14175.00 626.88 0.18 
7028.89 656.68 0.38 8437.10 663.06 0.33 14850.00 654.30 0.19 
7300.78 677.63 0.39 8765.17 684.81 0.34 15525.00 681.31 0.21 
7565.72 697.54 0.41 9107.59 706.98 0.36 16113.83 704.50 0.22 
7832.86 717.10 0.42 9413.13 726.26 0.38 16200.00 707.86 0.22 
8100.00 736.11 0.44 9450.00 728.56 0.38 16756.99 729.38 0.23 
8331.73 752.13 0.45 9734.72 746.03 0.39 17283.45 749.36 0.25 
8557.71 767.32 0.47 10011.39 762.56 0.41 17550.00 759.33 0.26 
8778.16 781.70 0.49 10280.21 778.19 0.43 18041.58 777.44 0.27 
8993.29 795.31 0.50 10536.07 792.65 0.44 18503.00 794.09 0.29 
9221.65 809.27 0.52 10800.00 807.11 0.46 18900.00 808.12 0.30 
9424.58 821.26 0.54 11033.45 819.51 0.48 19324.21 822.78 0.32 
9450.00 822.73 0.54 11260.80 831.20 0.49 19733.39 836.57 0.33 
9638.94 833.48 0.55 11482.34 842.23 0.51 20120.15 849.26 0.35 
9824.10 843.65 0.57 11698.38 852.62 0.53 20250.00 853.44 0.36 
10005.69 853.28 0.58 11924.19 863.09 0.55 20606.09 864.68 0.38 
10183.93 862.39 0.60 12150.00 873.15 0.56 20949.36 875.20 0.40 
10359.03 871.01 0.61 12339.51 881.26 0.58 21271.53 884.77 0.42 
10531.22 879.15 0.63 12525.31 888.92 0.60 21600.00 894.21 0.44 
10698.86 886.77 0.64 12707.63 896.15 0.61 21890.65 902.26 0.46 
10800.00 891.22 0.65 12886.73 902.96 0.63 22171.57 909.78 0.47 
10956.67 897.88 0.67 13062.86 909.39 0.64 22443.32 916.78 0.49 
11111.49 904.19 0.68 13236.24 915.45 0.66 22700.77 923.17 0.51 
11264.61 910.18 0.69 13405.27 921.10 0.67 22950.00 929.11 0.53 
11416.19 915.85 0.71 13500.00 924.16 0.68 23183.82 934.45 0.55 
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11566.38 921.22 0.72 13658.41 929.09 0.70 23411.50 939.44 0.57 
11715.34 926.30 0.73 13815.19 933.75 0.71 23633.51 944.10 0.59 
11863.19 931.11 0.75 13970.52 938.16 0.72 23850.28 948.44 0.61 
12008.50 935.61 0.76 14124.55 942.32 0.74 24075.14 952.73 0.63 
12150.00 939.78 0.77 14277.45 946.25 0.75 24300.00 956.79 0.65 
12288.24 943.66 0.78 14429.38 949.97 0.76 24491.80 960.08 0.67 
12426.13 947.33 0.79 14580.48 953.47 0.77 24680.62 963.16 0.68 
12563.78 950.82 0.80 14729.43 956.74 0.79 24866.78 966.05 0.70 
12701.28 954.12 0.81 14850.00 959.25 0.80 25050.57 968.74 0.71 
12838.76 957.24 0.82 14992.39 962.08 0.81 25232.27 971.26 0.73 
12976.31 960.20 0.83 15134.71 964.76 0.82 25412.16 973.62 0.75 
13114.04 962.99 0.84 15277.07 967.28 0.83 25588.86 975.79 0.76 
13252.06 965.64 0.85 15419.58 969.67 0.84 25650.00 976.52 0.77 
13389.36 968.11 0.86 15562.38 971.92 0.85 25817.72 978.42 0.78 
13500.00 970.00 0.87 15705.57 974.04 0.86 25984.79 980.21 0.79 
13633.45 972.15 0.87 15849.27 976.04 0.87 26151.42 981.88 0.81 
13767.68 974.19 0.88 15993.59 977.93 0.87 26317.80 983.45 0.82 
13902.77 976.12 0.89 16137.74 979.69 0.88 26484.12 984.91 0.83 
14038.82 977.94 0.90 16200.00 980.41 0.89 26650.59 986.28 0.84 
14175.93 979.66 0.90 16340.34 981.97 0.89 26825.29 987.62 0.85 
14314.19 981.27 0.91 16481.79 983.43 0.90 27000.00 988.86 0.86 
14453.70 982.80 0.92 16624.45 984.82 0.91 27160.79 989.91 0.87 
14594.57 984.23 0.92 16768.42 986.11 0.91 27322.62 990.90 0.88 
14735.90 985.57 0.93 16913.83 987.34 0.92 27485.66 991.82 0.89 
14850.00 986.58 0.93 17060.80 988.48 0.92 27650.08 992.68 0.90 
14989.97 987.75 0.94 17209.43 989.55 0.93 27816.03 993.48 0.91 
15131.70 988.84 0.94 17359.86 990.56 0.94 27983.71 994.23 0.91 
15275.29 989.87 0.94 17511.45 991.49 0.94 28166.85 994.98 0.92 
15420.85 990.83 0.95 17550.00 991.72 0.94 28350.00 995.66 0.93 
15568.50 991.73 0.95 17699.51 992.56 0.95 28517.89 996.22 0.94 
15718.36 992.58 0.96 17851.20 993.34 0.95 28688.26 996.75 0.94 
15870.56 993.37 0.96 18005.20 994.07 0.95 28861.29 997.24 0.95 
16035.28 994.15 0.96 18161.65 994.75 0.96 29037.18 997.69 0.95 
16200.00 994.86 0.97 18320.69 995.38 0.96 29216.13 998.11 0.96 
16355.24 995.48 0.97 18482.47 995.97 0.97 29398.36 998.50 0.96 
16513.28 996.05 0.97 18647.17 996.52 0.97 29582.71 998.85 0.96 
16674.28 996.59 0.97 18813.93 997.03 0.97 29700.00 999.06 0.97 
16838.39 997.08 0.98 18900.00 997.27 0.97 29885.74 999.36 0.97 
17005.78 997.54 0.98 19067.32 997.71 0.97 30075.47 999.64 0.97 
17176.65 997.97 0.98 19238.03 998.12 0.98 30269.45 999.89 0.98 
17363.33 998.39 0.98 19412.29 998.50 0.98 30467.97 1000.12 0.98 
17550.00 998.77 0.98 19590.33 998.85 0.98 30671.31 1000.33 0.98 
17727.52 999.09 0.99 19772.36 999.17 0.98 30878.00 1000.52 0.98 
17909.15 999.38 0.99 19958.61 999.46 0.99 31050.00 1000.67 0.98 
18095.10 999.66 0.99 20148.09 999.73 0.99 31262.15 1000.82 0.99 
18285.63 999.91 0.99 20250.00 999.86 0.99 31480.14 1000.97 0.99 
18481.02 1000.14 0.99 20442.23 1000.09 0.99 31704.38 1001.09 0.99 
18690.51 1000.36 0.99 20639.34 1000.30 0.99 31935.31 1001.21 0.99 
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18900.00 1000.55 0.99 20841.63 1000.50 0.99 32167.65 1001.31 0.99 
19106.09 1000.72 0.99 21049.42 1000.67 0.99 32400.00 1001.40 0.99 
19317.99 1000.87 0.99 21263.07 1000.83 0.99 32646.15 1001.48 0.99 
19536.06 1001.01 1.00 21481.35 1000.97 0.99 32900.58 1001.56 0.99 
19760.72 1001.13 1.00 21600.00 1001.04 0.99 33163.95 1001.62 1.00 
20005.36 1001.25 1.00 21823.65 1001.16 1.00 33456.98 1001.68 1.00 
20250.00 1001.35 1.00 22054.18 1001.27 1.00 33750.00 1001.73 1.00 
20490.94 1001.44 1.00 22292.08 1001.37 1.00 34037.69 1001.78 1.00 
20740.01 1001.52 1.00 22537.87 1001.45 1.00 34337.00 1001.81 1.00 
20997.80 1001.59 1.00 22789.93 1001.53 1.00 34648.96 1001.84 1.00 
21264.99 1001.65 1.00 22950.00 1001.57 1.00 34971.68 1001.87 1.00 
21540.36 1001.70 1.00 23211.72 1001.63 1.00 35100.00 1001.88 1.00 
21600.00 1001.71 1.00 23483.07 1001.69 1.00 35437.38 1001.90 1.00 
21882.59 1001.76 1.00 23764.82 1001.74 1.00 35790.93 1001.92 1.00 
22176.48 1001.80 1.00 24054.61 1001.78 1.00 36157.44 1001.94 1.00 
22482.67 1001.83 1.00 24300.00 1001.81 1.00 36450.00 1001.95 1.00 
22799.19 1001.86 1.00 24607.09 1001.84 1.00 36846.23 1001.96 1.00 
22950.00 1001.87 1.00 24927.58 1001.87 1.00 37264.98 1001.97 1.00 
23281.90 1001.89 1.00 25288.79 1001.89 1.00 37704.19 1001.98 1.00 
23629.52 1001.91 1.00 25650.00 1001.92 1.00 37800.00 1001.98 1.00 
23989.57 1001.93 1.00 26010.75 1001.93 1.00 38265.66 1001.98 1.00 
24300.00 1001.94 1.00 26390.13 1001.95 1.00 38754.10 1001.99 1.00 
24690.07 1001.95 1.00 26785.30 1001.96 1.00 39150.00 1001.99 1.00 
25101.99 1001.96 1.00 27000.00 1001.96 1.00 39697.42 1001.99 1.00 
25533.56 1001.97 1.00 27424.02 1001.97 1.00 40279.11 1001.99 1.00 
25650.00 1001.97 1.00 27887.01 1001.98 1.00 40500.00 1002.00 1.00 
26108.56 1001.98 1.00 28350.00 1001.98 1.00 41175.00 1002.00 1.00 
26589.04 1001.99 1.00 28848.49 1001.99 1.00 41850.00 1002.00 1.00 
27000.00 1001.99 1.00 29374.11 1001.99 1.00 42525.00 1002.00 1.00 
27539.15 1001.99 1.00 29700.00 1001.99 1.00 43200.00 1002.00 1.00 
28111.32 1001.99 1.00 30286.11 1001.99 1.00 43875.00 1002.00 1.00 
28350.00 1002.00 1.00 30912.74 1002.00 1.00 44550.00 1002.00 1.00 
29025.00 1002.00 1.00 31050.00 1002.00 1.00 45225.00 1002.00 1.00 
29700.00 1002.00 1.00 31725.00 1002.00 1.00 45900.00 1002.00 1.00 
30375.00 1002.00 1.00 32400.00 1002.00 1.00 46575.00 1002.00 1.00 
31050.00 1002.00 1.00 33075.00 1002.00 1.00 47250.00 1002.00 1.00 
31725.00 1002.00 1.00 33750.00 1002.00 1.00 47925.00 1002.00 1.00 
32400.00 1002.00 1.00 34425.00 1002.00 1.00 48600.00 1002.00 1.00 
33075.00 1002.00 1.00 35100.00 1002.00 1.00 49275.00 1002.00 1.00 
33750.00 1002.00 1.00 35775.00 1002.00 1.00 49950.00 1002.00 1.00 
34425.00 1002.00 1.00 36450.00 1002.00 1.00 50625.00 1002.00 1.00 
35100.00 1002.00 1.00 37125.00 1002.00 1.00 51300.00 1002.00 1.00 
35775.00 1002.00 1.00 37800.00 1002.00 1.00 51975.00 1002.00 1.00 
36450.00 1002.00 1.00 38475.00 1002.00 1.00 52650.00 1002.00 1.00 
37125.00 1002.00 1.00 39150.00 1002.00 1.00 53325.00 1002.00 1.00 
37800.00 1002.00 1.00 39825.00 1002.00 1.00 54000.00 1002.00 1.00 
38475.00 1002.00 1.00 40500.00 1002.00 1.00    
39150.00 1002.00 1.00 41175.00 1002.00 1.00    
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39825.00 1002.00 1.00 41850.00 1002.00 1.00    
40500.00 1002.00 1.00 42525.00 1002.00 1.00    
41175.00 1002.00 1.00 43200.00 1002.00 1.00    
41850.00 1002.00 1.00 43875.00 1002.00 1.00    
42525.00 1002.00 1.00 44550.00 1002.00 1.00    
43200.00 1002.00 1.00 45225.00 1002.00 1.00    
43875.00 1002.00 1.00 45900.00 1002.00 1.00    
44550.00 1002.00 1.00 46575.00 1002.00 1.00    
45225.00 1002.00 1.00 47250.00 1002.00 1.00    
45900.00 1002.00 1.00 47925.00 1002.00 1.00    
46575.00 1002.00 1.00 48600.00 1002.00 1.00    
47250.00 1002.00 1.00 49275.00 1002.00 1.00    
47925.00 1002.00 1.00 49950.00 1002.00 1.00    
48600.00 1002.00 1.00 50625.00 1002.00 1.00    
49275.00 1002.00 1.00 51300.00 1002.00 1.00    
49950.00 1002.00 1.00 51975.00 1002.00 1.00    
50625.00 1002.00 1.00 52650.00 1002.00 1.00    
51300.00 1002.00 1.00 53325.00 1002.00 1.00    
51975.00 1002.00 1.00 54000.00 1002.00 1.00    
52650.00 1002.00 1.00       
53325.00 1002.00 1.00       
54000.00 1002.00 1.00       
         
 
